

Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	OCT 11	Instructor-led and self paced STN learning resources available at https://cas.csod.com/Default.aspx?c=001
NEWS	2	APR 26	Expanded Swedish Patent Application Coverage in CA/CAPLUS Provides More Current and Complete Information
NEWS	3	APR 28	The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications
NEWS	4	MAY 02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS	5	MAY 12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS	6	MAY 23	Enhanced performance of STN biosequence searches
NEWS	7	JUN 20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS	8	JUN 20	INPADOC databases enhanced with first page images
NEWS	9	JUN 20	PATDPA database updates to end in June 2011
NEWS	10	JUN 26	MARPAT Enhancements Save Time and Increase Usability
NEWS	11	JUL 25	STN adds Australian patent full-text database, AUPATFULL, including the new numeric search feature.
NEWS	12	AUG 01	CA Sections Added to ACS Publications Web Editions Platform
NEWS	13	AUG 16	INPADOC: Coverage of German Patent Data resumed, enhanced legal status
NEWS	14	AUG 18	Upgrade now to STN Express, Version 8.5
NEWS	15	SEP 01	CAS Journal Coverage Now Includes Ahead-of-Print Articles for More Than 100 Journal Titles
NEWS	16	SEP 01	Older Versions of STN Express to be Discontinued Beginning in March 2012
NEWS	17	SEP 09	USAN Database Updates Offer Superior Currency on STN(R)
NEWS	18	SEP 26	STN Adds Canadian Patent Full-text Database - CANPATFULL
NEWS	19	SEP 26	GEOREF and ENCOMPLIT databases were reloaded on September 24, 2011.
NEWS	20	SEP 26	Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.
NEWS	21	SEP 26	ECLA Thesaurus in CA/CAPLUS Improves Patent Searching on STN
NEWS	22	SEP 26	Access AUPATFULL and CANPATFULL databases with STN Viewer
NEWS	23	OCT 26	New STN Revolutionizes Patent Searching for Professionals
NEWS	24	DEC 1	CA/CAPLUS Now Includes Examiner Citations for Japanese Patents
NEWS	25	DEC 1	CAS Expands Global Patent Coverage - Intellectual Property Corporation of Malaysia Becomes 62nd Authority on CA/CAPLUS
NEWS	26	DEC 5	STN on the Web Enhancements Include Compatibility with Microsoft Windows 7
NEWS	27	DEC 14	Removal of ITRD and PATIPC databases from STN
NEWS	28	DEC 15	Rolled-up IPC Core Codes Removed from IPC Reclassifications in Patent Databases on STN
NEWS	29	JAN 12	Structure Graphics Have Been Added to Abstracts for MARPAT and CA/CAPLUS on STN
NEWS	30	JAN 15	Online Access to Very Large Chemical Structure Images

Enhanced on STN

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:05:04 ON 25 JAN 2012

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	0.24

FILE 'REGISTRY' ENTERED AT 06:05:12 ON 25 JAN 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3
DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025.str



```

chain nodes :
8 9 11
ring nodes :
1 2 3 4 5
chain bonds :
2-8 5-9 9-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-8 3-4 4-5 5-9 9-11

```

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:Atom 9:CLASS 11:Atom

Generic attributes :

8:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

9:

Number of Carbon Atoms : less than 7

Element Count :

Node 8: Limited

N,Exact,1

C,Exact,5

L1 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 06:05:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 15027362 TO ITERATE

13.4% PROCESSED 2009192 ITERATIONS

464 ANSWERS

39.9% PROCESSED 6000000 ITERATIONS

2190 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.28

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 15027362 TO 15027362

PROJECTED ANSWERS: 5262 TO 5706

L2 2190 SEA SSS FUL L1

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	204.29	204.53

FILE 'REGISTRY' ENTERED AT 06:06:13 ON 25 JAN 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3
DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025a.str



chain nodes :

8 16 17 21 22

ring nodes :

1 2 3 4 5 9 10 11 12 13 14

chain bonds :

2-9 5-21 8-22 21-22

ring bonds :

1-2 1-5 2-3 3-4 4-5 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-5 2-3 2-9 3-4 4-5 5-21 8-22 21-22

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14

isolated ring systems :

containing 9 :

G1:O,N

G2:[@1],[@2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 16:Atom 17:Atom 21:CLASS 22:CLASS

Generic attributes :

16:

Saturation : Saturated

Type of Ring System : Monocyclic

17:

Type of Ring System : Monocyclic

L3 STRUCTURE UPLOADED

=> s 13 sss full

FULL SEARCH INITIATED 06:09:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 18825 TO ITERATE

100.0% PROCESSED 18825 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L4 3 SEA SSS FUL L3

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

205.85

410.38

FILE 'CAPLUS' ENTERED AT 06:09:06 ON 25 JAN 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2012 VOL 156 ISS 5

FILE LAST UPDATED: 24 Jan 2012 (20120124/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14

L5 1 L4

=> d 15 ibib

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:962228 CAPLUS

DOCUMENT NUMBER: 143:266932

TITLE: Preparation of tetrazole compounds and their use as metabotropic glutamate receptor antagonists

INVENTOR(S): Johansson, Martin; Minidis, Alexander; Staaf, Karin; Wensbo, David; McLeod, Donald; Edwards, Louise; Isaac, Methvin; O'Brien, Anne; Slassi, Abdelmalik; Xin, Tao

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080356	A1	20050901	WO 2005-US5217	20050217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214379	A1	20050901	AU 2005-214379	20050217
CA 2556263	A1	20050901	CA 2005-2556263	20050217
EP 1716125	A1	20061102	EP 2005-713793	20050217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1918137	A	20070221	CN 2005-80004370	20050217
BR 2005007498	A	20070710	BR 2005-7498	20050217
JP 2007523182	T	20070816	JP 2006-554236	20050217
SG 150539	A1	20090330	SG 2009-1214	20050217
RU 2372347	C2	20091110	RU 2006-127573	20050217
CN 101845023	A	20100929	CN 2010-10113361	20050217
US 20060004021	A1	20060105	US 2005-60463	20050218
US 7691892	B2	20100406		
AR 47812	A1	20060222	AR 2005-100615	20050218
NO 2006003470	A	20061117	NO 2006-3470	20060728
IN 2006DN04470	A	20070810	IN 2006-DN4470	20060802
KR 2007027504	A	20070309	KR 2006-7015943	20060807
MX 2006009019	A	20070308	MX 2006-9019	20060808
ZA 2006006594	A	20071128	ZA 2006-6594	20060808
US 20070197549	A1	20070823	US 2007-588756	20070309
PRIORITY APPLN. INFO.:			US 2004-545291P	P 20040218

CN 2005-80004370 A3 20050217
WO 2005-US5217 W 20050217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:266932; MARPAT 143:266932

OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS
RECORD (19 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15 hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2012 ACS on STN

IT 1044693-24-4


RL: PRPH (Prophetic)

(Preparation of tetrazole compounds and their use as metabotropic
glutamate receptor antagonists)

RN 1044693-24-4 CAPLUS

CN Pyridine, 4-[5-[(1E)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethenyl]-4-
ethyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Double bond geometry as shown.




IT 863713-09-1P 863713-13-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)

(preparation of tetrazole compds. and their use as metabotropic glutamate
receptor antagonists)


RN 863713-09-1 CAPLUS

CN Pyridine, 4-[5-[2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethenyl]-4-ethyl-4H-
1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 863713-13-7 CAPLUS

CN Pyridine, 4-[5-[2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethenyl]-4-
cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



```
=> file reg
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                               4.83         415.21
```

FILE 'REGISTRY' ENTERED AT 06:09:47 ON 25 JAN 2012
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3
 DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> file reg
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                               2.60         417.81
```

FILE 'REGISTRY' ENTERED AT 06:12:33 ON 25 JAN 2012
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3
 DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025ab.str



chain nodes :

8 16 17 21

ring nodes :

1 2 3 4 5 9 10 11 12 13 14

chain bonds :

2-9 5-21 8-21

ring bonds :

1-2 1-5 2-3 3-4 4-5 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-5 2-3 2-9 3-4 4-5 5-21 8-21

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14

isolated ring systems :

containing 9 :

G1:O,N

G2:[@1],[@2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom

13:Atom 14:Atom 16:Atom 17:Atom 21:CLASS

Generic attributes :

16:

Saturation : Saturated

Type of Ring System : Monocyclic

17:

Type of Ring System : Monocyclic

L6 STRUCTURE UPLOADED

=> s l6 sss full
FULL SEARCH INITIATED 06:13:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 122732 TO ITERATE

100.0% PROCESSED 122732 ITERATIONS 539 ANSWERS
SEARCH TIME: 00.00.02

L7 539 SEA SSS FUL L6

=> file capl		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	204.81	622.62

FILE 'CAPLUS' ENTERED AT 06:14:07 ON 25 JAN 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2012 VOL 156 ISS 5
FILE LAST UPDATED: 24 Jan 2012 (20120124/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7

L8 28 L7

=> d l8 1-28 ibib hitstr

L8 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2011:572510 CAPLUS
DOCUMENT NUMBER: 154:486357
TITLE: Preparation of heteropolycyclic compounds containing a
 1,2,4-oxadiazole ring and their use as metabotropic
 glutamate receptor antagonists
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA; AstraZeneca AB

SOURCE: Argent., Pat. Appl., 492pp.
 CODEN: ARXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AR 49472	A1	20060809	AR 2005-100611	20050218
PRIORITY APPLN. INFO.:			US 2004-779868	A 20040218

OTHER SOURCE(S): MARPAT 154:486357


IT 660422-54-8P 660422-55-9P 660422-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of five-membered heterocyclic compds. as mGluR5 receptor antagonists)


RN 660422-54-8 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 660422-55-9 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-ethyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 660422-56-0 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




IT 870973-99-2P 870974-03-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteropolycyclic compds. as mGluR5 receptor antagonists)


RN 870973-99-2 CAPLUS

CN Pyridine, 4-[5-[2-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 870974-03-1 CAPLUS

CN Pyridine, 4-[4-methyl-5-[2-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]ethyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



L8 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:60325 CAPLUS

DOCUMENT NUMBER: 154:234598

TITLE: Rapid Synthesis of 1,3,5-Substituted 1,2,4-Triazoles from Carboxylic Acids, Amidines, and Hydrazines

AUTHOR(S): Castanedo, Georgette M.; Seng, Pamela S.; Blaquiere, Nicole; Trapp, Sean; Staben, Steven T.

CORPORATE SOURCE: Discovery Chemistry Group, Genentech, Inc., South San Francisco, CA, 94080, USA

SOURCE: Journal of Organic Chemistry (2011), 76(4), 1177-1179
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

OTHER SOURCE(S): CASREACT 154:234598


IT 1263815-80-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of triazoles via regioselective heterocyclization of carboxylic acids, primary amidines with monosubstituted hydrazines)

RN 1263815-80-0 CAPLUS

CN Pyridine, 4-[5-(3-thienylmethyl)-1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2010:1535124 CAPLUS
DOCUMENT NUMBER: 154:46055
TITLE: Azole derivatives as Wnt pathway inhibitors and their
preparation and use in the treatment of diseases
affected by Wnt signaling pathway over-activation
INVENTOR(S): Holsworth, Dan; Waaler, Jo; Machon, Ondrej; Krauss,
Stefan
PATENT ASSIGNEE(S): Oslo University Hospital Hf, Norway; Golding, Louise
SOURCE: PCT Int. Appl., 182pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010139966	A1	20101209	WO 2010-GB1118	20100607
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2009-251497 A 20090605

OTHER SOURCE(S): CASREACT 154:46055; MARPAT 154:46055


IT 1257542-82-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azole derivs. as Wnt pathway inhibitors useful in prophylaxis and therapy of cancer and other diseases affected by Wnt signaling pathway over-activation)

RN 1257542-82-7 CAPLUS

CN Pyridine, 4-[4-(2-chlorophenyl)-5-[2-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]ethyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:881085 CAPLUS

DOCUMENT NUMBER: 153:174838

TITLE: Preparation of pyrrolidine-based compounds as dipeptidyl peptidase IV inhibitors

INVENTOR(S): Balasubramanian, Gopalan; Sakamuri, Sukumar; Singh, Gajendra; Dharmalingam, Sivanesan; Pooppady Xavier, Franklin; Narayanan, Shridhar; Mookkan, Jeyamurugan; Balasubramanian, Jeganatha Sivakumar; Rajalingam, Agneeswari; Kulathingal, Jayanarayan

PATENT ASSIGNEE(S): Orchid Research Laboratories Ltd., India

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010079413	A2	20100715	WO 2010-IB8	20100107
WO 2010079413	A3	20101202		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
IN 2009CH00065	A	20110527	IN 2009-CH65	20090109
CA 2749301	A1	20100715	CA 2010-2749301	20100107
AU 2010204144	A1	20110623	AU 2010-204144	20100107
KR 2011105820	A	20110927	KR 2011-7016632	20100107
EP 2376447	A2	20111019	EP 2010-729125	20100107
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,			


SI, SK, SM, TR
 CN 102272099 A 20111207 CN 2010-80003840 20100107
 US 20110257164 A1 20111020 US 2011-140997 20110620
 MX 2011007340 A 20110721 MX 2011-7340 20110708
 PRIORITY APPLN. INFO.: IN 2009-CH65 A 20090109
 WO 2010-IB8 W 20100107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 153:174838; MARPAT 153:174838

IT 1234626-35-7P, (2S,4S)-4-Fluoro-1-[2-[[[(1S,3S)-1,2,2-trimethyl-3-
 [[5-(pyridin-4-yl)-1,2,4-oxadiazol-3-
 yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of pyrrolidine-based compds. as dipeptidyl
 peptidase IV inhibitors for treating diabetes, its complications, and
 other disorders)
 RN 1234626-35-7 CAPLUS
 CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[2-[[[(1S,3S)-1,2,2-trimethyl-3-[[5-
 (4-pyridinyl)-1,2,4-oxadiazol-3-yl)methyl]cyclopentyl]amino]acetyl]-,
 (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L8 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:437160 CAPLUS

DOCUMENT NUMBER: 152:429549

TITLE: Preparation of pyrrolidinone and piperidinone based
 compounds as therapeutic calcium channel blockers

INVENTOR(S): Bhatia, Pramila A.; Doherty, George A.; Drizin, Irene;
 Mack, Helmut; Perner, Richard J.; Stewart, Andrew O.;
 Zhang, Qing Wei

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 219pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010039947	A1	20100408	WO 2009-US59215	20091001
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,				

SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
 ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 CA 2737480 A1 20100408 CA 2009-2737480 20091001
 US 20100093730 A1 20100415 US 2009-571862 20091001
 US 8044069 B2 20111025
 EP 2350002 A1 20110803 EP 2009-737258 20091001
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, SM, TR
 CN 102239146 A 20111109 CN 2009-80148415 20091001
 MX 2011003533 A 20110616 MX 2011-3533 20110401
 PRIORITY APPLN. INFO.: US 2008-102132P P 20081002
 WO 2009-US59215 W 20091001

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:429549; MARPAT 152:429549


IT 1219626-69-3P, 3,3-Diphenyl-1-[[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinone and piperidinone based compds. as therapeutic calcium channel blockers)

RN 1219626-69-3 CAPLUS

CN 2-Pyrrolidinone, 3,3-diphenyl-1-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:55379 CAPLUS

DOCUMENT NUMBER: 152:144687

TITLE: Preparation of disubstituted oxadiazoles as novel modulators of sphingosine phosphate receptors

INVENTOR(S): Roberts, Edward; Rosen, Hugh; Brown, Steven; Guerrero, Miguel A.; Peng, Xuemei; Poddutoori, Ramulu

PATENT ASSIGNEE(S): Scripps Research Institute, The, USA

SOURCE: U.S. Pat. Appl. Publ., 203 pp., Chemical Indexing Equivalent to 152:75043 (WO)
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 20100010001 A1 20100114 US 2009-465767 20090514
 AU 2009258242 A1 20091217 AU 2009-258242 20090514
 WO 2009151529 A1 20091217 WO 2009-US3014 20090514
 WO 2009151529 A9 20100408
 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 EP 2291080 A1 20110309 EP 2009-762826 20090514
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, TR, AL, BA, RS
 JP 2011523412 T 20110811 JP 2011-509488 20090514
 PRIORITY APPLN. INFO.: US 2008-127603P P 20080514
 US 2009-465767 A 20090514
 WO 2009-US3014 W 20090514

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 1201444-17-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of disubstituted oxadiazoles as novel modulators of sphingosine
 phosphate receptors)
 RN 1201444-17-8 CAPLUS
 CN Pyridine, 4-[5-(cyclopentylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



L8 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2009:1566247 CAPLUS
 DOCUMENT NUMBER: 152:75043
 TITLE: Preparation of disubstituted oxadiazoles as novel
 modulators of sphingosine phosphate receptors
 INVENTOR(S): Roberts, Edward; Rosen, Hugh; Brown, Steven; Morales,
 Miguel; Peng, Xuemei; Poddutoori, Ramulu
 PATENT ASSIGNEE(S): The Scripps Research Institute, USA
 SOURCE: PCT Int. Appl., 275pp.; Chemical Indexing Equivalent
 to 152:144687 (US)
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009151529	A1	20091217	WO 2009-US3014	20090514
WO 2009151529	A9	20100408		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2009258242	A1	20091217	AU 2009-258242	20090514
CA 2723904	A1	20091217	CA 2009-2723904	20090514
US 20100010001	A1	20100114	US 2009-465767	20090514
KR 2011010777	A	20110207	KR 2010-7028062	20090514
EP 2291080	A1	20110309	EP 2009-762826	20090514

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS

CN 102118972	A	20110706	CN 2009-80127478	20090514
JP 2011523412	T	20110811	JP 2011-509488	20090514

PRIORITY APPLN. INFO.: US 2008-127603P P 20080514
US 2009-465767 A 20090514
WO 2009-US3014 W 20090514

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:75043; MARPAT 152:75043


IT 1201444-17-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted oxadiazoles as novel modulators of sphingosine phosphate receptors)

RN 1201444-17-8 CAPLUS

CN Pyridine, 4-[5-(cyclopentylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:944287 CAPLUS

DOCUMENT NUMBER: 151:245698

TITLE: Preparation of imidazopyrazines as protein kinase inhibitors

INVENTOR(S): Rainka, Matthew Paul; Voss, Matthew Ernst; Peterson, Lisa Helen; Fleming, Mike; Belanger, David B.; Curran, Patrick J.; Kulkarni, Bheemashankar A.; Yu, Tao; Zhang, Yonglian; Xiao, Yushi; Kerekes, Angela D.; Tagat, Jayaram R.; Doll, Ronald J.; Siddiqui, M. Arshad

PATENT ASSIGNEE(S): Schering Corporation, USA; Albany Molecular Research, Inc.

SOURCE: PCT Int. Appl., 133pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009097233	A1	20090806	WO 2009-US31972	20090126
WO 2009097233	A9	20090924		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2710929	A1	20090806	CA 2009-2710929	20090126
------------	----	----------	-----------------	----------

PRIORITY APPLN. INFO.:

US 2008-24010P	P	20080128
----------------	---	----------

WO 2009-US31972	W	20090126
-----------------	---	----------

OTHER SOURCE(S): MARPAT 151:245698

IT 1111265-03-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel imidazopyrazines as inhibitors of protein kinases useful in treatment, prevention and combination therapy of protein kinase-mediated diseases)

RN 1111265-03-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1-[[3-(3-fluoro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-1H-pyrazol-4-yl]-6-methyl-N-[3-(1-piperidinylmethyl)-5-isothiazolyl]-, hydrochloride (1:?) (CA INDEX NAME)

PAGE 1-A



●x HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:846109 CAPLUS

DOCUMENT NUMBER: 151:92846

TITLE: Method using lifespan-altering compounds for altering
the lifespan of eukaryotic organisms, and screening
for such compounds

INVENTOR(S): Goldfarb, David Scott

PATENT ASSIGNEE(S): University of Rochester, USA

SOURCE: U.S. Pat. Appl. Publ., 57pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
JP 2011507910	T	20110310	JP 2010-539936	20081222
PRIORITY APPLN. INFO.:			US 2008-23801P	P 20080125
			US 2007-16362P	P 20071221
			US 2008-341615	20081222
			WO 2008-US88016	W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT 695167-68-1

RL: PAC (Pharmacological activity); BIOL (Biological study)

(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)

RN 695167-68-1 CAPLUS

CN Pyridine, 4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L8 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:846100 CAPLUS

DOCUMENT NUMBER: 151:92837

TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds

INVENTOR(S): Goldfarb, David Scott

PATENT ASSIGNEE(S): University of Rochester, USA

SOURCE: U.S. Pat. Appl. Publ., 57pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
JP 2011507910	T	20110310	JP 2010-539936	20081222
PRIORITY APPLN. INFO.:			US 2008-23801P	P 20080125
			US 2007-16362P	P 20071221
			US 2008-341615	20081222
			WO 2008-US88016	W 20081222


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 432014-95-4

RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)

RN 432014-95-4 CAPLUS

CN Pyridine, 4-[5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



L8 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:553181 CAPLUS

DOCUMENT NUMBER: 150:515186

TITLE: Pyridazinone derivatives as P2X7 receptor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of rheumatoid arthritis

INVENTOR(S): Shigeta, Yukihiro; Hirokawa, Yutaka; Nagai, Hiroshi; Nagae, Kei; Watanabe, Tsuneo; Io, Megumi; Matsuura, Yusuke; Kamon, Junji; Horikawa, Masato; Takeuchi, Kazuya

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 439pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009057827	A1	20090507	WO 2008-JP70261	20081030
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2008319735	A1	20090507	AU 2008-319735	20081030
CA 2699631	A1	20090507	CA 2008-2699631	20081030
EP 2203429	A1	20100707	EP 2008-844308	20081030
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
KR 2010084516	A	20100726	KR 2010-7008200	20081030
JP 2011502116	T	20110120	JP 2010-530685	20081030
ZA 2010001860	A	20110525	ZA 2010-1860	20100316
US 20100286390	A1	20101111	US 2010-680689	20100329
MX 2010004705	A	20100527	MX 2010-4705	20100429
CN 101842359	A	20100922	CN 2008-80114529	20100430
PRIORITY APPLN. INFO.:			JP 2007-284189	A 20071031
			JP 2008-229921	A 20080908
			WO 2008-JP70261	W 20081030

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:515186; MARPAT 150:515186

IT 1149585-67-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridazinone derivs. as P2X7 receptor inhibitors useful in the treatment of rheumatoid arthritis)

RN 1149585-67-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-chloro-2-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-5-[[(1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2009:143084 CAPLUS
 DOCUMENT NUMBER: 150:214420
 TITLE: Heterocyclic compounds as anti-mitotic agents and
 aurora kinase inhibitors and in combination as
 anti-cancer agents and their preparation,
 pharmaceutical compositions and use in the treatment
 of cancer
 INVENTOR(S): Basso, Andrea Dawn
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 583pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017701	A2	20090205	WO 2008-US9108	20080728
WO 2009017701	A3	20090507		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2008282885	A1	20090205	AU 2008-282885	20080728
CA 2694218	A1	20090205	CA 2008-2694218	20080728
KR 2010042287	A	20100423	KR 2010-7004497	20080728
EP 2182986	A2	20100512	EP 2008-794799	20080728
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
JP 2010535201	T	20101118	JP 2010-519219	20080728
AR 68048	A1	20091104	AR 2008-103276	20080729
IN 2010CN00569	A	20100730	IN 2010-CN569	20100129
ZA 2010000716	A	20101027	ZA 2010-716	20100129
MX 2010001340	A	20100602	MX 2010-1340	20100202
US 20100249030	A1	20100930	US 2010-670762	20100223
CN 101808666	A	20100818	CN 2008-80109598	20100330
PRIORITY APPLN. INFO.:			US 2007-953087P	P 20070731
			US 2008-23985P	P 20080128
			WO 2008-US9108	W 20080728

OTHER SOURCE(S): CASREACT 150:214420; MARPAT 150:214420

IT 1111265-03-2P 1111268-86-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of heterocyclic compds. as anti-mitotic agent
 and aurora kinase inhibitor useful in combination as anti-cancer agents
 in the treatment cancer)

RN 1111265-03-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1-[[3-(3-fluoro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-1H-pyrazol-4-yl]-6-methyl-N-[3-(1-piperidinylmethyl)-5-isothiazolyl]-, hydrochloride (1:?) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● x HCl

RN 1111268-86-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-[1-[[3-(3-fluoro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-1H-pyrazol-4-yl]-6-methyl-N-[3-(1-piperidinylmethyl)-5-isothiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)


L8 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2008:97047 CAPLUS

DOCUMENT NUMBER: 148:191965
 TITLE: Preparation of heteroaryl compounds, particularly 1,2,4-triazole derivatives as inhibitors of Rho kinase
 INVENTOR(S): Borchardt, Allen J.; Kahraman, Mehmet; Cook, Travis G.; Davis, Robert L.; Gardiner, Elisabeth M. M.; Malecha, James W.; Noble, Stewart A.; Prins, Thomas J.; Sertic, Michael; Siegel, Dana L.
 PATENT ASSIGNEE(S): Siegel, Dana, L., USA
 SOURCE: PCT Int. Appl., 228 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008011557	A2	20080124	WO 2007-US73967	20070720
WO 2008011557	A3	20080731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080021217 A1 20080124 US 2007-780735 20070720 US 20080021026 A1 20080124 US 2007-780834 20070720 PRIORITY APPLN. INFO.: US 2006-832634P P 20060720 US 2007-915772P P 20070503				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:191965; MARPAT 148:191965
 IT 1004303-71-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heteroaryl compds., particularly 1,2,4-triazole derivs. as inhibitors of Rho kinase)
 RN 1004303-71-2 CAPLUS
 CN Pyridine, 4-[3-[2-[2-(4-methoxyphenyl)-1,3-dioxolan-2-yl]ethyl]-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

ACCESSION NUMBER: 2006:1173938 CAPLUS
 DOCUMENT NUMBER: 145:471411
 TITLE: Preparation of
 4-[ω -(2-oxopyrrolidinyl/2-oxopiperidinyl)alkoxy]benzonitriles as androgen
 receptor modulators for treating conditions like
 excess sebum secretions and hair loss
 INVENTOR(S): Barrett, Stephen Douglas; Fedij, Victor; Hu, Lain-Yen;
 Iula, Donna Michele; Lefker, Bruce Allen; Raheja, Raj
 Kumar; Sexton, Karen Elaine; Van Camp, Jennifer Ann
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117677	A1	20061109	WO 2006-IB1266	20060424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006242927	A1	20061109	AU 2006-242927	20060424
CA 2603866	A1	20061109	CA 2006-2603866	20060424
CA 2603866	C	20110531		
EP 1888524	A1	20080220	EP 2006-744704	20060424
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 4174068	B1	20081029	JP 2008-509535	20060424
JP 2008540397	T	20081120		
AP 1932	A	20081231	AP 2007-4197	20060424
BR 2006010998	A2	20100810	BR 2006-10998	20060424
US 20060252796	A1	20061109	US 2006-415935	20060502
US 7674819	B2	20100309		
AR 53721	A1	20070516	AR 2006-101785	20060503
NL 1031752	A1	20061113	NL 2006-1031752	20060504
NL 1031752	C2	20070319		
US 20070072936	A1	20070329	US 2006-557225	20061107
US 7799823	B2	20100921		
IN 2007DN07726	A	20071109	IN 2007-DN7726	20071009
CN 101166718	A	20080423	CN 2006-80014500	20071031
ZA 2007009385	A	20081029	ZA 2007-9385	20071031
KR 2007116970	A	20071211	KR 2007-7025374	20071101
CR 9496	A	20071204	CR 2007-9496	20071102
MX 2007013823	A	20080205	MX 2007-13823	20071105
NO 2007006026	A	20071122	NO 2007-6026	20071122
PRIORITY APPLN. INFO.:			US 2005-678035P	P 20050505
			US 2005-682112P	P 20050518
			WO 2006-IB1266	W 20060424
			US 2006-415935	A1 20060502

OTHER SOURCE(S): CASREACT 145:471411; MARPAT 145:471411
 IT 914101-55-6P, 4-[[4,4-Dimethyl-2-oxo-1-[[3-(pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]methyl]pyrrolidin-3-yl]oxy]-2-trifluoromethylbenzonitrile
 RL: COS (Cosmetic use); CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (cosmetic/drug candidate; preparation of 4-[o-(2-oxopyrrolidinyl/2-oxopiperidinyl)alkoxy]benzonitriles as androgen receptor modulators for treating conditions like excess sebum secretions and hair loss)
 RN 914101-55-6 CAPLUS
 CN Benzonitrile, 4-[[4,4-dimethyl-2-oxo-1-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-3-pyrrolidinyl]oxy]-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

CN

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L8 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2006:206835 CAPLUS
 DOCUMENT NUMBER: 145:188802
 TITLE: Search for conditions for synthesis of O-(pyridinylcarbonyl)-3-aminopropionamidoximes and 3-(aminoethyl)-5-pyridinyl-1,2,4-oxadiazoles
 AUTHOR(S): Orazbaeva, M. A.; Kayukova, L. A.; Praliev, K. D.

CORPORATE SOURCE: Inst. Khim. Nauk im. A. B. Bekturova, MON RK, Almaty, Kazakhstan
 SOURCE: Izvestiya Natsional'noi Akademii Nauk Respubliki Kazakhstan, Seriya Khimicheskaya (2005), (6), 45-50
 CODEN: INANDJ
 PUBLISHER: Nauchno-Izdatel'skii Tsentr "Gylym"
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 145:188802
 IT 902799-95-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (acylation and heterocyclization of aminopropanamidoximes by pyridinecarbonyl chloride hydrochloride)
 RN 902799-95-5 CAPLUS
 CN Pyridine, 4-[3-[2-(1-piperidiny)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



L8 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2005:1292048 CAPLUS
 DOCUMENT NUMBER: 144:36353
 TITLE: Preparation of heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
 INVENTOR(S): Edwards, Louise; Isaac, Methvin; Johansson, Martin; Kers, Annika; Malmberg, Johan; McLeod, Donald; Mindis, Alexander; Staaf, Karin; Slassi, Abdelmalik; Stefanac, Tomislav; Stormann, Thomas; Wensbo, David; Xin, Tao; Arora, Jalaj
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; NPS Pharmaceuticals Inc.
 SOURCE: U.S. Pat. Appl. Publ., 175 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050272779	A1	20051208	US 2005-53752	20050209
US 7585881	B2	20090908		
AU 2005270208	A1	20060209	AU 2005-270208	20050215
CA 2555566	A1	20060209	CA 2005-2555566	20050215
WO 2006014185	A1	20060209	WO 2005-US4774	20050215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1723144	A1	20061122	EP 2005-802855	20050215
EP 1723144	B1	20101006		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1984907	A	20070620	CN 2005-80004306	20050215
BR 2005007497	A	20070710	BR 2005-7497	20050215
JP 2007523168	T	20070816	JP 2006-554165	20050215
CN 101096368	A	20080102	CN 2007-10127847	20050215
SG 146657	A1	20081030	SG 2008-6914	20050215
NZ 548954	A	20090731	NZ 2005-548954	20050215
RU 2370495	C2	20091020	RU 2006-128446	20050215
AT 483706	T	20101015	AT 2005-802855	20050215
PT 1723144	E	20101207	PT 2005-802855	20050215
ES 2352110	T3	20110215	ES 2005-802855	20050215
EP 2311830	A1	20110420	EP 2010-182161	20050215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
ZA 2006006551	A	20071128	ZA 2006-6551	20060807
NO 2006003599	A	20061027	NO 2006-3599	20060808
MX 2006009020	A	20061207	MX 2006-9020	20060808
KR 2007018006	A	20070213	KR 2006-7016018	20060808
IN 2006DN04751	A	20070831	IN 2006-DN4751	20060818
US 20070179188	A1	20070802	US 2007-588702	20070313
US 20070293545	A1	20071220	US 2007-840954	20070818
US 20080015234	A1	20080117	US 2007-840952	20070818
US 20080015204	A1	20080117	US 2007-840955	20070818
US 20080045571	A1	20080221	US 2007-840953	20070818
PRIORITY APPLN. INFO.:				
			US 2004-608960P	P 20040218
			US 2004-779868	T0 20040218
			US 2005-53752	A3 20050209
			CN 2005-80004306	A3 20050215
			EP 2005-802855	A3 20050215
			WO 2005-US4774	W 20050215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:36353; MARPAT 144:36353


IT 870973-99-2P 870974-03-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteropolycyclic compds. for treating and/or preventing mGluR5 receptor-mediated disorders)


RN 870973-99-2 CAPLUS

CN Pyridine, 4-[5-[2-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 870974-03-1 CAPLUS


CN Pyridine, 4-[4-methyl-5-[2-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]ethyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




IT 660422-54-8P 660422-55-9P 660422-56-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heteropolycyclic compds. for treating and/or preventing
 mGluR5 receptor-mediated disorders)
 RN 660422-54-8 CAPLUS
 CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-methyl-
 4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 660422-55-9 CAPLUS
 CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-ethyl-
 4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 660422-56-0 CAPLUS
 CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-
 cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
 RECORD (15 CITINGS)

L8 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2005:962228 CAPLUS
 DOCUMENT NUMBER: 143:266932
 TITLE: Preparation of tetrazole compounds and their use as
 metabotropic glutamate receptor antagonists
 INVENTOR(S): Johansson, Martin; Minidis, Alexander; Staaf, Karin;
 Wensbo, David; McLeod, Donald; Edwards, Louise; Isaac,

PATENT ASSIGNEE(S): Methvin; O'Brien, Anne; Slassi, Abdelmalik; Xin, Tao
 SOURCE: Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
 PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080356	A1	20050901	WO 2005-US5217	20050217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214379	A1	20050901	AU 2005-214379	20050217
CA 2556263	A1	20050901	CA 2005-2556263	20050217
EP 1716125	A1	20061102	EP 2005-713793	20050217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1918137	A	20070221	CN 2005-80004370	20050217
BR 2005007498	A	20070710	BR 2005-7498	20050217
JP 2007523182	T	20070816	JP 2006-554236	20050217
SG 150539	A1	20090330	SG 2009-1214	20050217
RU 2372347	C2	20091110	RU 2006-127573	20050217
CN 101845023	A	20100929	CN 2010-10113361	20050217
US 20060004021	A1	20060105	US 2005-60463	20050218
US 7691892	B2	20100406		
AR 47812	A1	20060222	AR 2005-100615	20050218
NO 2006003470	A	20061117	NO 2006-3470	20060728
IN 2006DN04470	A	20070810	IN 2006-DN4470	20060802
KR 2007027504	A	20070309	KR 2006-7015943	20060807
MX 2006009019	A	20070308	MX 2006-9019	20060808
ZA 2006006594	A	20071128	ZA 2006-6594	20060808
US 20070197549	A1	20070823	US 2007-588756	20070309
PRIORITY APPLN. INFO.:			US 2004-545291P	P 20040218
			CN 2005-80004370	A3 20050217
			WO 2005-US5217	W 20050217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 143:266932; MARPAT 143:266932

IT 863713-10-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrazole compds. and their use as metabotropic glutamate receptor antagonists)

RN 863713-10-4 CAPLUS

CN Pyridine, 4-[5-[2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl]-4-ethyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2005:888916 CAPLUS
 DOCUMENT NUMBER: 143:242011
 TITLE: Heterocyclic compounds for the treatment of gastro-esophageal reflux disease
 INVENTOR(S): Lehmann, Anders; Mattsson, Jan; Nilsson, Karolina
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077345	A1	20050825	WO 2005-US336	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-541056P P 20040203


OTHER SOURCE(S): MARPAT 143:242011

IT 660422-54-8 660422-55-9 660422-56-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heterocyclic compds. for the treatment of gastroesophageal reflux disease)


RN 660422-54-8 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 660422-55-9 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-ethyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 660422-56-0 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:588949 CAPLUS

DOCUMENT NUMBER: 143:115543

TITLE: Preparation of heterocyclic derivatives as GPCR receptor agonists

INVENTOR(S): Fyfe, Matthew; Gardner, Lisa; King-Underwood, John; Procter, Martin; Rasamison, Chrystelle; Schofield, Karen; Thomas, Gerard Hugh

PATENT ASSIGNEE(S): Prosidion Limited, UK

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061489	A1	20050707	WO 2004-GB50046	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004303604	A1	20050707	AU 2004-303604	20041223

AU 2004303604	B2	20110324		
CA 2549955	A1	20050707	CA 2004-2549955	20041223
EP 1711491	A1	20061018	EP 2004-806264	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898235	A	20070117	CN 2004-80039018	20041223
BR 2004018149	A	20070417	BR 2004-18149	20041223
JP 2007517010	T	20070628	JP 2006-546340	20041223
NZ 547965	A	20091224	NZ 2004-547965	20041223
IN 2006MN00699	A	20070309	IN 2006-MN699	20060614
IN 227515	A1	20090306		
MX 2006007135	A	20060907	MX 2006-7135	20060621
ZA 2006005164	A	20071128	ZA 2006-5164	20060622
KR 2006127011	A	20061211	KR 2006-7012739	20060623
IN 2008KN02387	A	20090123	IN 2008-KN2387	20080612
US 20090281060	A1	20091112	US 2008-584025	20080826
PRIORITY APPLN. INFO.:			US 2003-532370P	P 20031224
			WO 2004-GB50046	W 20041223
			IN 2006-MN699	A3 20060614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:115543; MARPAT 143:115543


IT 857652-32-5P 857652-39-2P 857652-40-5P
857653-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxadiazoles as GPCR receptor agonists)


RN 857652-32-5 CAPLUS

CN Pyridine, 4-[5-[(4-pentylcyclohexyl)methyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 857652-39-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 857652-40-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857653-65-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
 RECORD (13 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2004:143126 CAPLUS
 DOCUMENT NUMBER: 140:199331
 TITLE: Preparation of five-membered heterocyclic compounds as
 mGluR5 receptor antagonists
 INVENTOR(S): Wensbo, David; Xin, Tao; Stefanac, Tomislav; Arora,
 Jalaj; Edwards, Louise; Isaac, Methvin; Slassi,
 Abdelmalik; Stormann, Thomas M.; McLeod, Donald A.;
 Kers, Annika; Malmberg, Johan; Oscarsson, Karin;
 Gyback, Helena; Johansson, Martin; Minidis, Alexander;
 Waldman, Mangus; Yngve, Ulrika; Osterwall, Christoffer
 PATENT ASSIGNEE(S): Astra Zeneca Ab, Swed.; NPS Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 318 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014881	A2	20040219	WO 2003-US24846	20030808
WO 2004014881	A3	20040527		
WO 2004014881	B1	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,


BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494987	A1	20040219	CA 2003-2494987	20030808
AU 2003259068	A1	20040225	AU 2003-259068	20030808
AU 2003259068	B2	20090702		
US 20040152699	A1	20040805	US 2003-637012	20030808
EP 1529045	A2	20050511	EP 2003-785036	20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013265	A	20050705	BR 2003-13265	20030808
JP 2006503009	T	20060126	JP 2004-527872	20030808
JP 4637578	B2	20110223		
CN 1894241	A	20070110	CN 2003-823845	20030808
NZ 538225	A	20080530	NZ 2003-538225	20030808
RU 2352568	C2	20090420	RU 2005-106844	20030808
CN 101723941	A	20100609	CN 2009-10208474	20030808
ZA 2005000886	A	20060726	ZA 2005-886	20050131
IN 2005DN00486	A	20070119	IN 2005-DN486	20050208
IN 220812	A1	20080801		
MX 2005001594	A	20050920	MX 2005-1594	20050209
NO 2005001225	A	20050509	NO 2005-1225	20050309
US 20060122397	A1	20060608	US 2005-274611	20051114
US 7456200	B2	20081125		
JP 2010248214	A	20101104	JP 2010-135508	20100614
PRIORITY APPLN. INFO.:			US 2002-402040P	P 20020809
			JP 2004-527872	A3 20030808
			US 2003-637012	B3 20030808
			WO 2003-US24846	W 20030808


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:199331

IT 660422-54-8P 660422-55-9P 660422-56-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of five-membered heterocyclic compds. as mGluR5 receptor antagonists)
 RN 660422-54-8 CAPLUS
 CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 660422-55-9 CAPLUS
 CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-ethyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 660422-56-0 CAPLUS

CN Pyridine, 4-[5-[2-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-cyclopropyl-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)

L8 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1977:405980 CAPLUS

DOCUMENT NUMBER: 87:5980

ORIGINAL REFERENCE NO.: 87:969a,972a

TITLE: 1,2,4-Triazoles

INVENTOR(S): Baldwin, John J.; Novello, Frederick C.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 8 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4011218	A	19770308	US 1974-529151	19741203
US 3865945	A	19750211	US 1973-392841	19730829
US 3879404	A	19750422	US 1973-392842	19730829
US 4156085	A	19790522	US 1978-879530	19780221
US 4198513	A	19800415	US 1978-894450	19780407
US 4256887	A	19810317	US 1979-75344	19790913
PRIORITY APPLN. INFO.:			US 1970-75785	A2 19700925
			US 1972-269684	A1 19720707
			US 1972-269685	A3 19720707
			US 1973-392842	A3 19730829
			US 1975-543563	A1 19750123
			US 1976-740290	A3 19761109
			US 1978-894450	A3 19780407

IT 36646-16-9P 36646-36-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36646-16-9 CAPLUS


CN Pyridine, 3-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]methyl]- (CA INDEX NAME)



RN 36646-36-3 CAPLUS

CN Pyridine, 2-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]methyl]- (CA INDEX NAME)

NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L8 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1972:405480 CAPLUS

DOCUMENT NUMBER: 77:5480

ORIGINAL REFERENCE NO.: 77:967a,970a

TITLE: 1,2,4-Triazoles

INVENTOR(S): Baldwin, John J.; Novello, Frederick C.

PATENT ASSIGNEE(S): Merck and Co., Inc.

SOURCE: Ger. Offen., 29 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
DE 2147794	A	19720330	DE 1971-2147794	19710924
NL 7112373	A	19720328	NL 1971-12373	19710908
AU 7133427	A	19730322	AU 1971-33427	19710914
CA 950463	A1	19740702	CA 1971-122845	19710914
GB 1358893	A	19740703	GB 1971-43754	19710920
JP 49046622	B	19741211	JP 1971-73941	19710923
FR 2107984	A5	19720512	FR 1971-34442	19710924
FR 2107984	B1	19750801		
CH 562813	A5	19750613	CH 1971-13922	19710924
BE 781055	A1	19720922	BE 1972-115406	19720322
US 3865945	A	19750211	US 1973-392841	19730829
US 3879404	A	19750422	US 1973-392842	19730829
US 4156085	A	19790522	US 1978-879530	19780221
US 4198513	A	19800415	US 1978-894450	19780407
US 4256887	A	19810317	US 1979-75344	19790913
PRIORITY APPLN. INFO.:			US 1970-75785	A 19700925
			US 1972-269685	A3 19720707
			US 1973-392842	A3 19730829
			US 1975-543563	A1 19750123
			US 1976-740290	A3 19761109
			US 1978-894450	A3 19780407


OTHER SOURCE(S): MARPAT 77:5480

IT 36646-16-9P 36646-36-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36646-16-9 CAPLUS

CN Pyridine, 3-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]methyl]- (CA INDEX
NAME)



RN 36646-36-3 CAPLUS
 CN Pyridine, 2-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L8 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1971:76447 CAPLUS
 DOCUMENT NUMBER: 74:76447
 ORIGINAL REFERENCE NO.: 74:12411a,12414a
 TITLE: Piperazine derivatives, and their pharmacological activity
 INVENTOR(S): Mauvernay, Roland Y.
 SOURCE: Fr. M., 7 pp.
 CODEN: FMXXAJ
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6671		19690317	FR	
PRIORITY APPLN. INFO.:			MC	19660212

OTHER SOURCE(S): MARPAT 74:76447

IT 20491-84-3P 20491-85-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 20491-84-3 CAPLUS


CN Piperazine, 1-phenyl-4-[3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 20491-85-4 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

L8 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1971:13156 CAPLUS

DOCUMENT NUMBER: 74:13156

ORIGINAL REFERENCE NO.: 74:2121a, 2124a

TITLE: Therapeutic pyridyl-1,2,4-oxadiazoles

INVENTOR(S): Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso; Takacs, Kalman; Bako, Erzsebet; Leszkovszky, Gyorgy; Tardos, Laszlo; Vertesy, Csaba

PATENT ASSIGNEE(S): Chinoin Gyogyszer- es Vegyeszeti Termek Gyara Rt.

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1920037	A	19701112	DE 1969-1920037	19690419
US 3647809	A	19720307	US 1969-815520	19690408
IL 31990	A	19740516	IL 1969-31990	19690408
GB 1271302	A	19720419	GB 1969-1271302	19690414
AT 292727	B	19710910	AT 1969-3754	19690418
AT 292728	B	19710910	AT 1970-8156	19690418
FR 2007529	A5	19700113	FR 1969-12994	19690424
FR 2007529	B1	19730316		
CH 540925	A	19731015	CH 1969-6275	19690424
CH 542232	A	19731115	CH 1972-14769	19690424
BE 732131	A	19691001	BE 1969-732131	19690425
NL 6906401	A	19691028	NL 1969-6401	19690425
NO 124253	B	19720327	NO 1969-1733	19690425
BR 6908381	D0	19730208	BR 1969-208381	19690425
JP 48024394	B	19730720	JP 1969-32259	19690425
SE 368576	B	19740708	SE 1969-5909	19690425
CA 954858	A1	19740917	CA 1969-49755	19690425
PL 79435	B1	19750630	PL 1969-133199	19690425
PRIORITY APPLN. INFO.:			HU 1968-CI796	A 19680426

IT 27390-48-3P 30074-42-1P 30074-43-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27390-48-3 CAPLUS

CN Piperidine, 1-[2-[3-(2-ethyl-4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

RN 30074-42-1 CAPLUS
 CN Piperidine, 1-[2-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]-, maleate
 (1:1) (8CI) (CA INDEX NAME)

CM 1


CRN 27390-33-6
 CMF C14 H18 N4 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 30074-43-2 CAPLUS
 CN Morpholine, 4-[2-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]-, maleate
 (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27390-34-7
 CMF C13 H16 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L8 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1970:100719 CAPLUS

DOCUMENT NUMBER: 72:100719

ORIGINAL REFERENCE NO.: 72:18273a,18276a

TITLE: Pyridyloxadiazole derivatives

INVENTOR(S): Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso; Gonczi, Csaba; Takacs, Kalman; Bako, Erzsebet; Leszkovszky, Gyorgy; Tardos, Laszlo; Vertessy, Csaba

PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt

SOURCE: Hung., 24 pp.

CODEN: HUXXAT


DOCUMENT TYPE: Patent

LANGUAGE: Hungarian

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	HU 156976		19700131	HU	19680426
	FR 2007529			FR	
IT	27390-33-6P	27390-34-7P	27390-47-2P		
	27390-48-3P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	27390-33-6	CAPLUS			
CN	Piperidine, 1-[2-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]- (8CI) (CA INDEX NAME)				



RN 27390-34-7 CAPLUS


CN Morpholine, 4-[2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)




RN 27390-47-2 CAPLUS

CN Piperidine, 1-[2-[3-(2-ethyl-4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]- (8CI)

(CA INDEX NAME)




RN 27390-48-3 CAPLUS
CN Piperidine, 1-[2-[3-(2-ethyl-4-pyridyl)-1,2,4-oxadiazol-5-yl]ethyl]-,
dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl


L8 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 1970:12737 CAPLUS
DOCUMENT NUMBER: 72:12737
ORIGINAL REFERENCE NO.: 72:2325a,2328a
TITLE: Antiinflammatory
5-aryl-3-[3-(1-piperazinyl)propyl]-1,2,4-oxadiazoles
INVENTOR(S): Mauvernay, Roland Y.
SOURCE: Brit., 15 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 1164572		19690917	GB 1968-10238	19680301
PRIORITY APPLN. INFO.:			MC	19670308
IT 25220-40-0P	25220-41-1P	25220-50-2P		
25220-51-3P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 25220-40-0	CAPLUS			
CN Piperazine, 1-phenyl-4-[3-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-				
(CA INDEX NAME)				



RN 25220-41-1 CAPLUS


CN Piperazine, 1-phenyl-4-[3-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl


RN 25220-50-2 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[3-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)



RN 25220-51-3 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[3-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L8 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1969:114407 CAPLUS

DOCUMENT NUMBER: 70:114407

ORIGINAL REFERENCE NO.: 70:21339a,21342a

TITLE: Triazoles. X. Hydrogen bonding and infrared spectra

AUTHOR(S): Browne, E. J.; Polya, J. B.

CORPORATE SOURCE: Univ. Tasmania, Hobart, Australia

SOURCE: Journal of the Chemical Society [Section] C: Organic (1969), (7), 1056-60

CODEN: JSOOAX; ISSN: 0022-4952


DOCUMENT TYPE: Journal

LANGUAGE: English

IT 23164-52-5

RL: PRP (Properties)


(hydrogen bonding in)
 RN 23164-52-5 CAPLUS
 CN Pyridine, 4,4'-[methylenebis(s-triazole-5,3-diyl)]di- (8CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L8 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1968:452176 CAPLUS
 DOCUMENT NUMBER: 69:52176
 ORIGINAL REFERENCE NO.: 69:9755a,9758a
 TITLE: Analgetic and antiinflammatory
 5-(piperazinoalkylene)-1,2,4-oxadiazoles
 INVENTOR(S): Mauvernay, Roland Y.; Busch, Norbert
 PATENT ASSIGNEE(S): Mauvernay, Roland Y.
 SOURCE: Brit., 11 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1110360		19680418	GB 1967-5586	19670206
DE 1695392			DE	
PRIORITY APPLN. INFO.:			MC	19660216
IT 20491-84-3P	20491-85-4P			
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 20491-84-3	CAPLUS			
CN Piperazine, 1-phenyl-4-[3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)				



● 3 HCl

RN 20491-85-4 CAPLUS
 CN Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

124.64

747.26

FILE 'REGISTRY' ENTERED AT 06:18:55 ON 25 JAN 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 06:33:36 ON 25 JAN 2012

FILE 'REGISTRY' ENTERED AT 06:33:36 ON 25 JAN 2012

COPYRIGHT (C) 2012 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	4.16	751.42

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	4.16	751.42

FILE 'REGISTRY' ENTERED AT 06:33:48 ON 25 JAN 2012
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3
 DICTIONARY FILE UPDATES: 24 JAN 2012 HIGHEST RN 1354086-77-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express
 8.4\Queries\10584025ab3-py.str



chain nodes :

8 16 17 21

ring nodes :

1 2 3 4 5 9 10 11 12 13 14

chain bonds :

2-9 5-21 8-21

ring bonds :

1-2 1-5 2-3 3-4 4-5 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-5 2-3 2-9 3-4 4-5 5-21 8-21
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 9 :

G1:O,N

G2:[@1],[@2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 16:Atom 17:Atom 21:CLASS

Generic attributes :

16:

Saturation : Saturated

Type of Ring System : Monocyclic

17:

Type of Ring System : Monocyclic

L9 STRUCTURE UPLOADED

=> s l9 sss full

FULL SEARCH INITIATED 06:34:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 67488 TO ITERATE

100.0% PROCESSED 67488 ITERATIONS

912 ANSWERS

SEARCH TIME: 00.00.01

L10 912 SEA SSS FUL L9

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

203.77

955.19

FILE 'CAPLUS' ENTERED AT 06:34:26 ON 25 JAN 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2012 VOL 156 ISS 5

FILE LAST UPDATED: 24 Jan 2012 (20120124/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 110

L11 30 L10

=> d 111 1-30 ibib hitstr

L11 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:390644 CAPLUS

DOCUMENT NUMBER: 155:201200

TITLE: Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. [Erratum to document cited in CA155:029889]

AUTHOR(S): Thangapandian, Sundarapandian; John, Shalini; Sakkiah, Sugunadevi; Lee, Keun Woo

CORPORATE SOURCE: Division of Applied Life Science (BK21 Program), Environmental Biotechnology National Core Research Center (EB-NCRC), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University (GNU), Jinju, 660-701, S. Korea

SOURCE: Journal of Molecular Graphics
& Modelling (2011), 29(6), 894

CODEN: JMGMTI; ISSN: 1093-3263

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 1310491-13-4

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery (Erratum))

RN 1310491-13-4 CAPLUS

CN 3H-1,2,4-Triazole-3-thione, 5-[4-[2,5-dihydro-5-(3-pyridinyl)-1H-1,2,4-triazol-3-yl]butyl]-1,2-dihydro- (CA INDEX NAME)



L11 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:1482311 CAPLUS

DOCUMENT NUMBER: 155:29889

TITLE: Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery

AUTHOR(S): Sundarapandian, Thangapandian; Shalini, John; Sugunadevi, Sakkiah; Woo, Lee Keun

CORPORATE SOURCE: Division of Applied Life Science (BK21 Program),
Environmental Biotechnology National Core Research
Center (EB-NCRC), Plant Molecular Biology and
Biotechnology Research Center (PMBBRC), Gyeongsang
National University (GNU), Jinju, 660-701, S. Korea
JOURNAL OF MOLECULAR GRAPHICS

SOURCE:
& Modelling (2010),
29(3), 382-395
CODEN: JMGMEI; ISSN: 1093-3263

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 1310491-13-4

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)

(docking-enabled pharmacophore model for histone deacetylase 8
inhibitors and its application in anti-cancer drug discovery)

RN 1310491-13-4 CAPLUS

CN 3H-1,2,4-Triazole-3-thione, 5-[4-[2,5-dihydro-5-(3-pyridinyl)-1H-1,2,4-
triazol-3-yl]butyl]-1,2-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:1154529 CAPLUS

DOCUMENT NUMBER: 153:595427

TITLE: Azole derivatives as histamine H3 receptor
antagonists, Part 2: C-C and C-S coupled heterocycles

AUTHOR(S): Walter, M.; Isensee, K.; Kottke, T.; Ligneau, X.;
Camelin, J.-C.; Schwartz, J.-C.; Stark, H.

CORPORATE SOURCE: Institute of Pharmaceutical Chemistry, Biozentrum,
ZAFES/LIFF/CMP/ICNF, Johann Wolfgang Goethe
University, Frankfurt, 60438, Germany

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2010),

20(19), 5883-5886

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 153:595427


IT 1254304-54-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(azole derivs. as histamine H3 receptor antagonists)

RN 1254304-54-5 CAPLUS

CN Pyridine, 3-[5-[4-(1-piperidinyl)butyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:437160 CAPLUS

DOCUMENT NUMBER: 152:429549

TITLE: Preparation of pyrrolidinone and piperidinone based
compounds as therapeutic calcium channel blockers

INVENTOR(S): Bhatia, Pramila A.; Doherty, George A.; Drizin, Irene;
Mack, Helmut; Perner, Richard J.; Stewart, Andrew O.;
Zhang, Qing Wei

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 219pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010039947	A1	20100408	WO 2009-US59215	20091001
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2737480	A1	20100408	CA 2009-2737480	20091001
US 20100093730	A1	20100415	US 2009-571862	20091001
US 8044069	B2	20111025		
EP 2350002	A1	20110803	EP 2009-737258	20091001
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR				
CN 102239146	A	20111109	CN 2009-80148415	20091001
MX 2011003533	A	20110616	MX 2011-3533	20110401
PRIORITY APPLN. INFO.:			US 2008-102132P	P 20081002
			WO 2009-US59215	W 20091001

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:429549; MARPAT 152:429549

IT 1219626-03-5P, 3,3-Diphenyl-1-[[3-[6-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-2-one 1219626-54-6P,
3,3-Diphenyl-1-[[3-[6-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-2-one 1219626-55-7P,
3,3-Bis(4-fluorophenyl)-1-[[3-[6-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-2-one 1219626-57-9P
1219626-65-9P, 3,3-Diphenyl-1-[[3-[5-(trifluoromethyl)pyridin-3-


yl]-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-2-one 1219626-66-0P
 , 3,3-Diphenyl-1-[[3-[4-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-2-one 1219626-68-2P,
 3,3-Diphenyl-1-[[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-2-one 1219626-79-5P, tert-Butyl
 [5-[5-[(2-oxo-3,3-diphenylpyrrolidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl]pyridin-2-yl]carbamate 1219626-83-1P
 1219626-87-5P, 3-(4-Fluorophenyl)-1-[[3-[6-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-2-one 1219627-35-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinone and piperidinone based compds. as therapeutic calcium channel blockers)


RN 1219626-03-5 CAPLUS

CN 2-Piperidinone, 3,3-diphenyl-1-[[3-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 1219626-54-6 CAPLUS

CN 2-Pyrrolidinone, 3,3-diphenyl-1-[[3-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 1219626-55-7 CAPLUS


CN 2-Pyrrolidinone, 3,3-bis(4-fluorophenyl)-1-[[3-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 1219626-57-9 CAPLUS
 CN 2-Pyrrolidinone, 1-[[3-(6-chloro-3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-3,3-diphenyl- (CA INDEX NAME)




RN 1219626-65-9 CAPLUS
 CN 2-Pyrrolidinone, 3,3-diphenyl-1-[[3-[5-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1219626-66-0 CAPLUS
 CN 2-Pyrrolidinone, 3,3-diphenyl-1-[[3-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1219626-68-2 CAPLUS
 CN 2-Pyrrolidinone, 3,3-diphenyl-1-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



RN 1219626-79-5 CAPLUS
 CN Carbamic acid, N-[5-[5-[(2-oxo-3,3-diphenyl-1-pyrrolidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1219626-83-1 CAPLUS
 CN 2-Pyrrolidinone, 1-[[3-(6-amino-3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-3,3-diphenyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 1219626-87-5 CAPLUS
 CN 2-Pyrrolidinone, 3-(4-fluorophenyl)-1-[[3-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



RN 1219627-35-6 CAPLUS
 CN 2-Pyrrolidinone, 1-[[3-(6-amino-3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-3,3-diphenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2009:846111 CAPLUS
 DOCUMENT NUMBER: 151:92848
 TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds
 INVENTOR(S): Goldfarb, David Scott
 PATENT ASSIGNEE(S): University of Rochester, USA
 SOURCE: U.S. Pat. Appl. Publ., 57pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 20
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222

AU 2008345225 A1 20090709 AU 2008-345225 20081222
CA 2709784 A1 20090709 CA 2008-2709784 20081222
EP 2219646 A2 20100825 EP 2008-867410 20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, AL, BA, MK, RS
JP 2011507910 T 20110310 JP 2010-539936 20081222
PRIORITY APPLN. INFO.: US 2008-23801P P 20080125
US 2007-16362P P 20071221
US 2008-341615 20081222
WO 2008-US88016 W 20081222
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IT 431978-54-0
RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)
RN 431978-54-0 CAPLUS
CN Pyridine, 3-[5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



L11 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2009:487838 CAPLUS
DOCUMENT NUMBER: 150:464270
TITLE: Substituted 1,2,4-oxadiazoles and analogs thereof as
CB2 receptor modulators, useful in the treatment of
pain, respiratory and non-respiratory diseases
INVENTOR(S): Wu, Zhicai; Hartnett, John C.
PATENT ASSIGNEE(S): Merck & Co, Inc., USA
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009051705	A1	20090423	WO 2008-US11729	20081014
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2211619	A1	20100804	EP 2008-839447	20081014
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			

US 20100227845 A1 20100909 US 2010-738192 20100415
PRIORITY APPLN. INFO.: US 2007-999405P P 20071018
WO 2008-US11729 W 20081014

OTHER SOURCE(S): MARPAT 150:464270


IT 1146522-14-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(oxadiazoles and analogs as CB2 receptor modulators)

RN 1146522-14-6 CAPLUS

CN Pyridine, 2-butoxy-3-[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]- (CA
INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:1249176 CAPLUS

DOCUMENT NUMBER: 150:28356

TITLE: Identification and SAR around
N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-
[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a
selective $\alpha 2C$ adrenergic receptor antagonist

AUTHOR(S): Patel, Snahel D.; Habeski, Wendy M.; Min, Hyunsuk;
Zhang, Jiansu; Roof, Robin; Snyder, Bradley; Bora,
Gary; Campbell, Brian; Li, Cheryl; Hidayetoglu, Debra;
Johnson, Douglas S.; Chaudhry, Archana; Charlton,
Maura E.; Kablaoui, Natasha M.

CORPORATE SOURCE: Pfizer Global Research and Development, Cambridge
Laboratories, Cambridge, MA, 02139, USA

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2008),

18(20), 5689-5693

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:28356


IT 1092502-53-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)

(nicotinamides as $\alpha 2C$ adrenergic receptor antagonists)

RN 1092502-53-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]hexahydro-4-
[[3-(2-phenoxy-3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:771087 CAPLUS

DOCUMENT NUMBER: 149:128815

TITLE: Azacyclic compounds as inhibitors of cannabinoid
receptor 1 and their preparation, pharmaceutical
compositions and use in the treatment of CB1-mediated
diseases

INVENTOR(S): Liu, Hong; He, Xiaohui; Phillips, Dean; Zhu, Xuefeng;
Yang, Kunyong; Lau, Thomas; Wu, Baogen; Xie, Yongping;
Nguyen, Truc Ngoc; Wang, Xing

PATENT ASSIGNEE(S): IRM LLC, Bermuda

SOURCE: PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076754	A2	20080626	WO 2007-US87230	20071212
WO 2008076754	A3	20081224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007333992	A1	20080626	AU 2007-333992	20071212
CA 2672271	A1	20080626	CA 2007-2672271	20071212
KR 2009092322	A	20090831	KR 2009-7014668	20071212
EP 2121598	A2	20091125	EP 2007-865576	20071212
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2010513299	T	20100430	JP 2009-541554	20071212
AR 64353	A1	20090401	AR 2007-105623	20071214
MX 2009006339	A	20090821	MX 2009-6339	20090612
IN 2009DN04599	A	20100212	IN 2009-DN4599	20090714
CN 101600689	A	20091209	CN 2007-80050162	20090720
US 20100234365	A1	20100916	US 2010-519147	20100127
PRIORITY APPLN. INFO.:			US 2006-870339P	P 20061215
			US 2007-953595P	P 20070802

OTHER SOURCE(S): CASREACT 149:128815; MARPAT 149:128815
 IT 1035489-91-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of azacyclic compds. as inhibitors of
 cannabinoid receptor 1 useful in the treatment of CB1-associated diseases)
 RN 1035489-91-8 CAPLUS
 CN 2-Imidazolidinone, 3-(4-chlorophenyl)-1-[2-[5-(3-pyridinyl)-1,2,4-
 oxadiazol-3-yl]ethyl]-4-[3-(trifluoromethyl)phenyl]-, (4S)- (CA INDEX
 NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L11 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:319715 CAPLUS

DOCUMENT NUMBER: 148:331563

TITLE: Preparation of arylalkylpyridine derivatives for use
 as 5-lipoxygenase activating protein (FLAP) inhibitors
 INVENTOR(S): Ogawa, Anthony; Ujjainwalla, Feroze; Vande Bunte,
 Ellen K.; Chu, Lin; Ondeyka, Debra; Kopka, Ihor; Li,
 Bing; Ok, Hyun; Patel, Minal J.; Xu, Jinyou; Sisco,
 Rosemary

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 100pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008030369	A1	20080313	WO 2007-US18991	20070829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2007293373	A1	20080313	AU 2007-293373	20070829
CA 2666686	A1	20080313	CA 2007-2666686	20070829
EP 2064204	A1	20090603	EP 2007-837478	20070829

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

JP 2010502615	T	20100128	JP 2009-526695	20070829
US 20100168076	A1	20100701	US 2009-377136	20090211

PRIORITY APPLN. INFO.: US 2006-841758P P 20060901
US 2007-933886P P 20070608
US 2007-961598P P 20070723
WO 2007-US18991 W 20070829

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:331563; MARPAT 148:331563


IT 1011300-28-9P 1011300-30-3P 1011300-31-4P
1011300-32-5P 1011300-33-6P 1011300-34-7P
1011300-63-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylalkylpyridine derivs. for use as 5-lipoxygenase activating protein (FLAP) inhibitors)


RN 1011300-28-9 CAPLUS

CN Morpholine, 4-[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1011300-30-3 CAPLUS

CN Pyridine, 2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]-5-[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1011300-31-4 CAPLUS

CN Pyridine, 5-[5-[(4-fluoro-1-piperidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)



RN 1011300-32-5 CAPLUS


CN Pyridine, 2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]-5-[5-(1-pyrrolidinylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1011300-33-6 CAPLUS

CN Pyridine, 5-[5-[[(3S)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1011300-34-7 CAPLUS

CN Pyridine, 5-[5-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1011300-63-2 CAPLUS
 CN Morpholine, 4-[[3-[6-[1,2-dimethyl-1-[4-(2-pyridinylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




IT 1017807-51-0P 1017807-53-2P 1017807-61-2P
 1017807-64-5P 1017807-66-7P 1017807-68-9P
 1017807-71-4P 1017807-73-6P 1017807-76-9P
 1017807-78-1P 1017807-80-5P 1017807-82-7P
 1017811-56-1P 1017811-64-1P 1017811-76-5P
 1017811-88-9P 1017812-00-8P


RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prophetic drug candidate; preparation of arylalkylpyridine derivs. for use as 5-lipoxygenase activating protein (FLAP) inhibitors)

RN 1017807-51-0 CAPLUS
 CN 3-Azetidinol, 1-[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017807-53-2 CAPLUS
 CN Morpholine, 4-[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017807-61-2 CAPLUS

CN Pyridine, 2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]-5-[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1017807-64-5 CAPLUS

CN Pyridine, 5-[5-[(4-fluoro-1-piperidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)



RN 1017807-66-7 CAPLUS


CN Pyridine, 2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]-5-[5-(1-pyrrolidinylmethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1017807-68-9 CAPLUS


CN Pyridine, 5-[5-[[(3S)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1017807-71-4 CAPLUS
 CN Pyridine, 5-[5-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1017807-73-6 CAPLUS
 CN 3-Azetidinol, 1-[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017807-76-9 CAPLUS
 CN Pyridine, 5-[5-[[(3-fluoro-1-azetidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-78-1 CAPLUS
 CN Pyridine, 5-[5-[(3,3-difluoro-1-azetidiny)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-80-5 CAPLUS
 CN Pyridine, 5-[5-[(3-fluoro-1-azetidiny)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-82-7 CAPLUS
 CN Pyridine, 5-[5-[(3,3-difluoro-1-azetidiny)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017811-56-1 CAPLUS
 CN Morpholine, 4-[[3-[6-[1,2-dimethyl-1-[4-(2-pyrimidinylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017811-64-1 CAPLUS
 CN Morpholine, 4-[[3-[6-[1,2-dimethyl-1-[4-(2-thiazolylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017811-76-5 CAPLUS
 CN Morpholine, 4-[[3-[6-[2,2-dimethyl-1-[4-(2-pyridinylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



RN 1017811-88-9 CAPLUS
 CN Morpholine, 4-[[3-[6-[2,2-dimethyl-1-[4-(2-pyrimidinylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



RN 1017812-00-8 CAPLUS
 CN Morpholine, 4-[[3-[6-[2,2-dimethyl-1-[4-(2-thiazolylmethoxy)phenyl]propyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:619616 CAPLUS

DOCUMENT NUMBER: 147:31118

TITLE: Preparation of heterocycle-containing cyclohexane derivatives as NMDA subtype NR1/NR2B receptor antagonists

INVENTOR(S): Masui, Moriyasu; Mikamiyama, Hidenori; Tsuno, Naoki; Matsumura, Akira; Kai, Hiroyuki; Anan, Kousuke

PATENT ASSIGNEE(S): Shionogi & Co., Ltd.,

Japan
 SOURCE: PCT Int. Appl., 172pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063839	A1	20070607	WO 2006-JP323693	20061128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2005-345252 A 20051130

OTHER SOURCE(S): MARPAT 147:31118

IT 939041-91-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocycle-containing cyclohexane derivs. as NR1/NR2B receptor

antagonists for treating pains, stroke, head trauma, Alzheimer's disease, and other diseases)

RN 939041-91-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[3-[[cis-4-[(4-chlorophenyl)methyl]-1-hydroxycyclohexyl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:226910 CAPLUS

DOCUMENT NUMBER: 146:295903

TITLE: Preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compositions thereof

INVENTOR(S): Sindkhedkar, Milind D.; Bhavsar, Satish B.; Patil, Vijaykumar J.; Deshpande, Prasad K.; Patel, Mahesh V.

PATENT ASSIGNEE(S): Sindkhedkar, Milind, D., India; Bhavsar, Satish, B.; Patil, Vijaykumar, J.; Deshpande, Prasad, K.; Patel, Mahesh, V.

SOURCE: PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023507	A2	20070301	WO 2006-IN208	20060619
WO 2007023507	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005MU00723	A	20070706	IN 2005-MU723	20050620
EP 1912980	A2	20080423	EP 2006-821680	20060619
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20090018123	A1	20090115	US 2008-922239	20080808
PRIORITY APPLN. INFO.:			IN 2005-MU723	A 20050620
			WO 2006-IN208	W 20060619

OTHER SOURCE(S): CASREACT 146:295903; MARPAT 146:295903

IT 928158-11-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compns. thereof)

RN 928158-11-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]methyl]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)


L11 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2006:206835 CAPLUS

DOCUMENT NUMBER: 145:188802

TITLE: Search for conditions for synthesis of

O-(pyridinylcarbonyl)-3-aminopropionamidoximes and
 3-(aminoethyl)-5-pyridinyl-1,2,4-oxadiazoles
 AUTHOR(S): Orazbaeva, M. A.; Kayukova, L. A.; Praliev, K. D.
 CORPORATE SOURCE: Inst. Khim. Nauk im. A. B. Bekturova, MON RK, Almaty,
 Kazakhstan
 SOURCE: Izvestiya Natsional'noi Akademii Nauk Respubliki
 Kazakhstan, Seriya Khimicheskaya (2005), (6), 45-50
 CODEN: INANDJ
 PUBLISHER: Nauchno-Izdatel'skii Tsentr "Gylym"
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 145:188802
 IT 902799-94-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (acylation and heterocyclization of aminopropanamidoximes by
 pyridinecarbonyl chloride hydrochloride)
 RN 902799-94-4 CAPLUS
 CN Morpholine, 4-[2-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]ethyl]-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

L11 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2005:283475 CAPLUS
 DOCUMENT NUMBER: 142:355271
 TITLE: Substituted triazole derivatives as oxytocin
 antagonists, their preparation and use against sexual
 dysfunction
 INVENTOR(S): Brown, Alan Daniel; Ellis, David; Smith, Christopher
 Ronald
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028452	A1	20050331	WO 2004-IB2977	20040910
WO 2005028452	A9	20050721		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CA 2539297	A1	20050331	CA 2004-2539297	20040910
CA 2539297	C	20100720		
EP 1673355	A1	20060628	EP 2004-769366	20040910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014663	A	20061121	BR 2004-14663	20040910
JP 2007505888	T	20070315	JP 2006-526721	20040910
US 20050107382	A1	20050519	US 2004-944959	20040920
US 7291640	B2	20071106		
NL 1027084	A1	20050324	NL 2004-1027084	20040922
NL 1027084	C2	20060124		
MX 2006003158	A	20060605	MX 2006-3158	20060320
US 20080108625	A1	20080508	US 2007-928513	20071030
US 7649003	B2	20100119		
US 20100063064	A1	20100311	US 2009-621927	20091119
US 7875615	B2	20110125		

PRIORITY APPLN. INFO.:

	GB 2003-22159	A	20030922
	GB 2004-3150	A	20040212
	GB 2004-15110	A	20040705
	US 2004-535846P	P	20040112
	US 2004-556555P	P	20040326
	US 2004-588852P	P	20040716
	WO 2004-IB2977	W	20040910
	US 2004-944959	A3	20040920
	US 2007-928513	A3	20071030


OTHER SOURCE(S): CASREACT 142:355271; MARPAT 142:355271

IT 848953-71-9P 848953-73-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of triazole derivs. as oxytocin antagonists)


RN 848953-71-9 CAPLUS

CN Benzonitrile, 4-[5-[4-(6-methoxy-3-pyridinyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-2-pyridinyl]-3-methyl- (CA INDEX NAME)




RN 848953-73-1 CAPLUS

CN Pyridine, 2-(4-fluoro-2-methylphenyl)-5-[4-(6-methoxy-3-pyridinyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



IT 848953-21-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of triazole derivs. as oxytocin antagonists)
 RN 848953-21-9 CAPLUS
 CN Pyridine, 2-chloro-5-[4-(6-methoxy-3-pyridinyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
 RECORD (16 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2003:678512 CAPLUS
 DOCUMENT NUMBER: 139:214479
 TITLE: Preparation of 4-haloalkyl-3-heterocyclylpyridines,
 4-haloalkyl-5-heterocyclyl-pyrimidines and
 4-trifluoromethyl-3-oxadiazolylpyridines and their use
 as pesticides
 INVENTOR(S): Harmsen, Sven; Bastiaans, Henricus Maria Martinus;
 Schaper, Wolfgang; Tiebes, Jorg; Doller, Uwe; Jans,
 Daniela; Sanft, Ulrich; Hempel, Waltraud; Thonessen,
 Maria-theresia; Taapken, Thomas; Rook, Burkhard; Kern,
 Manfred
 PATENT ASSIGNEE(S): Hoechst Schering Agrevo GmbH, Germany
 SOURCE: U.S. Pat. Appl. Publ., 90 pp., Cont.-in-part of Ser.
 No. US 2001-808194, filed on 14 Mar 2001 which is
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030162812	A1	20030828	US 2002-56274	20020124
US 6699853	B2	20040302		
DE 19725450	A1	19981217	DE 1997-19725450	19970616
US 6239160	B1	20010529	US 1998-96748	19980612
DE 19858193	A1	20000621	DE 1998-19858193	19981217
US 20020013326	A1	20020131	US 2001-808194	20010314
US 6521610	B2	20030218		
PRIORITY APPLN. INFO.:			DE 1997-19725450	A 19970616
			US 1998-96748	A3 19980612
			DE 1998-19858193	A 19981217
			US 1999-461792	B3 19991215
			US 2001-808194	A2 20010314
OTHER SOURCE(S):			MARPAT 139:214479	
IT 1066483-57-5	1066484-31-8	1066485-08-2		
1066494-76-5	1066496-83-0	1066502-54-2		
RL: PRPH (Prophetic)				
(Preparation of 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines and their use as pesticides)				
RN 1066483-57-5	CAPLUS			
CN	Pyridine, 3-[5-(2-oxiranylmethyl)-1,2,4-oxadiazol-3-yl]-4-(trifluoromethyl)- (CA INDEX NAME)			




RN 1066484-31-8 CAPLUS
 CN Pyridine, 3-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1066485-08-2 CAPLUS
 CN Pyridine, 3-[3-(3-cyclohexylpropyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1066494-76-5 CAPLUS
 CN Pyridine, 3-[3-[2-(1H-tetrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1066496-83-0 CAPLUS
 CN Pyridine, 3-[3-(2-oxiranylmethyl)-1H-1,2,4-triazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1066502-54-2 CAPLUS
 CN Pyridine, 3-[3-(2-oxiranylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT 218276-88-1P 218276-90-5P 276682-76-9P
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines and their use as pesticides)
 RN 218276-88-1 CAPLUS
 CN Pyridine, 3-[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 218276-90-5 CAPLUS
 CN Pyridine, 3-[3-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 276682-76-9 CAPLUS
 CN 2,5-Pyrrolidinedione, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

L11 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:122994 CAPLUS

DOCUMENT NUMBER: 136:183826

TITLE: Preparation of heterocyclyl-alkyl-azole derivatives and use as pesticidal agents

INVENTOR(S): Schaper, Wolfgang; Bastiaans, Henricus Maria Martinus; Harmsen, Sven; Doeller, Uwe; Jans, Daniela; Hempel, Waltraud; Sanft, Ulrich; Thoenessen, Maria-Theresia

PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012229	A1	20020214	WO 2001-EP8876	20010801
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10039477	A1	20020221	DE 2000-10039477	20000808
AU 2002014948	A	20020218	AU 2002-14948	20010801
CA 2418945	A1	20030210	CA 2001-2418945	20010801
EP 1309588	A1	20030514	EP 2001-983437	20010801
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013062	A	20030701	BR 2001-13062	20010801
JP 2004505967	T	20040226	JP 2002-518204	20010801
US 20020132813	A1	20020919	US 2001-923197	20010806

IN 2003CN00167	A	20050408	IN 2003-CN167	20030128
MX 2003001208	A	20030630	MX 2003-1208	20030207
US 20040010145	A1	20040115	US 2003-418670	20030418
PRIORITY APPLN. INFO.:			DE 2000-10039477	A 20000808
			WO 2001-EP8876	W 20010801
			US 2001-923197	B1 20010806

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:183826

IT	1139494-12-4	1139494-13-5	1139494-14-6
	1139494-15-7	1139494-16-8	1139494-17-9
	1139494-18-0	1139494-19-1	1139494-20-4
	1139494-21-5	1139494-22-6	1139494-23-7
	1139494-24-8	1139494-25-9	1139494-26-0
	1139494-27-1	1139494-28-2	1139494-29-3
	1139494-30-6	1139494-31-7	1139494-32-8
	1139494-33-9	1139494-34-0	1139494-35-1
	1139494-37-3	1139494-38-4	1139494-42-0
	1139494-43-1	1139494-47-5	1139494-48-6
	1139494-49-7	1139494-50-0	1139494-51-1
	1139494-52-2	1139494-53-3	1139494-54-4
	1139494-55-5	1139494-58-8	1139494-59-9
	1139494-60-2	1139494-61-3	1139494-62-4
	1139494-63-5	1139494-64-6	1139494-65-7
	1139494-66-8	1139494-67-9	1139494-68-0
	1139494-69-1	1139494-70-4	1139494-71-5
	1139494-72-6	1139494-73-7	1139494-74-8
	1139494-75-9	1139494-76-0	1139494-77-1
	1139494-78-2	1139494-79-3	1139494-80-6
	1139494-81-7	1139494-82-8	1139494-83-9
	1139494-84-0	1139494-85-1	1139494-86-2
	1139494-87-3	1139494-88-4	1139494-89-5
	1139494-90-8	1139494-91-9	1139494-92-0
	1139494-93-1	1139494-94-2	1139494-95-3
	1139494-96-4	1139494-97-5	1139494-98-6
	1139494-99-7	1139495-00-3	1139495-01-4
	1139495-02-5	1139495-03-6	1139495-04-7
	1139495-05-8	1139495-06-9	1139495-07-0
	1139495-11-6	1139495-12-7	1139495-13-8
	1139495-14-9	1139495-15-0	1139495-16-1
	1139495-17-2	1139495-18-3	1139495-19-4
	1139495-20-7	1139495-22-9	1139495-23-0
	1139495-24-1	1139495-25-2	1139495-26-3
	1139495-27-4	1139495-28-5	1139495-29-6
	1139495-30-9	1139495-31-0	1139495-32-1
	1139495-33-2	1139495-34-3	1139495-35-4
	1139495-36-5	1139495-37-6	1139495-38-7
	1139495-39-8	1139495-40-1	1139495-41-2
	1139495-42-3	1139495-43-4	1139495-44-5
	1139495-45-6	1139495-46-7	1139495-47-8
	1139495-48-9	1139495-49-0	1139495-50-3
	1139495-52-5	1139495-53-6	1139495-54-7
	1139495-55-8	1139495-56-9	1139495-57-0
	1139495-58-1	1139495-59-2	1139495-60-5
	1139495-61-6	1139495-62-7	1139495-63-8
	1139495-64-9	1139495-65-0	1139495-66-1
	1139495-67-2	1139495-68-3	1139495-69-4
	1139495-70-7	1139495-71-8	1139495-72-9
	1139495-73-0	1139495-74-1	1139495-75-2
	1139495-76-3	1139495-77-4	1139495-78-5
	1139495-79-6	1139495-80-9	1139495-81-0
	1139495-82-1	1139495-83-2	1139495-84-3
	1139495-85-4	1139495-86-5	1139495-87-6


1139495-88-7	1139495-89-8	1139495-90-1
1139495-91-2	1139495-92-3	1139495-93-4
1139495-94-5	1139495-95-6	1139495-96-7
1139495-97-8	1139495-98-9	1139495-99-0
1139496-00-6	1139496-01-7	1139496-02-8
1139496-03-9	1139496-04-0	1139496-05-1
1139496-06-2	1139496-07-3	1139496-08-4
1139496-09-5	1139496-10-8	1139496-11-9
1139496-12-0	1139496-13-1	1139496-14-2
1139496-15-3	1139496-16-4	1139496-17-5
1139496-18-6	1139496-19-7	1139496-24-4
1139496-25-5	1139496-26-6	1139496-27-7
1139496-28-8	1139496-29-9	1139496-30-2
1139496-32-4	1139496-33-5	1139496-34-6
1139496-35-7	1139496-36-8	1139496-37-9
1139496-38-0	1139496-39-1	1139496-40-4
1139496-41-5	1139496-42-6	1139496-43-7
1139496-44-8	1139496-45-9	1139496-46-0
1139496-47-1	1139496-48-2	1139496-49-3
1139496-50-6	1139496-51-7	1139496-52-8
1139496-53-9	1139496-54-0	1139496-55-1
1139496-56-2	1139496-57-3	1139496-58-4
1139496-59-5	1139496-60-8	1139496-67-5
1139496-68-6	1139496-69-7	1139496-70-0
1139496-71-1	1139496-72-2	1139496-73-3
1139496-74-4		

RL: PRPH (Prophetic)

(Preparation of heterocyclyl-alkyl-azole derivatives and use as
pesticidal agents)


RN 1139494-12-4 CAPLUS

CN Pyridine, 3-[3-[4-[(ethylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-
oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-13-5 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(ethylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-
oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-14-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-15-7 CAPLUS

CN Pyridine, 3-[3-[2-(4-hexyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-16-8 CAPLUS

CN Pyridine, 3-[3-[2-[(4-(5-hexen-1-yl)-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-17-9 CAPLUS

CN Pyridine, 3-[3-[2-[4-(5-hexen-1-yl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-18-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(1,1-dimethylethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-19-1 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(1,1-dimethylethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-20-4 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[4-[(trimethylsilyl)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-21-5 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-[4-[(trimethylsilyl)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-22-6 CAPLUS

CN Pyridine, 3-[3-[4-methyl-4-phenyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-23-7 CAPLUS

CN Pyridine, 3-[3-[2-(4-methyl-4-phenyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-24-8 CAPLUS

CN Pyridine, 3-[3-[[4-(2-thienyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-25-9 CAPLUS

CN Pyridine, 3-[3-[2-[4-(2-thienyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-26-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-27-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-28-2 CAPLUS

CN Pyridine, 3-[3-[[4-(methoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-29-3 CAPLUS

CN Pyridine, 3-[3-[2-[4-(methoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-30-6 CAPLUS

CN Pyridine, 3-[3-[2-[4-(chloromethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-31-7 CAPLUS

CN Pyridine, 3-[3-[2-[4-(chloromethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-32-8 CAPLUS

CN Pyridine, 3-[3-[2-[4-(fluoromethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-33-9 CAPLUS

CN 1,3-Dioxolane-4-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139494-34-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-(ethoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-35-1 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(methylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-37-3 CAPLUS

CN Pyridine, 3-[3-(1,3-dioxolan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, 1-oxide (CA INDEX NAME)




RN 1139494-38-4 CAPLUS


CN Pyridine, 3-[3-[3-(1,3-dioxolan-2-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-42-0 CAPLUS
 CN Pyridine, 3-[3-(1,3-dioxan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, 1-oxide (CA INDEX NAME)




RN 1139494-43-1 CAPLUS
 CN Pyridine, 3-[3-[3-(1,3-dioxan-2-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-47-5 CAPLUS
 CN Pyridine, 3-[3-[(4,7-dihydro-1,3-dioxepin-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-48-6 CAPLUS
 CN Pyridine, 3-[3-[2-(4-methyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-49-7 CAPLUS
 CN Pyridine, 3-[3-[(4,4-dimethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-50-0 CAPLUS
 CN Pyridine, 3-[3-[2-(4,4-dimethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-51-1 CAPLUS
 CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,4,5-trimethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-52-2 CAPLUS
 CN Pyridine, 3-[3-[(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-53-3 CAPLUS
 CN Pyridine, 3-[3-[(4-ethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-54-4 CAPLUS
 CN Pyridine, 3-[3-[2-(4-ethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-55-5 CAPLUS
 CN Pyridine, 3-[3-[2-(4-propyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139494-58-8 CAPLUS
 CN Pyridine, 3-[3-[2-(5-methoxy-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-59-9 CAPLUS
 CN Pyridine, 3-[3-[2-(5-methoxy-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-60-2 CAPLUS

CN Pyridine, 3-[3-[(5-ethoxy-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-61-3 CAPLUS

CN Pyridine, 3-[3-[2-(5-ethoxy-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-62-4 CAPLUS

CN 1,3-Dioxane-5-methanol, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139494-63-5 CAPLUS

CN Pyridine, 3-[3-[[4-(2-pyridinylmethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-64-6 CAPLUS

CN Pyridine, 3-[3-[2-[4-(2-pyridinylmethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-65-7 CAPLUS

CN Pyridine, 3-[3-[[4-[(phenylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-66-8 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(phenylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-67-9 CAPLUS

CN Pyridine, 3-[3-[[4-[[[(phenylmethyl)thio]methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-68-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-[[[(phenylmethyl)thio]methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-69-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-70-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-71-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-72-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1139494-73-7 CAPLUS


CN Pyridine, 3-[3-[[4-[(2-methoxyphenoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139494-74-8 CAPLUS


CN Pyridine, 3-[3-[2-[4-[(2-methoxyphenoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)

1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-75-9 CAPLUS

CN Pyridine, 3-[3-[[4-[(2,2,2-trifluoroethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-76-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2,2,2-trifluoroethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-77-1 CAPLUS

CN Pyridine, 3-[3-[[4-(phenoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-78-2 CAPLUS


CN Pyridine, 3-[3-[2-[4-(phenoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-79-3 CAPLUS
 CN Pyridine, 3-[3-[[4-[(phenylmethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-80-6 CAPLUS
 CN Pyridine, 3-[3-[2-[4-[(phenylmethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-81-7 CAPLUS
 CN Pyridine, 3-[3-[2-(4-phenyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139494-82-8 CAPLUS
 CN Pyridine, 3-[3-[[4-(phenylmethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-83-9 CAPLUS
 CN Pyridine, 3-[3-[2-[4-(phenylmethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-84-0 CAPLUS

CN Pyridine, 3-[3-[(4-ethenyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-85-1 CAPLUS

CN Pyridine, 3-[3-[2-(4-ethenyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-86-2 CAPLUS

CN 1,3-Dioxolane-4-acetonitrile, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139494-87-3 CAPLUS

CN 1,3-Dioxolane-4-acetonitrile, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139494-88-4 CAPLUS

CN Acetamide, N-[[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-89-5 CAPLUS

CN Acetamide, N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-90-8 CAPLUS

CN Acetamide, N-methyl-N-[[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-91-9 CAPLUS

CN Acetamide, N-methyl-N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-92-0 CAPLUS


CN Pyridine, 3-[3-[[4-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-93-1 CAPLUS
 CN Pyridine, 3-[3-[2-[4-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-94-2 CAPLUS
 CN Methanesulfonamide, N-[[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)



RN 1139494-95-3 CAPLUS
 CN Methanesulfonamide, N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-96-4 CAPLUS
 CN Pyridine, 3-[3-[4-[(2-propen-1-yloxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-97-5 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2-propen-1-yloxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-98-6 CAPLUS

CN Pyridine, 3-[3-[4-[(2-propyn-1-yloxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-99-7 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2-propyn-1-yloxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-00-3 CAPLUS

CN 1,3-Dioxolane-4-methanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 4-acetate (CA INDEX NAME)




RN 1139495-01-4 CAPLUS


CN 1,3-Dioxolane-4-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 4-acetate (CA INDEX NAME)




RN 1139495-02-5 CAPLUS
 CN 1,3-Dioxolane-4-butanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-03-6 CAPLUS
 CN 1,3-Dioxolane-4-butanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-04-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1139495-05-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139495-06-9 CAPLUS
 CN Pyridine, 3-[3-[[4-[(2-methoxyethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-07-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2-methoxyethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-11-6 CAPLUS

CN 1,3-Dioxane-5-carboxylic acid, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139495-12-7 CAPLUS

CN 1,3-Dioxane-5-carboxylic acid, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139495-13-8 CAPLUS

CN Pyridine, 3-[3-[[(5-phenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-14-9 CAPLUS

CN Pyridine, 3-[3-[2-(5-phenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-15-0 CAPLUS

CN Pyridine, 3-[3-[2-[[5,5-bis(methoxymethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-16-1 CAPLUS

CN Pyridine, 3-[3-[2-[5,5-bis(methoxymethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-17-2 CAPLUS


CN Pyridine, 3-[3-[2-[5-(phenylmethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-18-3 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(phenylmethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-19-4 CAPLUS
 CN Pyridine, 3-[3-[5-ethyl-5-[(2-propen-1-yloxy)methyl]-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-20-7 CAPLUS
 CN Pyridine, 3-[3-[2-[(2S,4R)-4-methyl-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-22-9 CAPLUS
 CN Pyridine, 3-[3-[2-(4,4-dimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-23-0 CAPLUS
 CN Acetamide, N-[(4S,5R)-4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-24-1 CAPLUS
 CN Acetamide, N-[(4S,5R)-4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-25-2 CAPLUS
 CN Acetamide, N-[(4S,5S)-4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-26-3 CAPLUS
 CN Acetamide, N-[(4S,5S)-4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-27-4 CAPLUS
 CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,4,6-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-28-5 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[(4,5,5-trimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-29-6 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-30-9 CAPLUS

CN Pyridine, 3-[3-[(4-ethenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-31-0 CAPLUS

CN Pyridine, 3-[3-[2-(4-ethenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-32-1 CAPLUS

CN Pyridine, 3-[3-[[4-methyl-6-(2-propen-1-yl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-33-2 CAPLUS

CN Pyridine, 3-[3-[2-[4-methyl-6-(2-propen-1-yl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-34-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139495-35-4 CAPLUS

CN Pyridine, 3-[3-[2-(4,4,6,6-tetramethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-36-5 CAPLUS

CN 1,3-Dioxane-4-ethanol, 4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-37-6 CAPLUS

CN 1,3-Dioxane-4-ethanol, 4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-38-7 CAPLUS

CN Pyridine, 3-[3-[[4-(3-fluoropropyl)-4-methyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-39-8 CAPLUS


CN Pyridine, 3-[3-[2-[4-(3-fluoropropyl)-4-methyl-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-40-1 CAPLUS
 CN Pyridine, 3-[3-[5,5-dimethyl-4-(1-methylethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-41-2 CAPLUS
 CN Pyridine, 3-[3-[2-[5,5-dimethyl-4-(1-methylethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-42-3 CAPLUS
 CN Pyridine, 3-[3-[(4-phenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-43-4 CAPLUS
 CN Pyridine, 3-[3-[2-(4-phenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-44-5 CAPLUS
 CN Pyridine, 3-[3-[(5,5-dimethyl-4-phenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-45-6 CAPLUS

CN Pyridine, 3-[3-[2-(5,5-dimethyl-4-phenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-46-7 CAPLUS

CN Pyridine, 3-[3-[2-(5-methylene-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-47-8 CAPLUS

CN Acetamide, N-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl)methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-48-9 CAPLUS


CN Acetamide, N-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-49-0 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-50-3 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1139495-52-5 CAPLUS
 CN 1,3-Dioxan-5-one, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, O-methyloxime (CA INDEX NAME)




RN 1139495-53-6 CAPLUS
 CN 1,3-Dioxan-5-one, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, O-methyloxime (CA INDEX NAME)




RN 1139495-54-7 CAPLUS

CN Acetamide, N-[5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-55-8 CAPLUS

CN Acetamide, N-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-56-9 CAPLUS

CN 1,3-Dioxane-5-methanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-57-0 CAPLUS

CN 1,3-Dioxane-5-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-58-1 CAPLUS


CN Pyridine, 3-[3-[5-(fluoromethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-59-2 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(fluoromethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-60-5 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(2-fluoroethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-61-6 CAPLUS
 CN Pyridine, 3-[3-[2-(5-ethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-62-7 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(2-ethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-63-8 CAPLUS

CN Pyridine, 3-[3-[2-(5-propyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-64-9 CAPLUS

CN Pyridine, 3-[3-[(5-ethyl-5-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-65-0 CAPLUS

CN Pyridine, 3-[3-[2-(5-ethyl-5-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-66-1 CAPLUS

CN Pyridine, 3-[3-[(5,5-diethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-67-2 CAPLUS

CN Pyridine, 3-[3-[2-(5,5-diethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-68-3 CAPLUS

CN 1,3-Dioxane-5,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
5,5-dimethyl ester (CA INDEX NAME)




RN 1139495-69-4 CAPLUS

CN 1,3-Dioxane-5,5-dicarboxylic acid,
2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-,
5,5-dimethyl ester (CA INDEX NAME)




RN 1139495-70-7 CAPLUS

CN 1,3-Dioxane-5,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
5,5-diethyl ester (CA INDEX NAME)




RN 1139495-71-8 CAPLUS


CN 1,3-Dioxane-5,5-dicarboxylic acid,
2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-,
5,5-diethyl ester (CA INDEX NAME)




RN 1139495-72-9 CAPLUS
CN Pyridine, 3-[3-[(2-methyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-
4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-73-0 CAPLUS
CN Pyridine, 3-[3-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-
4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-74-1 CAPLUS
CN Pyridine, 3-[3-[(2-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-
(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-75-2 CAPLUS
CN Pyridine, 3-[3-[2-(2-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-
(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-76-3 CAPLUS
 CN Pyridine, 3-[3-[2-(1,3-dithiolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-77-4 CAPLUS
 CN Pyridine, 3-[3-(1,3-dithian-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-78-5 CAPLUS
 CN Pyridine, 3-[3-[2-(1,3-dithian-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-79-6 CAPLUS
 CN Pyridine, 3-[3-[(2-methyl-1,3-dithiolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-80-9 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1,3-dithiolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-81-0 CAPLUS

CN Pyridine, 3-[3-[(2-methyl-1,3-dithian-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-82-1 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1,3-dithian-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-83-2 CAPLUS

CN Pyridine, 3-[3-(1,3-oxathiolan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-84-3 CAPLUS


CN Pyridine, 3-[3-[2-(1,3-oxathiolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-85-4 CAPLUS
 CN 1,3-Dioxolan-4-one, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-86-5 CAPLUS
 CN 1,3-Dioxolan-4-one, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-87-6 CAPLUS
 CN 1,3-Dioxolan-4-one, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-88-7 CAPLUS
 CN 1,3-Dioxolan-4-one, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-89-8 CAPLUS
 CN 1,3-Dioxolan-4-one, 5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-90-1 CAPLUS
 CN 1,3-Dioxolan-4-one, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-91-2 CAPLUS
 CN 1,3-Dioxan-4-one, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-92-3 CAPLUS
 CN 1,3-Dioxan-4-one, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-93-4 CAPLUS
 CN 1,3-Dioxan-4-one, 6-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-94-5 CAPLUS
 CN 1,3-Dioxan-4-one, 6-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-95-6 CAPLUS
 CN 1,3-Dioxan-4-one, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139495-96-7 CAPLUS
 CN 1,3-Dioxan-4-one, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-97-8 CAPLUS
 CN 1,3-Dioxan-4-one, 6,6-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-98-9 CAPLUS

CN 1,3-Dioxan-4-one, 6,6-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-99-0 CAPLUS

CN 5-Oxazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-00-6 CAPLUS

CN 5-Oxazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-01-7 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-02-8 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-03-9 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 5-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-04-0 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-05-1 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-4,4-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-06-2 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-4,4-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-07-3 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-08-4 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-09-5 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139496-10-8 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139496-11-9 CAPLUS

CN 4-Oxazolidinone, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-12-0 CAPLUS

CN 4-Oxazolidinone, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-13-1 CAPLUS

CN 4-Oxazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-14-2 CAPLUS

CN 4-Oxazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-15-3 CAPLUS

CN 4-Oxazolidinone, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-16-4 CAPLUS

CN 4-Oxazolidinone, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-17-5 CAPLUS


CN 4-Oxazolidinone, 3,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-18-6 CAPLUS
 CN 4-Oxazolidinone, 3,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-19-7 CAPLUS
 CN 1,3-Dioxane-5-methanol, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1139496-24-4 CAPLUS
 CN Pyridine, 3-[3-[5-(1,1-dimethylethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-25-5 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(1,1-dimethylethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-26-6 CAPLUS

CN Pyridine, 3-[3-[(5-methyl-5-nitro-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-27-7 CAPLUS

CN 1,3-Dioxane-5,5-dimethanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-28-8 CAPLUS

CN 1,3-Dioxane-5,5-dimethanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-29-9 CAPLUS

CN Pyridine, 3-[3-[[5,5-bis(fluoromethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-30-2 CAPLUS

CN Pyridine, 3-[3-[2-[5,5-bis(fluoromethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-32-4 CAPLUS

CN 4-Imidazolidinone, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-33-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-34-6 CAPLUS

CN 4-Imidazolidinone, 3,5,5-trimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-35-7 CAPLUS

CN 4-Imidazolidinone, 1,3,5,5-tetramethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-36-8 CAPLUS

CN 4-Imidazolidinone, 1,3,5,5-tetramethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-37-9 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-38-0 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-39-1 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-40-4 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-41-5 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-1-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-42-6 CAPLUS


CN 4(1H)-Pyrimidinone, tetrahydro-1-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-43-7 CAPLUS
 CN 4(1H)-Pyrimidinone, tetrahydro-1,3-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-44-8 CAPLUS
 CN 4(1H)-Pyrimidinone, tetrahydro-1,3-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-45-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139496-46-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139496-47-1 CAPLUS
 CN Ethanone, 1-[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-48-2 CAPLUS
 CN Ethanone, 1-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-49-3 CAPLUS
 CN Ethanone, 1-[3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-50-6 CAPLUS
 CN Ethanone, 1-[3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-51-7 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-52-8 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-53-9 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 1139496-54-0 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-55-1 CAPLUS
 CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-56-2 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-57-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-58-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-59-5 CAPLUS


CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-3-methyl-2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-60-8 CAPLUS
 CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester
 (CA INDEX NAME)




RN 1139496-67-5 CAPLUS
 CN 4-Oxazolidinone, 5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139496-68-6 CAPLUS
 CN 4-Oxazolidinone, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-69-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139496-70-0 CAPLUS

CN 4-Oxazolidinone, 3,5,5-trimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-71-1 CAPLUS

CN Ethanone, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-72-2 CAPLUS

CN Ethanone, 1-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-73-3 CAPLUS

CN Ethanone, 1-[5-methyl-2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)



RN 1139496-74-4 CAPLUS

CN Ethanone, 1-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




IT	1139496-75-5	1139496-76-6	1139496-77-7
	1139496-78-8	1139496-79-9	1139496-80-2
	1139496-81-3	1139496-82-4	1139496-83-5
	1139496-84-6	1139496-85-7	1139496-86-8
	1139496-87-9	1139496-88-0	1139496-89-1
	1139496-90-4	1139496-91-5	1139496-92-6
	1139496-93-7	1139496-94-8	1139497-17-8
	1139497-18-9	1139497-19-0	1139497-20-3
	1139497-21-4	1139497-22-5	1139497-23-6
	1139497-24-7	1139497-25-8	1139497-26-9
	1139497-27-0	1139497-28-1	1139497-29-2
	1139497-30-5	1139497-31-6	1196240-70-6
	1196240-71-7	1196240-73-9	1196240-74-0
	1196240-75-1	1196240-78-4	1196240-79-5
	1196240-80-8	1196240-81-9	1196240-84-2
	1196240-85-3	1196240-86-4	

RL: PRPH (Prophetic)

(Preparation of heterocycl-alkyl-azole derivatives and use as
pesticidal agents)


RN 1139496-75-5 CAPLUS

CN Ethanone, 1-[4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-76-6 CAPLUS

CN Ethanone, 1-[4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-77-7 CAPLUS

CN Ethanone, 1-[4,4-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-78-8 CAPLUS

CN Ethanone, 1-[4,4-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-79-9 CAPLUS

CN Ethanone, 1-[dihydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-2H-1,3-oxazin-3(4H)-yl]- (CA INDEX NAME)




RN 1139496-80-2 CAPLUS

CN Ethanone, 1-[dihydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-2H-1,3-oxazin-3(4H)-yl]- (CA INDEX NAME)




RN 1139496-81-3 CAPLUS


CN 2H-1,3-Oxazine-3(4H)-carboxylic acid,
dihydro-5,5-dimethyl-2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-
oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-82-4 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-carboxylic acid,
dihydro-5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-
oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-83-5 CAPLUS
CN Pyridine, 3-[3-[2-[5-ethyl-5-[(2-propen-1-yloxy)methyl]-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-84-6 CAPLUS
CN Pyridine, 3-[3-[2-[5-(phenylmethoxy)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-85-7 CAPLUS
CN Pyridine, 3-[3-[2-[5-(phenylmethoxy)-1,3-dioxan-2-yl]ethyl]-1,2,4-
oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-86-8 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 5-acetate (CA INDEX NAME)




RN 1139496-87-9 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 5-benzoate (CA INDEX NAME)



RN 1139496-88-0 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 5-benzoate (CA INDEX NAME)




RN 1139496-89-1 CAPLUS
 CN Pyridine, 3-[3-[5-(cyclopropylmethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-90-4 CAPLUS


CN Pyridine, 3-[3-[2-[5-(cyclopropylmethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-91-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139496-92-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1139496-93-7 CAPLUS
CN Benzamide, N-[5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139496-94-8 CAPLUS
CN Benzamide, N-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139497-17-8 CAPLUS

CN 6H-1,3-Oxazin-6-one, 3-acetyltetrahydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-18-9 CAPLUS

CN 6H-1,3-Oxazin-6-one, 3-acetyltetrahydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-19-0 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-carboxylic acid, dihydro-6-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139497-20-3 CAPLUS


CN 2H-1,3-Oxazine-3(4H)-carboxylic acid, dihydro-6-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139497-21-4 CAPLUS
 CN 4-Imidazolidinone, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-22-5 CAPLUS
 CN 4-Imidazolidinone, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-23-6 CAPLUS
 CN 4-Imidazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-24-7 CAPLUS
 CN 4-Imidazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-25-8 CAPLUS
 CN 4-Imidazolidinone, 1,3-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-26-9 CAPLUS
 CN 4-Imidazolidinone, 1,3-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-27-0 CAPLUS
 CN 4-Imidazolidinone, 1-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139497-28-1 CAPLUS
 CN 4-Imidazolidinone, 1-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-29-2 CAPLUS
 CN 4-Imidazolidinone, 1-acetyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-30-5 CAPLUS

CN 4-Imidazolidinone, 1-acetyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1139497-31-6 CAPLUS


CN 4-Imidazolidinone, 5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1196240-70-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1196240-71-7 CAPLUS


CN 1,3-Dioxolane-4,5-dicarboxylic acid, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 4,5-bis(1-methylethyl) ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-73-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1196240-74-0 CAPLUS
CN 1,3-Dioxolane-4,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
4,5-diethyl ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-75-1 CAPLUS
CN 1,3-Dioxolane-4,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
4,5-dimethyl ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-78-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1196240-79-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1196240-80-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1196240-81-9 CAPLUS

CN Pyridine, 3-[3-[2-[(4S,5S)-4,5-bis(methoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1196240-84-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1196240-85-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1196240-86-4 CAPLUS

CN Pyridine, 3-[3-[2-(5-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



IT	398125-52-5P	398125-53-6P	398125-54-7P
	398125-55-8P	398125-56-9P	398125-57-0P


398125-58-1P	398125-59-2P	398125-60-5P
398125-61-6P	398125-62-7P	398125-63-8P
398125-64-9P	398125-65-0P	398125-66-1P
398125-67-2P	398125-68-3P	398125-69-4P
399035-42-8P		

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclyl-alkyl-azole derivs. and use as pesticidal agents)


RN 398125-52-5 CAPLUS

CN Pyridine, 3-[3-(1,3-dioxepan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-53-6 CAPLUS

CN Pyridine, 3-[3-(1,3-dioxan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-54-7 CAPLUS

CN Pyridine, 3-[3-(1,3-dioxolan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-55-8 CAPLUS

CN Pyridine, 3-[3-[2-(1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-56-9 CAPLUS
 CN Pyridine, 3-[3-[(4-methyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-57-0 CAPLUS
 CN Pyridine, 3-[3-[[4R,5R]-4,5-dimethyl-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 398125-58-1 CAPLUS
 CN Pyridine, 3-[3-[(4-propyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-59-2 CAPLUS
 CN Pyridine, 3-[3-[[4-(fluoromethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-60-5 CAPLUS
 CN 1,3-Dioxolane-4-methanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 398125-61-6 CAPLUS

CN Pyridine, 3-[3-[[4-(ethoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-62-7 CAPLUS


CN Pyridine, 3-[3-[[4-[(methylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-63-8 CAPLUS

CN Pyridine, 3-[3-[[[(4R,5R)-4,5-bis(methoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 398125-64-9 CAPLUS

CN Pyridine, 3-[3-[[[(2R,4S)-4-methyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 398125-65-0 CAPLUS


CN Pyridine, 3-[3-[[(4R,6R)-4,6-dimethyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 398125-66-1 CAPLUS

CN Pyridine, 3-[3-[(4,4-dimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-67-2 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[(4,4,6-trimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 398125-68-3 CAPLUS


CN Pyridine, 3-[3-[(5,5-dimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-69-4 CAPLUS

CN Pyridine, 3-[3-[(trans-5-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 399035-42-8 CAPLUS

CN Pyridine, 3-[3-[[(4R,5S)-4,5-dimethyl-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:107339 CAPLUS

DOCUMENT NUMBER: 136:167289

TITLE: Preparation of lactam inhibitors of factor Xa which are useful for the treatment of thrombosis

INVENTOR(S): Stein, Philip D.; Shi, Yan; O'Connor, Stephen P.; Li, Chi

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010159	A1	20020207	WO 2001-US23932	20010730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020045616	A1	20020418	US 2001-916941	20010727
US 6511973	B2	20030128		
CA 2418071	A1	20020207	CA 2001-2418071	20010730
EP 1305309	A1	20030502	EP 2001-961808	20010730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000773	A2	20030929	HU 2003-773	20010730
JP 2004507464	T	20040311	JP 2002-515888	20010730
PRIORITY APPLN. INFO.:			US 2000-222498P	P 20000802
			WO 2001-US23932	W 20010730

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:167289

IT 396069-87-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lactam inhibitors of factor Xa for treatment of thrombosis)

RN 396069-87-7 CAPLUS

CN 2,5-Pyridinedicarboxamide, N5-[[[(3S)-hexahydro-2-oxo-1-[[3-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl)methyl]-1H-azepin-3-yl]imino][(2-methyl-5-benzofuranyl)amino)methyl]-N2,N2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2001:851132 CAPLUS

DOCUMENT NUMBER: 136:5994

TITLE: Preparation of triazole derivatives as glycine

transporter inhibitors useful as learning improving agents

INVENTOR(S): Tobe, Takahiko; Sugane, Takashi; Hamaguchi, Wataru; Shimada, Itsuro; Maeno, Kyoichi; Miyata, Junji; Kimizuka, Tetsuya; Suzuki, Takeshi; Kohara, Atsuyuki; Morita, Takuma; Arlt, Michael; Greiner, Hartmut

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent Gesellschaft mit Beschränkter Haftung

SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087855	A1	20011122	WO 2001-JP4128	20010517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001056769	A	20011126	AU 2001-56769	20010517
CA 2409819	A1	20021118	CA 2001-2409819	20010517
CA 2409819	C	20090915		
EP 1293503	A1	20030319	EP 2001-930192	20010517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002415	A2	20031128	HU 2003-2415	20010517
BR 2001010961	A	20040629	BR 2001-10961	20010517
CN 1237055	C	20060118	CN 2001-809616	20010517
JP 3873746	B2	20070124	JP 2001-584251	20010517
NO 2002005517	A	20021118	NO 2002-5517	20021118
MX 2002011373	A	20030626	MX 2002-11373	20021118
US 20030216385	A1	20031120	US 2002-276720	20021118
KR 776119	B1	20071116	KR 2002-7015529	20021118
IN 2002KN01528	A	20050311	IN 2002-KN1528	20021216
ZA 2002010245	A	20040318	ZA 2002-10245	20021218
US 20040214818	A1	20041028	US 2004-848386	20040519
US 7034047	B2	20060425		
US 20060025461	A1	20060202	US 2005-232011	20050922
US 7084164	B2	20060801		
PRIORITY APPLN. INFO.:			JP 2000-148419	A 20000519
			JP 2001-47921	A 20010223
			WO 2001-JP4128	W 20010517
			US 2002-276720	A3 20021118
			US 2004-848386	A3 20040519

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:5994


IT 374887-52-2P 374887-53-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of triazole derivs. as glycine transporter inhibitors)

RN 374887-52-2 CAPLUS

CN Pyridine, 5-[4-(2,6-difluorophenyl)-5-[(tetrahydro-2-furanyl)methyl]-4H-1,2,4-triazol-3-yl]-2-phenyl- (CA INDEX NAME)



RN 374887-53-3 CAPLUS
 CN Pyridine, 5-[4-(2,6-difluorophenyl)-5-[(tetrahydro-2H-pyran-4-yl)methyl]-4H-1,2,4-triazol-3-yl]-2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2001:488525 CAPLUS

DOCUMENT NUMBER: 135:76877

TITLE: Preparation of azolylalkyl(pyridinyl)oxadiazoles and analogs as acaricides and insecticides

INVENTOR(S): Schaper, Wolfgang; Bastiaans, Henricus; Harmsen, Sven; Doeller, Uwe; Tiebes, Joerg; Jans, Daniela; Hempel, Waltraud; Sanft, Ulrich; Thoenessen, Maria-theresia

PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany

SOURCE: Ger. Offen., 34 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962901	A1	20010705	DE 1999-19962901	19991223
WO 2001047918	A2	20010705	WO 2000-EP12375	20001208
WO 2001047918	A3	20020314		
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1244658	A2	20021002	EP 2000-981349	20001208

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2000017029	A	20030107	BR 2000-17029	20001208
JP 2004500367	T	20040108	JP 2001-549388	20001208
US 20020010098	A1	20020124	US 2000-746111	20001221
ZA 2002004961	A	20030414	ZA 2002-4961	20020620
MX 2002006318	A	20021213	MX 2002-6318	20020621
US 20040009992	A1	20040115	US 2003-463252	20030617

PRIORITY APPLN. INFO.:

DE 1999-19962901	A	19991223
WO 2000-EP12375	W	20001208
US 2000-746111	B1	20001221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:76877


IT 1066494-76-5	1099089-35-6	1099089-37-8
1099089-41-4	1099089-43-6	1099089-44-7
1099089-46-9	1099089-50-5	1099089-52-7
1099089-54-9	1099089-55-0	1099089-59-4
1099089-61-8	1099089-63-0	1099089-64-1
1099089-68-5	1099089-69-6	1099089-72-1
1099089-73-2	1099089-76-5	1099089-78-7
1099089-81-2	1099089-82-3	1099089-85-6
1099090-02-4	1099090-04-6	1099090-10-4
1099090-13-7	1099090-16-0	1099090-19-3
1099090-24-0	1099090-26-2	1099090-27-3
1099090-29-5	1099090-32-0	1099090-34-2
1099090-36-4	1099090-42-2	1099090-44-4
1099090-45-5	1099090-59-1	1099090-60-4
1099090-62-6	1099090-63-7	1099090-68-2
1099090-69-3	1099090-73-9	1099090-75-1
1099090-76-2	1099090-77-3	1099090-78-4
1099090-79-5	1099090-80-8	1099090-83-1
1099090-92-2	1099090-93-3	1099090-94-4
1099090-95-5	1099090-96-6	1099090-97-7
1099090-98-8	1099090-99-9	1099091-00-5
1099091-01-6	1099091-02-7	1099091-03-8
1099091-04-9	1099091-05-0	1099091-06-1
1099091-07-2	1099091-08-3	1099091-09-4
1099091-10-7	1099091-11-8	1099091-12-9
1099091-13-0	1099091-14-1	1099091-15-2
1099091-19-6	1099091-20-9	1099091-21-0
1099091-24-3	1099091-25-4	1099091-26-5
1099091-27-6	1099091-28-7	1099091-33-4
1099091-34-5	1099091-35-6	1099091-36-7
1099091-37-8	1099091-45-8	1099091-48-1
1099091-50-5	1099091-51-6	1099091-56-1
1099091-57-2	1099091-59-4	1099091-60-7
1099091-64-1	1099091-65-2	1099091-70-9
1099091-71-0	1099091-72-1	1099091-73-2
1099091-74-3	1099091-75-4	1099091-76-5
1099091-79-8	1099091-80-1	1099091-81-2
1099091-82-3	1099091-83-4	1099091-84-5
1099091-85-6	1099091-86-7	1099091-87-8
1099091-88-9	1099091-89-0	1099091-90-3
1099091-91-4	1099091-92-5	1099091-93-6
1099091-94-7	1099091-95-8	1099091-96-9
1099091-98-1	1099091-99-2	1099092-07-5
1099092-10-0	1099092-11-1	1099092-12-2
1099092-15-5	1099092-16-6	1099092-18-8
1099092-21-3	1099092-22-4	1099092-24-6
1099092-26-8	1099092-29-1	1099092-31-5
1099092-32-6	1099092-35-9	1099092-38-2
1099092-40-6	1099092-54-2	1099092-57-5

RL: PRPH (Prophetic)

(Preparation of azolylalkyl(pyridinyl)oxadiazoles and analogs as acaricides and insecticides)


RN 1066494-76-5 CAPLUS

CN Pyridine, 3-[3-[2-(1H-tetrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-35-6 CAPLUS

CN Pyridine, 3-[3-[2-(2H-1,2,3-triazol-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-37-8 CAPLUS

CN Pyridine, 3-[3-[3-(2H-1,2,3-triazol-2-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-41-4 CAPLUS

CN Pyridine, 3-[3-[3-(1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-43-6 CAPLUS

CN Pyridine, 3-[3-[3-(5-methyl-1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-44-7 CAPLUS

CN Pyridine, 3-[3-[(3,5-dimethyl-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-46-9 CAPLUS

CN Pyridine, 3-[3-[2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-50-5 CAPLUS

CN Pyridine, 3-[3-[3-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-52-7 CAPLUS

CN Pyridine, 3-[3-[(5-methyl-1H-tetrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-54-9 CAPLUS

CN Pyridine, 3-[3-[2-(5-methyl-1H-tetrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-55-0 CAPLUS

CN 1H-Imidazole-4-methanol, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099089-59-4 CAPLUS

CN Pyridine, 3-[3-[3-[4-(fluoromethyl)-1H-imidazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-61-8 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-methyl-1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099089-63-0 CAPLUS

CN Pyridine, 3-[3-[[2-(methylthio)-1H-imidazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-64-1 CAPLUS

CN Pyridine, 3-[3-[2-[5-(methylthio)-1H-imidazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-68-5 CAPLUS

CN Pyridine, 3-[3-[2-[5-(methylthio)-1H-1,2,4-triazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-69-6 CAPLUS

CN Pyridine, 3-[3-[(3-chloro-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-72-1 CAPLUS

CN Pyridine, 3-[3-[2-(3-chloro-1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-73-2 CAPLUS

CN Pyridine, 3-[3-[3-(3-chloro-1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-76-5 CAPLUS

CN Pyridine, 3-[3-[(3-chloro-4H-1,2,4-triazol-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099089-78-7 CAPLUS


CN 1H-Imidazole-4-acetonitrile, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099089-81-2 CAPLUS
 CN 1H-Imidazole-4-acetonitrile, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099089-82-3 CAPLUS
 CN 1H-1,2,4-Triazole-3-acetonitrile, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099089-85-6 CAPLUS
 CN Formamide, N-[1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 1099090-02-4 CAPLUS
 CN Pyridine, 3-[3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-04-6 CAPLUS
 CN Pyridine, 3-[3-[3-(4,5-dichloro-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-10-4 CAPLUS

CN Pyridine, 3-[3-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-13-7 CAPLUS

CN Pyridine, 4-(chlorodifluoromethyl)-3-[3-(1H-imidazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099090-16-0 CAPLUS

CN Pyridine, 3-[3-[3-(1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-19-3 CAPLUS

CN Pyridine, 3-[3-[4-(1H-imidazol-1-yl)butyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-24-0 CAPLUS

CN Pyridine, 3-[3-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-26-2 CAPLUS

CN Pyridine, 3-[3-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-27-3 CAPLUS

CN Pyridine, 3-[3-[3-(2-methyl-4-nitro-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-29-5 CAPLUS

CN Pyridine, 3-[3-[3-(4-bromo-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-32-0 CAPLUS


CN Pyridine, 3-[3-[2-(4-nitro-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-34-2 CAPLUS
 CN 1H-Pyrazole-4-carbonitrile, 3-(trifluoromethyl)-1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099090-36-4 CAPLUS
 CN Pyridine, 3-[3-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099090-42-2 CAPLUS
 CN Pyridine, 3-[3-[3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-44-4 CAPLUS
 CN Pyridine, 3-[3-[2-(4,5-dichloro-2-methyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-45-5 CAPLUS

CN Pyridine, 3-[3-[3-(4,5-dichloro-2-methyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-59-1 CAPLUS

CN Pyridine, 3-[3-[3-(4,5-dichloro-2-methyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-60-4 CAPLUS

CN Pyridine, 3-[3-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-62-6 CAPLUS

CN Pyridine, 3-[3-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-63-7 CAPLUS

CN 1H-Pyrazol-5-amine, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099090-68-2 CAPLUS

CN 1H-Imidazol-4-amine, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099090-69-3 CAPLUS

CN Pyridine, 3-[3-[(3-methyl-4H-1,2,4-triazol-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-73-9 CAPLUS

CN Pyridine, 3-[3-[(3-methyl-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-75-1 CAPLUS

CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099090-76-2 CAPLUS

CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099090-77-3 CAPLUS

CN 1H-Pyrazol-4-amine, 3,5-dimethyl-1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099090-78-4 CAPLUS


CN Pyridine, 3-[3-[(3-ethoxy-5-methyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-79-5 CAPLUS
 CN Pyridine, 3-[3-[2-(3-ethoxy-5-methyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-80-8 CAPLUS
 CN Pyridine, 3-[3-[3-(3-ethoxy-5-methyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099090-83-1 CAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, ethyl ester (CA INDEX NAME)




RN 1099090-92-2 CAPLUS
 CN 1H-Imidazole-4-methanol, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099090-93-3 CAPLUS

CN Pyridine, 3-[3-[[4-(fluoromethyl)-1H-imidazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-94-4 CAPLUS

CN Pyridine, 3-[3-[2-[4-(fluoromethyl)-1H-imidazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-95-5 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-methyl-1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099090-96-6 CAPLUS


CN Pyridine, 3-[3-[3-[5-(methylthio)-1H-imidazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-97-7 CAPLUS
 CN Pyridine, 3-[3-[3-[5-(methylthio)-1H-1,2,4-triazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-98-8 CAPLUS
 CN Pyridine, 3-[3-[2-(3-chloro-4H-1,2,4-triazol-4-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099090-99-9 CAPLUS
 CN Pyridine, 3-[3-[3-(3-chloro-4H-1,2,4-triazol-4-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099091-00-5 CAPLUS
 CN 1H-Imidazole-4-acetonitrile, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099091-01-6 CAPLUS
 CN 1H-1,2,4-Triazole-3-acetonitrile, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099091-02-7 CAPLUS

CN 1H-1,2,4-Triazole-3-acetonitrile, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099091-03-8 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[(3,4,5-trimethyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099091-04-9 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[3-(3,4,5-trimethyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099091-05-0 CAPLUS


CN Formamide, N-[1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1H-imidazol-2-yl]- (CA INDEX NAME)




RN 1099091-06-1 CAPLUS
 CN 1H-Pyrazol-4-amine, 3,5-dimethyl-1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099091-07-2 CAPLUS
 CN Formamide, N-[1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1H-imidazol-2-yl]- (CA INDEX NAME)




RN 1099091-08-3 CAPLUS
 CN 1H-Pyrazol-4-amine, 3,5-dimethyl-1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1099091-09-4 CAPLUS
 CN Pyridine, 3-[3-[[5-(methylthio)-1H-1,2,4-triazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-10-7 CAPLUS
 CN Pyridine, 3-[3-[[3-methyl-5-(methylthio)-1H-1,2,4-triazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-11-8 CAPLUS

CN Pyridine, 3-[3-[2-[3-methyl-5-(methylthio)-1H-1,2,4-triazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-12-9 CAPLUS

CN Pyridine, 3-[3-[5-(methylthio)-1H-tetrazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-13-0 CAPLUS

CN Pyridine, 3-[3-[3-[3-methyl-5-(methylthio)-1H-1,2,4-triazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-14-1 CAPLUS

CN Pyridine, 3-[3-[2-[5-(methylthio)-1H-tetrazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-15-2 CAPLUS

CN Pyridine, 3-[3-[3-[5-(methylthio)-1H-tetrazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-19-6 CAPLUS

CN Acetamide, N-[1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1099091-20-9 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1099091-21-0 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]-, methyl ester (CA INDEX NAME)




RN 1099091-24-3 CAPLUS

CN 1H-Imidazole-4-acetic acid, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1099091-25-4 CAPLUS

CN 1H-Imidazole-4-acetic acid, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]-, methyl ester (CA INDEX NAME)




RN 1099091-26-5 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, ethyl ester (CA INDEX NAME)




RN 1099091-27-6 CAPLUS

CN Pyridine, 3-[3-[(5-phenyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-28-7 CAPLUS

CN Pyridine, 3-[3-[(4-phenyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-33-4 CAPLUS

CN Pyridine, 3-[3-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-34-5 CAPLUS

CN Pyridine, 3-[3-[(2-(4,5-dichloro-1H-imidazol-1-yl)ethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-35-6 CAPLUS


CN Pyridine, 3-[3-[(2-(1H-1,2,3-triazol-1-yl)ethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-36-7 CAPLUS
 CN Pyridine, 3-[3-[3-(1H-1,2,3-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-37-8 CAPLUS
 CN Pyridine, 3-[3-[5-(1H-1,2,4-triazol-1-yl)pentyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-45-8 CAPLUS
 CN Pyridine, 3-[3-(4H-1,2,4-triazol-4-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-48-1 CAPLUS
 CN Pyridine, 3-[3-[3-(4H-1,2,4-triazol-4-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-50-5 CAPLUS
 CN Pyridine, 3-[3-[3-(5-chloro-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-51-6 CAPLUS
 CN Pyridine, 3-[3-[(3,5-dichloro-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-56-1 CAPLUS
 CN Pyridine, 3-[3-[(5-methyl-1H-1,2,4-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099091-57-2 CAPLUS
 CN Pyridine, 3-[3-(1H-tetrazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-59-4 CAPLUS
 CN Pyridine, 3-[3-[2-(3,5-dichloro-1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-60-7 CAPLUS

CN Pyridine, 3-[3-[3-(1H-tetrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-64-1 CAPLUS

CN Pyridine, 3-[3-[3-(5-methyl-1H-tetrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-65-2 CAPLUS

CN Pyridine, 3-[3-[3-(5-cyclopropyl-1H-tetrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-70-9 CAPLUS

CN Pyridine, 3-[3-[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-71-0 CAPLUS

CN Pyridine, 3-[3-[(3-methyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-72-1 CAPLUS

CN Pyridine, 3-[3-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-73-2 CAPLUS

CN 1H-Imidazol-5-amine, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099091-74-3 CAPLUS

CN Pyridine, 3-[3-[3-(2,4-dimethyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-75-4 CAPLUS

CN 1H-Imidazole-4-methanol, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099091-76-5 CAPLUS

CN Pyridine, 3-[3-[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-79-8 CAPLUS

CN Pyridine, 3-[3-[2-(4H-1,2,4-triazol-4-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-80-1 CAPLUS


CN Pyridine, 3-[3-[2-(5-chloro-1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-81-2 CAPLUS
 CN Pyridine, 3-[3-[3-(5-chloro-1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-82-3 CAPLUS
 CN Pyridine, 3-[3-[3-(3,5-dichloro-1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-83-4 CAPLUS
 CN Pyridine, 3-[3-[2-(5-methyl-1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099091-84-5 CAPLUS
 CN Pyridine, 3-[3-[2-(5-cyclopropyl-1H-tetrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-85-6 CAPLUS
 CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099091-86-7 CAPLUS

CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099091-87-8 CAPLUS

CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099091-88-9 CAPLUS

CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)




RN 1099091-89-0 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-methyl-1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1099091-90-3 CAPLUS

CN Pyridine, 3-[3-[(4-chloro-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-91-4 CAPLUS

CN Pyridine, 3-[3-[2-(4-chloro-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099091-92-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1099091-93-6 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(3,4,5-trimethyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099091-94-7 CAPLUS

CN Acetamide, N-[1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1099091-95-8 CAPLUS

CN Acetamide, N-[1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 1099091-96-9 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1099091-98-1 CAPLUS

CN 1H-Imidazole-4-acetic acid, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1099091-99-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]propyl]-, ethyl ester (CA INDEX NAME)




RN 1099092-07-5 CAPLUS

CN Pyridine, 3-[3-[2-(1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-10-0 CAPLUS

CN Pyridine, 3-[3-[5-(1H-imidazol-1-yl)pentyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-11-1 CAPLUS

CN Pyridine, 3-[3-[2-(4-methyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-12-2 CAPLUS

CN Pyridine, 3-[3-[3-(4-methyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-15-5 CAPLUS

CN Pyridine, 3-[3-[(2-ethyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-16-6 CAPLUS

CN Pyridine, 3-[3-[3-(2-ethyl-1H-imidazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-18-8 CAPLUS


CN Pyridine, 3-[3-[2-(2-methyl-4-nitro-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-21-3 CAPLUS
 CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-[4-(trifluoromethyl)-1H-pyrazol-1-yl]ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099092-22-4 CAPLUS
 CN Pyridine, 4-(trifluoromethyl)-3-[3-[3-[4-(trifluoromethyl)-1H-pyrazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099092-24-6 CAPLUS
 CN Pyridine, 3-[3-[2-(4-methyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-26-8 CAPLUS
 CN Pyridine, 3-[3-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-29-1 CAPLUS
 CN Pyridine, 3-[3-[3-(4-nitro-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-31-5 CAPLUS
 CN 1H-Pyrazole-4-carbonitrile, 3-(trifluoromethyl)-1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1099092-32-6 CAPLUS
 CN Pyridine, 3-[3-[2-(4-bromo-3-methyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099092-35-9 CAPLUS
 CN Pyridine, 3-[3-[3-(4-bromo-3-methyl-1H-pyrazol-1-yl)propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-38-2 CAPLUS
 CN Pyridine, 3-[3-[3-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1099092-40-6 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[3-(trifluoromethyl)-1H-pyrazol-1-yl]propyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1099092-54-2 CAPLUS

CN Pyridine, 3-[3-[(2,4-dimethyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1099092-57-5 CAPLUS

CN Pyridine, 3-[3-[2-(2,4-dimethyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT	347916-36-3P	347916-39-6P	347916-42-1P
	347916-45-4P	347916-50-1P	347916-52-3P
	347916-54-5P	347916-56-7P	347916-58-9P
	347916-60-3P	347916-62-5P	347916-64-7P
	347916-66-9P	347916-68-1P	347916-70-5P
	347916-72-7P	347916-73-8P	347916-74-9P
	347916-75-0P	347916-76-1P	347916-77-2P
	347916-78-3P	347916-79-4P	347916-81-8P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolylalkyl(pyridinyl)oxadiazoles and analogs as acaricides and insecticides)


RN 347916-36-3 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-39-6 CAPLUS

CN Pyridine, 3-[3-[2-(4-bromo-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-42-1 CAPLUS

CN Pyridine, 3-[3-(1H-imidazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-45-4 CAPLUS

CN Pyridine, 3-[3-[(5-methyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-50-1 CAPLUS

CN Pyridine, 3-[3-[2-(2-ethyl-4-methyl-1H-imidazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-52-3 CAPLUS

CN Pyridine, 3-[3-[(2-methyl-4-nitro-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-54-5 CAPLUS

CN Pyridine, 3-[3-(1H-pyrazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-56-7 CAPLUS

CN Pyridine, 3-[3-[(4-methyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-58-9 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[[4-(trifluoromethyl)-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 347916-60-3 CAPLUS

CN Pyridine, 3-[3-[(4-methyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-62-5 CAPLUS

CN Pyridine, 3-[3-[(4-bromo-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-64-7 CAPLUS

CN Pyridine, 3-[3-[(4-nitro-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-66-9 CAPLUS

CN 1H-Pyrazole-4-carbonitrile, 3-(trifluoromethyl)-1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 347916-68-1 CAPLUS

CN Pyridine, 3-[3-[(4-bromo-3-methyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-70-5 CAPLUS

CN Pyridine, 3-[3-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-72-7 CAPLUS

CN Pyridine, 3-[3-[(4,5-dichloro-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-73-8 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[[3-(trifluoromethyl)-1H-pyrazol-1-yl]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 347916-74-9 CAPLUS

CN Pyridine, 3-[3-[(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-75-0 CAPLUS

CN Pyridine, 3-[3-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-76-1 CAPLUS

CN Pyridine, 3-[3-[(1H-1,2,3-triazol-1-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-77-2 CAPLUS


CN Pyridine, 3-[3-[(2H-1,2,3-triazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 347916-78-3 CAPLUS
 CN Pyridine, 3-[3-(1H-1,2,4-triazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 347916-79-4 CAPLUS
 CN Pyridine, 3-[3-[2-(1H-1,2,4-triazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 347916-81-8 CAPLUS
 CN Pyridine, 3-[3-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L11 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2000:421136 CAPLUS

DOCUMENT NUMBER: 133:58805

TITLE: Preparation of
 4-trifluoromethyl-3-oxadiazolylpyridines as
 insecticides, acaricides, and nematocides.

INVENTOR(S): Harmsen, Sven; Bastiaans, Henricus Maria Martinus;
 Schaper, Wolfgang; Tiebes, Jorg; Doller, Uwe; Jans,
 Daniela; Sanft, Ulrich; Hempel, Waltraut; Thonessen,
 Maria-Theresia

PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035913	A1	20000622	WO 1999-EP9684	19991209
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19858193	A1	20000621	DE 1998-19858193	19981217
EP 1140922	A1	20011010	EP 1999-963446	19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002532497	T	20021002	JP 2000-588173	19991209
PRIORITY APPLN. INFO.:			DE 1998-19858193	A 19981217
			WO 1999-EP9684	W 19991209

OTHER SOURCE(S): MARPAT 133:58805


IT 1066494-76-5

RL: PRPH (Prophetic)

(Preparation of 4-trifluoromethyl-3-oxadiazolylpyridines as insecticides, acaricides, and nematocides.)

RN 1066494-76-5 CAPLUS

CN Pyridine, 3-[3-[2-(1H-tetrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT 276682-76-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-trifluoromethyl-3-oxadiazolylpyridines as insecticides, acaricides, and nematocides)

RN 276682-76-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)


REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN


ACCESSION NUMBER: 2000:420911 CAPLUS

DOCUMENT NUMBER: 133:54868
 TITLE: Preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as repellents
 INVENTOR(S): Knauf, Werner; Chapple, Andrew Charles; Wojtech, Eva; Rook, Burkhard
 PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035285	A1	20000622	WO 1999-EP9949	19991215
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19858191	A1	20000621	DE 1998-19858191	19981217
PRIORITY APPLN. INFO.:			DE 1998-19858191	A 19981217
OTHER SOURCE(S): MARPAT 133:54868				
IT 1066484-31-8	1066502-54-2			
RL: PRPH (Prophetic)				
(Preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as repellents)				
RN 1066484-31-8	CAPLUS			
CN	Pyridine, 3-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)			




RN 1066502-54-2 CAPLUS
 CN Pyridine, 3-[3-(2-oxiranylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT 218276-88-1P 218276-90-5P 218277-43-1P
 276684-85-6P 276684-87-8P 276684-95-8P
 276684-96-9P 276685-38-2P
 RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as insect repellent)


RN 218276-88-1 CAPLUS
 CN Pyridine, 3-[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 218276-90-5 CAPLUS
 CN Pyridine, 3-[3-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 218277-43-1 CAPLUS
 CN Oxazolium, 3-(2-chloroethyl)-4,5-dihydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, chloride (1:1) (CA INDEX NAME)




RN 276684-85-6 CAPLUS
 CN Pyridine, 3-[3-(2-thienylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 276684-87-8 CAPLUS
 CN Pyridine, 3-[3-(cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 276684-95-8 CAPLUS
 CN Pyridine, 3-[3-(2-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 276684-96-9 CAPLUS
 CN Pyridine, 3-[3-[2-(1H-pyrrol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 276685-38-2 CAPLUS
 CN 2-Pyrrolidinone, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1999:9849 CAPLUS
 DOCUMENT NUMBER: 130:66513
 TITLE: Preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as pesticides.
 INVENTOR(S): Tiebes, Jorg; Taapken, Thomas; Rook, Burkhard; Kern, Manfred; Sanft, Ulrich
 PATENT ASSIGNEE(S): Hoechst Schering Agrevo G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857969	A1	19981223	WO 1998-EP3321	19980603
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19725450	A1	19981217	DE 1997-19725450	19970616
CA 2294888	A1	19981223	CA 1998-2294888	19980603
AU 9886243	A	19990104	AU 1998-86243	19980603
AU 754182	B2	20021107		
EP 991648	A1	20000412	EP 1998-937442	19980603
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, PT				
TR 9903102	T2	20000421	TR 1999-3102	19980603
HU 2000002729	A2	20001128	HU 2000-2729	19980603
HU 2000002729	A3	20010228		
JP 2002504127	T	20020205	JP 1999-503659	19980603
CN 1102149	C	20030226	CN 1998-806236	19980603
BR 9810139	A	20000808	BR 1998-10139	19980606
TW 508352	B	20021101	TW 1998-109414	19980612
ZA 9805180	A	19981217	ZA 1998-5180	19980615
IN 1998MA01293	A	20050304	IN 1998-MA1293	19980615
MX 9912073	A	20010710	MX 1999-12073	19991216
PRIORITY APPLN. INFO.:			DE 1997-19725450	A 19970616
			WO 1998-EP3321	W 19980603

OTHER SOURCE(S): MARPAT 130:66513


IT 1066484-31-8 1066502-54-2

RL: PRPH (Prophetic)

(Preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as pesticides.)


RN 1066484-31-8 CAPLUS

CN Pyridine, 3-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1066502-54-2 CAPLUS


CN Pyridine, 3-[3-(2-oxiranylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT 218276-88-1P 218276-90-5P 218277-43-1P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as pesticides)
 RN 218276-88-1 CAPLUS
 CN Pyridine, 3-[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 218276-90-5 CAPLUS
 CN Pyridine, 3-[3-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 218277-43-1 CAPLUS
 CN Oxazolium, 3-(2-chloroethyl)-4,5-dihydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, chloride (1:1) (CA INDEX NAME)



● Cl⁻

OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1997:618093 CAPLUS

DOCUMENT NUMBER: 127:293249

ORIGINAL REFERENCE NO.: 127:57319a,57322a

TITLE: Preparation of quinoxalinediones as NMDA receptor antagonists

INVENTOR(S): Bull, David John; Carr, Christopher Lee; Fray, Michael Jonathan; Gautier, Elisabeth Colette Louise; Mowbray, Charles Eric; Stobie, Alan

PATENT ASSIGNEE(S): Pfizer Research and Development Company, N.V., UK; Pfizer Inc.; Bull, David John; Carr, Christopher Lee; Fray, Michael Jonathan; Gautier, Elisabeth Colette Louise; Mowbray, Charles Eric; Stobie, Alan

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732873	A1	19970912	WO 1997-EP995	19970227
W: AU, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, LK, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 454004	B	20010911	TW 1997-101412	19970205
CA 2248366	A1	19970912	CA 1997-2248366	19970227
CA 2248366	C	20020604		
AU 9720231	A	19970922	AU 1997-20231	19970227
AU 717972	B2	20000406		
EP 885212	A1	19981223	EP 1997-908156	19970227
EP 885212	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
CN 1213369	A	19990407	CN 1997-192923	19970227
CN 1103770	C	20030326		
JP 11506123	T	19990602	JP 1997-531429	19970227
JP 3110467	B2	20001120		
BR 9707851	A	19990727	BR 1997-7851	19970227
HU 9900975	A2	19990728	HU 1999-975	19970227
HU 9900975	A3	20011228		
NZ 331060	A	20000128	NZ 1997-331060	19970227
AT 208773	T	20011115	AT 1997-908156	19970227
ES 2163742	T3	20020201	ES 1997-908156	19970227
PT 885212	E	20020228	PT 1997-908156	19970227
IL 125491	A	20030706	IL 1997-125491	19970227
SK 283467	B6	20030805	SK 1998-1214	19970227
CZ 292792	B6	20031217	CZ 1998-2864	19970227
IN 1997DE00512	A	20050311	IN 1997-DE512	19970227
ZA 9701987	A	19980907	ZA 1997-1987	19970307
CA 2281580	A1	19980903	CA 1998-2281580	19980224
CA 2281580	C	20030422		
AU 9868279	A	19980918	AU 1998-68279	19980224
AU 723467	B2	20000824		
EP 973766	A1	20000126	EP 1998-913660	19980224
EP 973766	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

SI, LV, FI, RO

BR 9808126	A	20000308	BR 1998-8126	19980224
NZ 336842	A	20000526	NZ 1998-336842	19980224
JP 2000509730	T	20000802	JP 1998-537327	19980224
JP 3588363	B2	20041110		
HU 2000003612	A2	20011028	HU 2000-3612	19980224
HU 2000003612	A3	20030428		
CN 1121403	C	20030917	CN 1998-802879	19980224
AT 282608	T	20041215	AT 1998-913660	19980224
ES 2230685	T3	20050501	ES 1998-913660	19980224
ZA 9801603	A	19990826	ZA 1998-1603	19980226
NO 9804058	A	19981106	NO 1998-4058	19980903
US 6376490	B1	20020423	US 1998-157806	19980904
BG 63340	B1	20011031	BG 1998-102760	19980909
US 6333326	B1	20011225	US 1999-367303	19990802
NO 9904135	A	19991022	NO 1999-4135	19990826
MX 9907937	A	20000731	MX 1999-7937	19990826
HK 1025317	A1	20040102	HK 2000-104471	20000720
CN 1443763	A	20030924	CN 2003-107362	20030320
JP 2004269547	A	20040930	JP 2004-196277	20040702

PRIORITY APPLN. INFO.:

GB 1996-5027	A	19960309
WO 1997-EP995	W	19970227
GB 1997-15783	A	19970725
JP 1998-537327	A3	19980224
WO 1998-EP1275	W	19980224

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 127:293249

IT 197077-36-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxalinediones as NMDA receptor antagonists)

RN 197077-36-4 CAPLUS

CN 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro-5-[3-(4-morpholinylmethyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-4-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 197078-83-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoxalinediones as NMDA receptor antagonists)

RN 197078-83-4 CAPLUS

CN Quinoxaline, 6,7-dichloro-2,3-dimethoxy-5-[3-(4-morpholinylmethyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-4-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (21 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:890145 CAPLUS

DOCUMENT NUMBER: 123:313628

ORIGINAL REFERENCE NO.: 123:56215a,56218a

TITLE: Heteroaryl mupirocin derivatives useful as
antibacterial, antifungal or herbicidal agents

INVENTOR(S): Brown, Pamela; O'Hanlon, Peter John

PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9516686	A1	19950622	WO 1994-EP4136	19941213
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			GB 1993-25832	A 19931217
OTHER SOURCE(S):		MARPAT 123:313628		
IT 169603-37-6P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(preparation of heteroaryl mupirocin derivs. as antibacterial agents)				
RN 169603-37-6 CAPLUS				
CN L-Altritol, 1,5-anhydro-2,6-dideoxy-2-[[3-[1-methyl-2- [(trimethylsilyl)oxy]propyl]oxiranyl]methyl]-6-[3-(3-pyridinyl)-1,2,4- oxadiazol-5-yl]-3,4-bis-O-(trimethylsilyl)-, [2S-[2 α ,3 β (1S*,2R*)]]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 169603-38-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroaryl mupirocin derivs. as antibacterial agents)
 RN 169603-38-7 CAPLUS
 CN L-Altritol, 1,5-anhydro-2,6-dideoxy-2-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-6-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]-, [2S-[2 α ,3 β (1R*,2R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1971:76447 CAPLUS
 DOCUMENT NUMBER: 74:76447
 ORIGINAL REFERENCE NO.: 74:12411a,12414a
 TITLE: Piperazine derivatives, and their pharmacological activity
 INVENTOR(S): Mauvernay, Roland Y.
 SOURCE: Fr. M., 7 pp.
 CODEN: FMXXAJ
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

FR 6671	19690317	FR	
PRIORITY APPLN. INFO.:		MC	19660212
OTHER SOURCE(S):	MARPAT 74:76447		
IT 19580-59-7P	20491-83-2P	20492-08-4P	
21504-41-6P			
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)			
RN 19580-59-7	CAPLUS		
CN	Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX NAME)		




RN	20491-83-2	CAPLUS
CN	Piperazine, 1-phenyl-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)	




●3 HCl

RN	20492-08-4	CAPLUS
CN	Piperazine, 1-phenyl-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX NAME)	



RN	21504-41-6	CAPLUS
CN	Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)	



●3 HCl

L11 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1971:13156 CAPLUS

DOCUMENT NUMBER: 74:13156

ORIGINAL REFERENCE NO.: 74:2121a,2124a

TITLE: Therapeutic pyridyl-1,2,4-oxadiazoles

INVENTOR(S): Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso; Takacs, Kalman; Bako, Erzsebet; Leszkovszky, Gyorgy; Tardos, Laszlo; Vertesy, Csaba

PATENT ASSIGNEE(S): Chinoin Gyogyszer- es Vegyeszeti Termek Gyara Rt.

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1920037	A	19701112	DE 1969-1920037	19690419
US 3647809	A	19720307	US 1969-815520	19690408
IL 31990	A	19740516	IL 1969-31990	19690408
GB 1271302	A	19720419	GB 1969-1271302	19690414
AT 292727	B	19710910	AT 1969-3754	19690418
AT 292728	B	19710910	AT 1970-8156	19690418
FR 2007529	A5	19700113	FR 1969-12994	19690424
FR 2007529	B1	19730316		
CH 540925	A	19731015	CH 1969-6275	19690424
CH 542232	A	19731115	CH 1972-14769	19690424
BE 732131	A	19691001	BE 1969-732131	19690425
NL 6906401	A	19691028	NL 1969-6401	19690425
NO 124253	B	19720327	NO 1969-1733	19690425
BR 6908381	D0	19730208	BR 1969-208381	19690425
JP 48024394	B	19730720	JP 1969-32259	19690425
SE 368576	B	19740708	SE 1969-5909	19690425
CA 954858	A1	19740917	CA 1969-49755	19690425
PL 79435	B1	19750630	PL 1969-133199	19690425
			HU 1968-CI796	A 19680426

PRIORITY APPLN. INFO.:

IT 30074-40-9P 30252-03-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 30074-40-9 CAPLUS

CN Piperidine, 1-[[3-(3-pyridyl)-1,2,4-oxadiazol-5-yl]methyl]-, maleate (1:1)
(8CI) (CA INDEX NAME)

CM 1

CRN 15328-07-1

CMF C13 H16 N4 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 30252-03-0 CAPLUS

CN Pyridine, 3-[5-[2-(1-pyrrolidinyl)ethyl]-1,2,4-oxadiazol-3-yl]-, maleate
(1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27390-25-6

CMF C13 H16 N4 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L11 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN


ACCESSION NUMBER: 1970:100719 CAPLUS

DOCUMENT NUMBER: 72:100719

ORIGINAL REFERENCE NO.: 72:18273a,18276a

TITLE: Pyridyloxadiazole derivatives
 INVENTOR(S): Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso;
 Gonczi, Csaba; Takacs, Kalman; Bako, Erzsebet;
 Leszkovszky, Gyorgy; Tardos, Laszlo; Vertessy, Csaba
 PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt
 SOURCE: Hung., 24 pp.
 CODEN: HUXXAT
 DOCUMENT TYPE: Patent
 LANGUAGE: Hungarian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	HU 156976		19700131	HU	19680426
	FR 2007529			FR	
IT	15328-07-1P	27199-52-6P	27390-24-5P		
	27390-25-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	15328-07-1	CAPLUS			
CN	Piperidine, 1-[[3-(3-pyridyl)-1,2,4-oxadiazol-5-yl]methyl]- (8CI) (CA INDEX NAME)				



RN 27199-52-6 CAPLUS
 CN Pyridine, 3-[5-[2-(1-pyrrolidinyl)ethyl]-1,2,4-oxadiazol-3-yl]-, maleate
 (8CI) (CA INDEX NAME)

CM 1


CRN 27390-25-6
 CMF C13 H16 N4 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 27390-24-5 CAPLUS
CN Piperidine, 1-[[3-(3-pyridyl)-1,2,4-oxadiazol-5-yl]methyl]-, maleate (8CI)
(CA INDEX NAME)

CM 1


CRN 15328-07-1
CMF C13 H16 N4 O




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 27390-25-6 CAPLUS
CN Pyridine, 3-[5-[2-(1-pyrrolidinyl)ethyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



L11 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 1970:12737 CAPLUS
DOCUMENT NUMBER: 72:12737
ORIGINAL REFERENCE NO.: 72:2325a,2328a
TITLE: Antiinflammatory
5-aryl-3-[3-(1-piperazinyl)propyl]-1,2,4-oxadiazoles
INVENTOR(S): Mauvernay, Roland Y.
SOURCE: Brit., 15 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1164572		19690917	GB 1968-10238	19680301

PRIORITY APPLN. INFO.:

MC

19670308


IT 25220-42-2P 25220-43-3P 25220-52-4P

25220-53-5P 25220-60-4P 25304-45-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 25220-42-2 CAPLUS

CN Piperazine, 1-phenyl-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-
(CA INDEX NAME)



RN 25220-43-3 CAPLUS


CN Piperazine, 1-phenyl-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-,
hydrochloride (1:3) (CA INDEX NAME)



●3 HCl


RN 25220-52-4 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-
yl]propyl]- (CA INDEX NAME)




RN 25220-53-5 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-
yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 25220-60-4 CAPLUS
 CN Piperazine, 1-(4-chlorophenyl)-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 25304-45-4 CAPLUS
 CN Piperazine, 1-(4-chlorophenyl)-4-[3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]propyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L11 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1969:114407 CAPLUS
 DOCUMENT NUMBER: 70:114407
 ORIGINAL REFERENCE NO.: 70:21339a,21342a
 TITLE: Triazoles. X. Hydrogen bonding and infrared spectra
 AUTHOR(S): Browne, E. J.; Polya, J. B.
 CORPORATE SOURCE: Univ. Tasmania, Hobart, Australia
 SOURCE: Journal of the Chemical Society [Section] C: Organic
 (1969), (7), 1056-60
 CODEN: JSOAX; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English


IT 23164-59-2
 RL: PRP (Properties)
 (hydrogen bonding in)
 RN 23164-59-2 CAPLUS
 CN Pyridine, 3,3'-[methylenebis(s-triazole-5,3-diyl)]di- (8CI) (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L11 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1968:452176 CAPLUS
 DOCUMENT NUMBER: 69:52176
 ORIGINAL REFERENCE NO.: 69:9755a,9758a
 TITLE: Analgetic and antiinflammatory
 5-(piperazinoalkylene)-1,2,4-oxadiazoles
 INVENTOR(S): Mauvernay, Roland Y.; Busch, Norbert
 PATENT ASSIGNEE(S): Mauvernay, Roland Y.
 SOURCE: Brit., 11 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1110360		19680418	GB 1967-5586	19670206
DE 1695392			DE	
PRIORITY APPLN. INFO.:			MC	19660216
IT 19580-59-7P	20491-83-2P	20492-08-4P		
21504-41-6P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 19580-59-7	CAPLUS			
CN Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX NAME)				




RN 20491-83-2 CAPLUS
 CN Piperazine, 1-phenyl-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 20492-08-4 CAPLUS
CN Piperazine, 1-phenyl-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-
(CA INDEX NAME)



RN 21504-41-6 CAPLUS
CN Piperazine, 1-(4-fluorophenyl)-4-[3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]propyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

L11 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 1967:464402 CAPLUS
DOCUMENT NUMBER: 67:64402
ORIGINAL REFERENCE NO.: 67:12135a,12138a
TITLE: 3-(β-Pyridyl)-5-dialkylaminoalkyl-1,2,4-oxadiazoles
PATENT ASSIGNEE(S): Laboratoires Toraude
SOURCE: Neth. Appl., 26 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6611571		19670220	NL 1966-11571	19660817

FR 5654
PRIORITY APPLN. INFO.:

FR
GB 19650818
GB 19660708


OTHER SOURCE(S): MARPAT 67:64402

IT 15328-07-1P 15328-08-2P 15328-09-3P
15328-10-6P 15328-11-7P 15328-12-8P
15328-13-9P 15328-15-1P 15328-16-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 15328-07-1 CAPLUS

CN Piperidine, 1-[[3-(3-pyridyl)-1,2,4-oxadiazol-5-yl]methyl]- (8CI) (CA INDEX NAME)



RN 15328-08-2 CAPLUS

CN Piperidine, 1-[[3-(3-pyridyl)-1,2,4-oxadiazol-5-yl]methyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl


RN 15328-09-3 CAPLUS

CN Piperazine, 1,4-bis[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 15328-10-6 CAPLUS
CN Piperazine, 1,4-bis[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA
INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 15328-11-7 CAPLUS
CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-
(CA INDEX NAME)




RN 15328-12-8 CAPLUS
CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 15328-13-9 CAPLUS
 CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 15328-15-1 CAPLUS
 CN Morpholine, 4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 15328-16-2 CAPLUS
 CN 1H-Azepine, hexahydro-1-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	142.78	1097.97

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

CAS Information Use Policies apply and are available at:

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

```
=>
Connecting via Winsock to STN at pto-stn on port 23
```

LOGINID:SSPTASXS1626

```
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
```

NEWS	1	FEB	1	Instructor-led and on-demand STN training options available from CAS
NEWS	2	MAY	02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS	3	MAY	12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS	4	MAY	23	Enhanced performance of STN biosequence searches
NEWS	5	JUN	20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In

NEWS 6 JUN 20 INPADOC databases enhanced with first page images
 NEWS 7 JUN 20 PATDPA database updates to end in June 2011
 NEWS 8 JUN 26 MARPAT Enhancements Save Time and Increase Usability
 NEWS 9 JUL 25 STN adds Australian patent full-text database,
 AUPATFULL, including the new numeric search feature.
 NEWS 10 AUG 01 CA Sections Added to ACS Publications Web Editions
 Platform
 NEWS 11 AUG 16 INPADOC: Coverage of German Patent Data resumed,
 enhanced legal status
 NEWS 12 AUG 18 Upgrade now to STN Express, Version 8.5
 NEWS 13 SEP 01 CAS Journal Coverage Now Includes Ahead-of-Print
 Articles for More Than 100 Journal Titles
 NEWS 14 SEP 01 Older Versions of STN Express to be Discontinued
 Beginning in March 2012
 NEWS 15 SEP 09 USAN Database Updates Offer Superior Currency on STN(R)
 NEWS 16 SEP 26 STN Adds Canadian Patent Full-text Database - CANPATFULL
 NEWS 17 SEP 26 GEOREF and ENCOMPLIT databases were reloaded on
 September 24, 2011.
 NEWS 18 SEP 26 Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.
 NEWS 19 SEP 26 ECLA Thesaurus in CA/CAPLUS Improves Patent Searching on STN
 NEWS 20 SEP 26 Access AUPATFULL and CANPATFULL databases with STN Viewer
 NEWS 21 OCT 26 New STN Revolutionizes Patent Searching for Professionals
 NEWS 22 DEC 1 CA/CAPLUS Now Includes Examiner Citations for Japanese Patents
 NEWS 23 DEC 1 CAS Expands Global Patent Coverage - Intellectual Property
 Corporation of Malaysia Becomes 62nd Authority on CA/CAPLUS
 NEWS 24 DEC 5 STN on the Web Enhancements Include Compatibility with
 Microsoft Windows 7
 NEWS 25 DEC 14 Removal of ITRD and PATIPC databases from STN
 NEWS 26 DEC 15 Rolled-up IPC Core Codes Removed from IPC Reclassifications in
 Patent Databases on STN
 NEWS 27 JAN 12 Structure Graphics Have Been Added to Abstracts for
 MARPAT and CA/CAPLUS on STN
 NEWS 28 JAN 15 Online Access to Very Large Chemical Structure Images
 Enhanced on STN
 NEWS 29 JAN 26 IFICLS Updates Resume on STN
 NEWS 30 JAN 31 MEDLINE Reload - Updated MeSH Vocabulary and Two New
 Fields on STN
 NEWS 31 FEB 1 INPADOC Databases Enhanced with Japanese Patent
 Classifications, Current U.S. Classification and Japanese
 Legal Status.
 NEWS 32 FEB 3 Access More Than 32,000 Harmonized Tariff Codes Now in
 CHEMLIST on STN

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,
 AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN customer
 agreement. This agreement limits use to scientific research. Use
 for software development or design, implementation of commercial
 gateways, or use of CAS and STN data in the building of commercial
 products is prohibited and may result in loss of user privileges
 and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 02:36:35 ON 09 FEB 2012

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.24

0.24

FILE 'REGISTRY' ENTERED AT 02:36:51 ON 09 FEB 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2012 HIGHEST RN 1355771-51-5

DICTIONARY FILE UPDATES: 7 FEB 2012 HIGHEST RN 1355771-51-5

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengar+s\Documents\STN Express 8.4\Queries\10584025ok.str



chain nodes :

6 7 9 10 11 12 18

ring nodes :

1 2 3 4 5

chain bonds :

2-7 5-6 6-9 9-18

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 2-7 3-4 4-5 5-6 6-9 9-18

G1:[@1],[@2],[@3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 9:CLASS 10:Atom 11:Atom
12:Atom 18:CLASS

Generic attributes :

6:

Number of Carbon Atoms : less than 7

7:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : Exactly 1

Type of Ring System : Monocyclic

10:

Saturation : Saturated

Type of Ring System : Monocyclic

11:

Saturation : Saturated

Type of Ring System : Monocyclic

12:

Saturation : Saturated

Type of Ring System : Monocyclic

Element Count :

Node 7: Limited

N,Exact,1

C,Exact,5


Node 11: Limited

N,Min,1

L1 STRUCTURE UPLOADED

=>

Uploading C:\Users\sshterengar\Documents\STN Express 8.4\Queries\10584025okk.str



chain nodes :

6 7 9 10 11 12 18

ring nodes :

1 2 3 4 5

chain bonds :

2-7 5-6 6-9 9-18

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 2-7 3-4 4-5 5-6 6-9 9-18

G1:[@1],[@2],[@3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 9:CLASS 10:Atom 11:Atom
12:Atom 18:CLASS

Generic attributes :

6:

Number of Carbon Atoms : less than 7

7:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : Exactly 1

Type of Ring System : Monocyclic

10:

Saturation : Saturated

Type of Ring System : Monocyclic

11:

Saturation : Saturated

Type of Ring System : Monocyclic

12:

Saturation : Saturated

Type of Ring System : Monocyclic

Element Count :

Node 7: Limited

N,Exact,1

C,Exact,5

Node 11: Limited

N,Min,1

L2 STRUCTURE UPLOADED

=> s 11 sss full

FULL SEARCH INITIATED 02:37:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 580132 TO ITERATE

100.0% PROCESSED 580132 ITERATIONS

961 ANSWERS

SEARCH TIME: 00.00.03

L3 961 SEA SSS FUL L1

=> s 12 sss full

FULL SEARCH INITIATED 02:37:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 580132 TO ITERATE

100.0% PROCESSED 580132 ITERATIONS

299 ANSWERS

SEARCH TIME: 00.00.03

L4 299 SEA SSS FUL L2

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

407.02

407.26

FILE 'CAPLUS' ENTERED AT 02:37:39 ON 09 FEB 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2012 VOL 156 ISS 7
FILE LAST UPDATED: 8 Feb 2012 (20120208/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

CAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L5 14 L3

=> s 14

L6 5 L4

=> s 15 or 16

L7 19 L5 OR L6

=> d 17 1-19 ibib hitstr

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:297440 CAPLUS

DOCUMENT NUMBER: 154:361045

TITLE: Preparation of 5-phenylquinazoline derivatives as potassium ion channel inhibitors

INVENTOR(S): Johnson, James A.; Lloyd, John; Finlay, Heather; Jiang, Ji; Neels, James; Dhondi, Naveen Kumar; Gunaga, Prashantha; Banerjee, Abhisek; Adisechan, Ashokkumar

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 495pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2011028741 A1 20110310 WO 2010-US47430 20100901
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ,
TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AR 78326 A1 20111102 AR 2010-103247 20100903
PRIORITY APPLN. INFO.: US 2009-239452P P 20090903
OTHER SOURCE(S): CASREACT 154:361045; MARPAT 154:361045


IT 1272355-35-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of phenyl-quinazoline derivs. as potassium ion channel
inhibitors for treatment of arrhythmia)

RN 1272355-35-7 CAPLUS

CN Methanone, (4-amino-1-piperidinyl) [3-[5-[5-phenyl-4-[(2-
pyridinylmethyl)amino]-2-quinazolinyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




IT 1272357-21-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of phenyl-quinazoline derivs. as potassium ion channel
inhibitors for treatment of arrhythmia)

RN 1272357-21-7 CAPLUS

CN Carbamic acid, N-[1-[[3-[5-[5-phenyl-4-[(2-pyridinylmethyl)amino]-2-
quinazolinyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]carbonyl]-4-piperidinyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:881085 CAPLUS

DOCUMENT NUMBER: 153:174838

TITLE: Preparation of pyrrolidine-based compounds as dipeptidyl peptidase IV inhibitors

INVENTOR(S): Balasubramanian, Gopalan; Sakamuri, Sukumar; Singh, Gajendra; Dharmalingam, Sivanesan; Pooppady Xavier, Franklin; Narayanan, Shridhar; Mookkan, Jeyamurugan; Balasubramanian, Jeganatha Sivakumar; Rajalingam, Agneeswari; Kulathingal, Jayanarayan

PATENT ASSIGNEE(S): Orchid Research Laboratories Ltd., India

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010079413	A2	20100715	WO 2010-IB8	20100107
WO 2010079413	A3	20101202		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2009CH00065	A	20110527	IN 2009-CH65	20090109
CA 2749301	A1	20100715	CA 2010-2749301	20100107
AU 2010204144	A1	20110623	AU 2010-204144	20100107

KR 2011105820 A 20110927 KR 2011-7016632 20100107
 EP 2376447 A2 20111019 EP 2010-729125 20100107
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, SM, TR
 CN 102272099 A 20111207 CN 2010-80003840 20100107
 US 20110257164 A1 20111020 US 2011-140997 20110620
 MX 2011007340 A 20110721 MX 2011-7340 20110708
 PRIORITY APPLN. INFO.: IN 2009-CH65 A 20090109
 WO 2010-IB8 W 20100107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 153:174838; MARPAT 153:174838

IT 1234626-35-7P, (2S,4S)-4-Fluoro-1-[2-[[[(1S,3S)-1,2,2-trimethyl-3-
 [[5-(pyridin-4-yl)-1,2,4-oxadiazol-3-
 yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrrolidine-based compds. as dipeptidyl
 peptidase IV inhibitors for treating diabetes, its complications, and
 other disorders)

RN 1234626-35-7 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[2-[[[(1S,3S)-1,2,2-trimethyl-3-[[5-
 (4-pyridinyl)-1,2,4-oxadiazol-3-yl)methyl]cyclopentyl]amino]acetyl]-,
 (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:877726 CAPLUS

DOCUMENT NUMBER: 153:204198

TITLE: Preparation of piperidine-containing compounds for
 treating and preventing metabolic and cerebrovascular
 diseases

INVENTOR(S): Rodriguez, Martha E.; Mareska, David A.; Hans, Jeremy
 J.; Harvey, Darren M.; Groneberg, Robert D.;
 O'Sullivan, Michael

PATENT ASSIGNEE(S): Array BioPharma Inc., USA

SOURCE: PCT Int. Appl., 338 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010080864	A1	20100715	WO 2010-US20304	20100107
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 EP 2375899 A1 20111019 EP 2010-729483 20100107
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR
 US 20110275608 A1 20111110 US 2011-143998 20110711
 PRIORITY APPLN. INFO.: US 2009-143868P P 20090112
 WO 2010-US20304 W 20100107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 153:204198; MARPAT 153:204198


IT 1235472-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-piperidinylmethyl amides for treating and preventing metabolic and cerebrovascular diseases)

RN 1235472-85-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-amino-5-cyano-6-ethoxy-N-[[1-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:242017 CAPLUS

DOCUMENT NUMBER: 152:278644


TITLE: Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate

AUTHOR(S): Shen, Hong C.; Ding, Fa-Xiang; Raghavan, Subharekha; Deng, Qiaolin; Luell, Silvi; Forrest, Michael J.; Carballo-Jane, Ester; Wilsie, Larissa C.; Krsmanovic, Mihajlo L.; Taggart, Andrew K.; Wu, Kenneth K.; Wu, Tsuei-Ju; Cheng, Kang; Ren, Ning; Cai, Tian-Quan; Chen, Qing; Wang, Junying; Wolff, Michael S.; Tong, Xinchun; Holt, Tom G.; Waters, M. Gerard; Hammond, Milton L.; Tata, James R.; Colletti, Steven L.


CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Merck

& Co., Inc., Rahway, NJ,


SOURCE: 07065-0900, USA
 Journal of Medicinal Chemistry (2010), 53(6),
 2666-2670
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 152:278644
 IT 1208866-45-8P 1208866-46-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (biaryl cyclohexene carboxylic acid derivs. as potent and selective
 high affinity niacin receptor agonists with reduced flushing profiles)
 RN 1208866-45-8 CAPLUS
 CN 1-Cyclohexene-1-carboxylic acid, 2-[[[1-[[3-(5-hydroxy-2-pyridinyl)-1,2,4-
 oxadiazol-5-yl]methyl]cyclopropyl]carbonyl]amino]- (CA INDEX NAME)



RN 1208866-46-9 CAPLUS
 CN 1-Cyclohexene-1-carboxylic acid, 2-[[[1-[[3-(5-hydroxy-2-pyridinyl)-1,2,4-
 oxadiazol-5-yl]methyl]cyclobutyl]carbonyl]amino]- (CA INDEX NAME)




IT 1208866-58-3P 1208866-59-4P 1208866-60-7P
 1208866-61-8P 1208866-62-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (biaryl cyclohexene carboxylic acid derivs. as potent and selective
 high affinity niacin receptor agonists with reduced flushing profiles)
 RN 1208866-58-3 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-[[3-[5-[(4-methoxyphenyl)methoxy]-2-
 pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]-, (4-methoxyphenyl)methyl ester
 (CA INDEX NAME)




RN 1208866-59-4 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[3-(5-hydroxy-2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1208866-60-7 CAPLUS

CN 1-Cyclohexene-1-carboxylic acid, 2-[[[1-[3-(5-hydroxy-2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]cyclopropyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 1208866-61-8 CAPLUS

CN 1,3-Dioxolan-4-one, 5-[[[3-[5-[(4-methoxyphenyl)methoxy]-2-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]-2,2-dimethyl- (CA INDEX NAME)



RN 1208866-62-9 CAPLUS

CN 1,3-Dioxolan-4-one, 5-[[3-(5-hydroxy-2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-2,2-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
 REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:1249176 CAPLUS

DOCUMENT NUMBER: 150:28356

TITLE: Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective α_2C adrenergic receptor antagonist

AUTHOR(S): Patel, Snahel D.; Habeski, Wendy M.; Min, Hyunsuk; Zhang, Jiansu; Roof, Robin; Snyder, Bradley; Bora, Gary; Campbell, Brian; Li, Cheryl; Hidayetoglu, Debra; Johnson, Douglas S.; Chaudhry, Archana; Charlton, Maura E.; Kablaoui, Natasha M.

CORPORATE SOURCE: Pfizer Global Research and Development, Cambridge Laboratories, Cambridge, MA, 02139, USA

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2008), 18(20), 5689-5693
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 150:28356

IT 1092502-53-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (nicotinamides as α_2C adrenergic receptor antagonists)

RN 1092502-53-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]hexahydro-4-[[3-(2-phenoxy-3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:770711 CAPLUS
 DOCUMENT NUMBER: 149:104431
 TITLE: 2-Adamantyl-butyramide derivatives as selective
 11 β -HSD1 inhibitors and their preparation,
 pharmaceutical compositions and use in the treatment
 of diseases
 INVENTOR(S): Roche, Didier; Cardinato, Denis; Doare, Liliane
 PATENT ASSIGNEE(S): Merck Sante, Fr.
 SOURCE: Eur. Pat. Appl., 32pp.; Chemical Indexing Equivalent
 to 149:104430 (WO)
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1935420	A1	20080625	EP 2006-292011	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
AU 2007334983	A1	20080626	AU 2007-334983	20071122
CA 2673430	A1	20080626	CA 2007-2673430	20071122
WO 2008074384	A1	20080626	WO 2007-EP10124	20071122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2094263	A1	20090902	EP 2007-856225	20071122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2010513337	T	20100430	JP 2009-541801	20071122
AR 64474	A1	20090401	AR 2007-105757	20071220
US 20100022597	A1	20100128	US 2009-520141	20090619
PRIORITY APPLN. INFO.:			EP 2006-292011	A 20061221
			WO 2007-EP10124	W 20071122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT 1034144-12-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of adamantyl butyramide derivs. as selective
 11- β -HSD1 inhibitors useful in the treatment of diseases)

RN 1034144-12-1 CAPLUS

CN Cyclopentaneacetamide, 1-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-N-
 tricyclo[3.3.1.1^{3,7}]dec-2-yl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:769948 CAPLUS

DOCUMENT NUMBER: 149:104430

TITLE: 2-Adamantyl-butamide derivatives as selective
11 β -HSD1 inhibitors and their preparation,
pharmaceutical compositions and use in the treatment
of diseases

INVENTOR(S): Roche, Didier; Carniato, Denis; Doare, Liliane;
Charon, Christine; Lerich, Caroline

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 67pp.; Chemical Indexing Equivalent to
149:104431 (EP)
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008074384	A1	20080626	WO 2007-EP10124	20071122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1935420	A1	20080625	EP 2006-292011	20061221
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
AU 2007334983	A1	20080626	AU 2007-334983	20071122
CA 2673430	A1	20080626	CA 2007-2673430	20071122

EP 2094263 A1 20090902 EP 2007-856225 20071122
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2010513337 T 20100430 JP 2009-541801 20071122
 US 20100022597 A1 20100128 US 2009-520141 20090619
 PRIORITY APPLN. INFO.: EP 2006-292011 A 20061221
 WO 2007-EP10124 W 20071122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:104430; MARPAT 149:104430


IT 1034144-12-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of adamantyl butyramide derivs. as selective
 11- β -HSD1 inhibitors useful in the treatment of diseases)

RN 1034144-12-1 CAPLUS

CN Cyclopentaneacetamide, 1-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-N-
 tricyclo[3.3.1.1^{3,7}]dec-2-yl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:319715 CAPLUS

DOCUMENT NUMBER: 148:331563

TITLE: Preparation of arylalkylpyridine derivatives for use
 as 5-lipoxygenase activating protein (FLAP) inhibitors
 INVENTOR(S): Ogawa, Anthony; Ujjainwalla, Feroze; Vande Bunte,
 Ellen K.; Chu, Lin; Ondeyka, Debra; Kopka, Ihor; Li,
 Bing; Ok, Hyun; Patel, Minal J.; Xu, Jinyou; Sisco,
 Rosemary

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 100pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008030369	A1	20080313	WO 2007-US18991	20070829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2007293373	A1	20080313	AU 2007-293373	20070829
CA 2666686	A1	20080313	CA 2007-2666686	20070829
EP 2064204	A1	20090603	EP 2007-837478	20070829
EP 2064204	B1	20120201		

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

JP 2010502615	T	20100128	JP 2009-526695	20070829
US 20100168076	A1	20100701	US 2009-377136	20090211

PRIORITY APPLN. INFO.: US 2006-841758P P 20060901
US 2007-933886P P 20070608
US 2007-961598P P 20070723
WO 2007-US18991 W 20070829

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:331563; MARPAT 148:331563


IT 1011300-31-4P 1011300-33-6P 1011300-34-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylalkylpyridine derivs. for use as 5-lipoxygenase activating protein (FLAP) inhibitors)

RN 1011300-31-4 CAPLUS


CN Pyridine, 5-[5-[(4-fluoro-1-piperidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)



RN 1011300-33-6 CAPLUS


CN Pyridine, 5-[5-[[[(3S)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1011300-34-7 CAPLUS
 CN Pyridine, 5-[5-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 1017807-51-0P 1017807-64-5P 1017807-68-9P
 1017807-71-4P 1017807-73-6P 1017807-76-9P
 1017807-78-1P 1017807-80-5P 1017807-82-7P
 RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prophetic drug candidate; preparation of arylalkylpyridine derivs. for use as 5-lipoxygenase activating protein (FLAP) inhibitors)
 RN 1017807-51-0 CAPLUS
 CN 3-Azetidinol, 1-[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017807-64-5 CAPLUS
 CN Pyridine, 5-[5-[[(4-fluoro-1-piperidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-68-9 CAPLUS
 CN Pyridine, 5-[5-[[[(3S)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1017807-71-4 CAPLUS
 CN Pyridine, 5-[5-[[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1017807-73-6 CAPLUS
 CN 3-Azetidinol, 1-[[[3-[6-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 1017807-76-9 CAPLUS

CN Pyridine, 5-[5-[(3-fluoro-1-azetidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-78-1 CAPLUS

CN Pyridine, 5-[5-[(3,3-difluoro-1-azetidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-1,2-dimethylpropyl]- (CA INDEX NAME)




RN 1017807-80-5 CAPLUS

CN Pyridine, 5-[5-[(3-fluoro-1-azetidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)



RN 1017807-82-7 CAPLUS

CN Pyridine, 5-[5-[(3,3-difluoro-1-azetidinyl)methyl]-1,2,4-oxadiazol-3-yl]-2-[1-[4-(5-methoxy-3-pyridinyl)phenyl]-2,2-dimethylpropyl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:619616 CAPLUS

DOCUMENT NUMBER: 147:31118

TITLE: Preparation of heterocycle-containing cyclohexane derivatives as NMDA subtype NR1/NR2B receptor antagonists

INVENTOR(S): Masui, Moriyasu; Mikamiyama, Hidenori; Tsuno, Naoki; Matsumura, Akira; Kai, Hiroyuki; Anan, Kousuke

PATENT ASSIGNEE(S): Shionogi & Co., Ltd.,

Japan

SOURCE: PCT Int. Appl., 172pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063839	A1	20070607	WO 2006-JP323693	20061128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2005-345252 A 20051130

OTHER SOURCE(S): MARPAT 147:31118

IT 939041-91-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocycle-containing cyclohexane derivs. as NR1/NR2B receptor

antagonists for treating pains, stroke, head trauma, Alzheimer's disease, and other diseases)

RN 939041-91-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[3-[[cis-4-[(4-chlorophenyl)methyl]-1-hydroxycyclohexyl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

88

THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2006:1173938 CAPLUS

DOCUMENT NUMBER: 145:471411

TITLE: Preparation of

4-[ω -(2-oxopyrrolidinyl/2-oxopiperidinyl)alkoxy]benzonitriles as androgen receptor modulators for treating conditions like excess sebum secretions and hair loss

INVENTOR(S): Barrett, Stephen Douglas; Fedij, Victor; Hu, Lain-Yen; Iula, Donna Michele; Lefker, Bruce Allen; Raheja, Raj Kumar; Sexton, Karen Elaine; Van Camp, Jennifer Ann

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 94pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117677	A1	20061109	WO 2006-IB1266	20060424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006242927	A1	20061109	AU 2006-242927	20060424
CA 2603866	A1	20061109	CA 2006-2603866	20060424
CA 2603866	C	20110531		
EP 1888524	A1	20080220	EP 2006-744704	20060424
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 4174068	B1	20081029	JP 2008-509535	20060424
JP 2008540397	T	20081120		
AP 1932	A	20081231	AP 2007-4197	20060424
BR 2006010998	A2	20100810	BR 2006-10998	20060424
US 20060252796	A1	20061109	US 2006-415935	20060502
US 7674819	B2	20100309		
AR 53721	A1	20070516	AR 2006-101785	20060503
NL 1031752	A1	20061113	NL 2006-1031752	20060504
NL 1031752	C2	20070319		
US 20070072936	A1	20070329	US 2006-557225	20061107
US 7799823	B2	20100921		
IN 2007DN07726	A	20071109	IN 2007-DN7726	20071009
CN 101166718	A	20080423	CN 2006-80014500	20071031
ZA 2007009385	A	20081029	ZA 2007-9385	20071031
KR 2007116970	A	20071211	KR 2007-7025374	20071101
CR 9496	A	20071204	CR 2007-9496	20071102
MX 2007013823	A	20080205	MX 2007-13823	20071105
NO 2007006026	A	20071122	NO 2007-6026	20071122
PRIORITY APPLN. INFO.:			US 2005-678035P	P 20050505
			US 2005-682112P	P 20050518

WO 2006-IB1266

W 20060424

US 2006-415935

A1 20060502

OTHER SOURCE(S): CASREACT 145:471411; MARPAT 145:471411


IT 914101-55-6P, 4-[[4,4-Dimethyl-2-oxo-1-[[3-(pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]methyl]pyrrolidin-3-yl]oxy]-2-trifluoromethylbenzonitrile

RL: COS (Cosmetic use); CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (cosmetic/drug candidate; preparation of 4-[ω-(2-oxopyrrolidinyl/2-oxopiperidinyl)alkoxy]benzonitriles as androgen receptor modulators for treating conditions like excess sebum secretions and hair loss)

RN 914101-55-6 CAPLUS

CN Benzonitrile, 4-[[4,4-dimethyl-2-oxo-1-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-3-pyrrolidinyl]oxy]-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

CN

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:588949 CAPLUS

DOCUMENT NUMBER: 143:115543


TITLE: Preparation of heterocyclic derivatives as GPCR receptor agonists

INVENTOR(S): Fyfe, Matthew; Gardner, Lisa; King-Underwood, John;
 Procter, Martin; Rasamison, Chrystelle; Schofield,
 Karen; Thomas, Gerard Hugh
 PATENT ASSIGNEE(S): Prosidion Limited, UK
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061489	A1	20050707	WO 2004-GB50046	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303604	A1	20050707	AU 2004-303604	20041223
AU 2004303604	B2	20110324		
CA 2549955	A1	20050707	CA 2004-2549955	20041223
EP 1711491	A1	20061018	EP 2004-806264	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898235	A	20070117	CN 2004-80039018	20041223
BR 2004018149	A	20070417	BR 2004-18149	20041223
JP 2007517010	T	20070628	JP 2006-546340	20041223
NZ 547965	A	20091224	NZ 2004-547965	20041223
IN 2006MN00699	A	20070309	IN 2006-MN699	20060614
IN 227515	A1	20090306		
MX 2006007135	A	20060907	MX 2006-7135	20060621
ZA 2006005164	A	20071128	ZA 2006-5164	20060622
KR 2006127011	A	20061211	KR 2006-7012739	20060623
IN 2008KN02387	A	20090123	IN 2008-KN2387	20080612
US 20090281060	A1	20091112	US 2008-584025	20080826
PRIORITY APPLN. INFO.:			US 2003-532370P	P 20031224
			WO 2004-GB50046	W 20041223
			IN 2006-MN699	A3 20060614


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:115543; MARPAT 143:115543
 IT 857652-32-5P 857652-39-2P 857652-40-5P
 857653-65-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted oxadiazoles as GPCR receptor agonists)
 RN 857652-32-5 CAPLUS
 CN Pyridine, 4-[5-[(4-pentylcyclohexyl)methyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 857652-39-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 857652-40-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857653-65-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2003:242329 CAPLUS

DOCUMENT NUMBER: 138:271690

TITLE: Preparation of 2-(piperidinomethyl)morpholines as modulators of chemokine (especially CCR3) activity

INVENTOR(S): Sangane, Hitesh; Springthorpe, Brian

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024962	A1	20030327	WO 2002-SE1651	20020912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002334543	A1	20030401	AU 2002-334543	20020912
EP 1430050	A1	20040623	EP 2002-798881	20020912
EP 1430050	B1	20060802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005506330	T	20050303	JP 2003-528809	20020912
AT 334981	T	20060815	AT 2002-798881	20020912
ES 2269806	T3	20070401	ES 2002-798881	20020912
US 20040242577	A1	20041202	US 2004-489811	20040317
US 7238691	B2	20070703		
PRIORITY APPLN. INFO.:			GB 2001-22503	A 20010918
			WO 2002-SE1651	W 20020912


OTHER SOURCE(S): MARPAT 138:271690

IT 503455-30-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-(piperidinomethyl)morpholines as modulators of chemokine (especially CCR3) activity)

RN 503455-30-9 CAPLUS

CN 1-Propanone, 1-[2-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-morpholinyl]-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:122994 CAPLUS

DOCUMENT NUMBER: 136:183826

TITLE: Preparation of heterocyclyl-alkyl-azole derivatives and use as pesticidal agents

INVENTOR(S): Schaper, Wolfgang; Bastiaans, Henricus Maria Martinus;
Harmsen, Sven; Doeller, Uwe; Jans, Daniela; Hempel,
Waltraud; Sanft, Ulrich; Thoenessen, Maria-Theresia
PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany
SOURCE: PCT Int. Appl., '79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012229	A1	20020214	WO 2001-EP8876	20010801
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10039477	A1	20020221	DE 2000-10039477	20000808
AU 2002014948	A	20020218	AU 2002-14948	20010801
CA 2418945	A1	20030210	CA 2001-2418945	20010801
EP 1309588	A1	20030514	EP 2001-983437	20010801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013062	A	20030701	BR 2001-13062	20010801
JP 2004505967	T	20040226	JP 2002-518204	20010801
US 20020132813	A1	20020919	US 2001-923197	20010806
IN 2003CN00167	A	20050408	IN 2003-CN167	20030128
MX 2003001208	A	20030630	MX 2003-1208	20030207
US 20040010145	A1	20040115	US 2003-418670	20030418
PRIORITY APPLN. INFO.:			DE 2000-10039477	A 20000808
			WO 2001-EP8876	W 20010801
			US 2001-923197	B1 20010806

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:183826

IT 1139494-12-4	1139494-13-5	1139494-14-6
1139494-15-7	1139494-16-8	1139494-17-9
1139494-18-0	1139494-19-1	1139494-20-4
1139494-21-5	1139494-22-6	1139494-23-7
1139494-26-0	1139494-27-1	1139494-28-2
1139494-29-3	1139494-30-6	1139494-31-7
1139494-32-8	1139494-33-9	1139494-34-0
1139494-35-1	1139494-48-6	1139494-49-7
1139494-50-0	1139494-51-1	1139494-52-2
1139494-53-3	1139494-54-4	1139494-55-5
1139494-58-8	1139494-59-9	1139494-60-2
1139494-61-3	1139494-62-4	1139494-63-5
1139494-64-6	1139494-65-7	1139494-66-8
1139494-67-9	1139494-68-0	1139494-69-1
1139494-70-4	1139494-71-5	1139494-72-6
1139494-73-7	1139494-74-8	1139494-75-9
1139494-76-0	1139494-77-1	1139494-78-2
1139494-79-3	1139494-80-6	1139494-82-8
1139494-83-9	1139494-84-0	1139494-85-1
1139494-86-2	1139494-87-3	1139494-88-4
1139494-89-5	1139494-90-8	1139494-91-9
1139494-92-0	1139494-93-1	1139494-94-2
1139494-95-3	1139494-96-4	1139494-97-5
1139494-98-6	1139494-99-7	1139495-00-3


1139495-01-4	1139495-02-5	1139495-03-6
1139495-04-7	1139495-05-8	1139495-06-9
1139495-07-0	1139495-11-6	1139495-12-7
1139495-15-0	1139495-16-1	1139495-17-2
1139495-18-3	1139495-19-4	1139495-20-7
1139495-22-9	1139495-23-0	1139495-24-1
1139495-25-2	1139495-26-3	1139495-27-4
1139495-28-5	1139495-29-6	1139495-30-9
1139495-31-0	1139495-32-1	1139495-33-2
1139495-34-3	1139495-35-4	1139495-36-5
1139495-37-6	1139495-38-7	1139495-39-8
1139495-40-1	1139495-41-2	1139495-44-5
1139495-45-6	1139495-47-8	1139495-48-9
1139495-49-0	1139495-50-3	1139495-54-7
1139495-55-8	1139495-56-9	1139495-57-0
1139495-58-1	1139495-59-2	1139495-60-5
1139495-61-6	1139495-62-7	1139495-63-8
1139495-64-9	1139495-65-0	1139495-66-1
1139495-67-2	1139495-68-3	1139495-69-4
1139495-70-7	1139495-71-8	1139495-72-9
1139495-73-0	1139495-74-1	1139495-75-2
1139495-79-6	1139495-80-9	1139495-81-0
1139495-82-1	1139495-87-6	1139495-88-7
1139495-89-8	1139495-90-1	1139495-93-4
1139495-94-5	1139495-95-6	1139495-96-7
1139495-97-8	1139495-98-9	1139495-99-0
1139496-00-6	1139496-01-7	1139496-02-8
1139496-03-9	1139496-04-0	1139496-05-1
1139496-06-2	1139496-07-3	1139496-08-4
1139496-09-5	1139496-10-8	1139496-13-1
1139496-14-2	1139496-17-5	1139496-18-6
1139496-19-7	1139496-24-4	1139496-25-5
1139496-26-6	1139496-27-7	1139496-28-8
1139496-29-9	1139496-30-2	1139496-33-5
1139496-34-6	1139496-35-7	1139496-36-8
1139496-39-1	1139496-40-4	1139496-43-7
1139496-44-8	1139496-45-9	1139496-46-0
1139496-47-1	1139496-48-2	1139496-49-3
1139496-50-6	1139496-51-7	1139496-52-8
1139496-53-9	1139496-54-0	1139496-55-1
1139496-56-2	1139496-57-3	1139496-58-4
1139496-59-5	1139496-60-8	1139496-69-7
1139496-70-0	1139496-71-1	1139496-72-2
1139496-73-3	1139496-74-4	1139496-75-5
1139496-76-6	1139496-77-7	1139496-78-8
1139496-79-9	1139496-80-2	1139496-81-3
1139496-82-4	1139496-83-5	1139496-84-6
1139496-85-7	1139496-86-8	1139496-87-9
1139496-88-0	1139496-89-1	1139496-90-4
1139496-91-5	1139496-92-6	1139496-93-7
1139496-94-8	1139497-17-8	1139497-18-9
1139497-19-0	1139497-20-3	1139497-23-6
1139497-24-7	1139497-25-8	1139497-26-9
1196240-70-6	1196240-71-7	1196240-73-9
1196240-74-0	1196240-75-1	1196240-78-4
1196240-79-5		

RL: PRPH (Prophetic)

(Preparation of heterocycl-alkyl-azole derivatives and use as
pesticidal agents)


RN 1139494-12-4 CAPLUS

CN Pyridine, 3-[3-[[4-[(ethylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-
oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-13-5 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(ethylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-14-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-15-7 CAPLUS

CN Pyridine, 3-[3-[2-(4-hexyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-16-8 CAPLUS

CN Pyridine, 3-[3-[4-(5-hexen-1-yl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-17-9 CAPLUS

CN Pyridine, 3-[3-[2-[4-(5-hexen-1-yl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-18-0 CAPLUS

CN Pyridine, 3-[3-[[4-[(1,1-dimethylethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-19-1 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(1,1-dimethylethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-20-4 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[[4-[(trimethylsilyl)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-21-5 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-[4-[(trimethylsilyl)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-22-6 CAPLUS

CN Pyridine, 3-[3-[(4-methyl-4-phenyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-23-7 CAPLUS

CN Pyridine, 3-[3-[2-(4-methyl-4-phenyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-26-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-27-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139494-28-2 CAPLUS

CN Pyridine, 3-[3-[[4-(methoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-29-3 CAPLUS

CN Pyridine, 3-[3-[2-[4-(methoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-30-6 CAPLUS

CN Pyridine, 3-[3-[2-[4-(chloromethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-31-7 CAPLUS

CN Pyridine, 3-[3-[2-[4-(chloromethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-32-8 CAPLUS

CN Pyridine, 3-[3-[2-[4-(fluoromethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-33-9 CAPLUS

CN 1,3-Dioxolane-4-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139494-34-0 CAPLUS

CN Pyridine, 3-[3-[2-[4-(ethoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-35-1 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(methylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-48-6 CAPLUS

CN Pyridine, 3-[3-[2-(4-methyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-49-7 CAPLUS

CN Pyridine, 3-[3-[4-(4,4-dimethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-50-0 CAPLUS

CN Pyridine, 3-[3-[2-(4,4-dimethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-51-1 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,4,5-trimethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139494-52-2 CAPLUS

CN Pyridine, 3-[3-[(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-53-3 CAPLUS


CN Pyridine, 3-[3-[2-(4-ethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-54-4 CAPLUS
 CN Pyridine, 3-[3-[2-(4-ethyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-55-5 CAPLUS
 CN Pyridine, 3-[3-[2-(4-propyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-58-8 CAPLUS
 CN Pyridine, 3-[3-[2-(5-methoxy-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139494-59-9 CAPLUS
 CN Pyridine, 3-[3-[2-(5-methoxy-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-60-2 CAPLUS
 CN Pyridine, 3-[3-[2-(5-ethoxy-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-61-3 CAPLUS

CN Pyridine, 3-[3-[2-(5-ethoxy-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-62-4 CAPLUS

CN 1,3-Dioxane-5-methanol, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139494-63-5 CAPLUS

CN Pyridine, 3-[3-[[4-(2-pyridinylmethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-64-6 CAPLUS


CN Pyridine, 3-[3-[2-[4-(2-pyridinylmethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-65-7 CAPLUS
 CN Pyridine, 3-[3-[4-[(phenylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-66-8 CAPLUS
 CN Pyridine, 3-[3-[2-[4-[(phenylthio)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-67-9 CAPLUS
 CN Pyridine, 3-[3-[4-[(phenylmethyl)thio]methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-68-0 CAPLUS
 CN Pyridine, 3-[3-[2-[4-[(phenylmethyl)thio]methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-69-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139494-70-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139494-71-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139494-72-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139494-73-7 CAPLUS
CN Pyridine, 3-[3-[[4-[(2-methoxyphenoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-74-8 CAPLUS
CN Pyridine, 3-[3-[2-[4-[(2-methoxyphenoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-75-9 CAPLUS
 CN Pyridine, 3-[3-[[4-[(2,2,2-trifluoroethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-76-0 CAPLUS
 CN Pyridine, 3-[3-[2-[4-[(2,2,2-trifluoroethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139494-77-1 CAPLUS
 CN Pyridine, 3-[3-[[4-(phenoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-78-2 CAPLUS
 CN Pyridine, 3-[3-[2-[4-(phenoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-79-3 CAPLUS

CN Pyridine, 3-[3-[4-[(phenylmethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-80-6 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(phenylmethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-82-8 CAPLUS

CN Pyridine, 3-[3-[4-(phenylmethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-83-9 CAPLUS

CN Pyridine, 3-[3-[2-[4-(phenylmethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-84-0 CAPLUS


CN Pyridine, 3-[3-[4-(ethenyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-85-1 CAPLUS
 CN Pyridine, 3-[3-[2-(4-ethenyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-86-2 CAPLUS
 CN 1,3-Dioxolane-4-acetonitrile, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139494-87-3 CAPLUS
 CN 1,3-Dioxolane-4-acetonitrile, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139494-88-4 CAPLUS
 CN Acetamide, N-[[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-89-5 CAPLUS

CN Acetamide, N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-90-8 CAPLUS

CN Acetamide, N-methyl-N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-91-9 CAPLUS

CN Acetamide, N-methyl-N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-92-0 CAPLUS

CN Pyridine, 3-[3-[4-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-93-1 CAPLUS

CN Pyridine, 3-[3-[2-[4-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-94-2 CAPLUS

CN Methanesulfonamide, N-[[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-95-3 CAPLUS

CN Methanesulfonamide, N-[[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxolan-4-yl]methyl]- (CA INDEX NAME)




RN 1139494-96-4 CAPLUS

CN Pyridine, 3-[3-[[4-[(2-propen-1-yloxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-97-5 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2-propen-1-yloxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-98-6 CAPLUS

CN Pyridine, 3-[3-[4-[(2-propyn-1-yloxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139494-99-7 CAPLUS

CN Pyridine, 3-[3-[2-[4-[(2-propyn-1-yloxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-00-3 CAPLUS

CN 1,3-Dioxolane-4-methanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 4-acetate (CA INDEX NAME)




RN 1139495-01-4 CAPLUS

CN 1,3-Dioxolane-4-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 4-acetate (CA INDEX NAME)




RN 1139495-02-5 CAPLUS


CN 1,3-Dioxolane-4-butanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-03-6 CAPLUS
 CN 1,3-Dioxolane-4-butanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-04-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139495-05-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1139495-06-9 CAPLUS
 CN Pyridine, 3-[3-[4-[(2-methoxyethoxy)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-07-0 CAPLUS
 CN Pyridine, 3-[3-[2-[4-[(2-methoxyethoxy)methyl]-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-11-6 CAPLUS

CN 1,3-Dioxane-5-carboxylic acid, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139495-12-7 CAPLUS

CN 1,3-Dioxane-5-carboxylic acid, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139495-15-0 CAPLUS

CN Pyridine, 3-[3-[2-[5,5-bis(methoxymethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-16-1 CAPLUS

CN Pyridine, 3-[3-[2-[5,5-bis(methoxymethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-17-2 CAPLUS

CN Pyridine, 3-[3-[[5-(phenylmethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-18-3 CAPLUS

CN Pyridine, 3-[3-[2-[5-(phenylmethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-19-4 CAPLUS


CN Pyridine, 3-[3-[[5-ethyl-5-[(2-propen-1-yloxy)methyl]-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-20-7 CAPLUS

CN Pyridine, 3-[3-[2-[(2S,4R)-4-methyl-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-22-9 CAPLUS
 CN Pyridine, 3-[3-[2-(4,4-dimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-23-0 CAPLUS
 CN Acetamide, N-[(4S,5R)-4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-24-1 CAPLUS
 CN Acetamide, N-[(4S,5R)-4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1139495-25-2 CAPLUS
 CN Acetamide, N-[(4S,5S)-4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1139495-26-3 CAPLUS


CN Acetamide, N-[(4S,5S)-4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1139495-27-4 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,4,6-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-28-5 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,5,5-trimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-29-6 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[2-(4,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 1139495-30-9 CAPLUS

CN Pyridine, 3-[3-[(4-ethenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-31-0 CAPLUS

CN Pyridine, 3-[3-[2-(4-ethenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-32-1 CAPLUS

CN Pyridine, 3-[3-[2-(4-ethenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-33-2 CAPLUS


CN Pyridine, 3-[3-[2-[4-methyl-6-(2-propen-1-yl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-34-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139495-35-4 CAPLUS
CN Pyridine, 3-[3-[2-(4,4,6,6-tetramethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-36-5 CAPLUS
CN 1,3-Dioxane-4-ethanol, 4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-37-6 CAPLUS
CN 1,3-Dioxane-4-ethanol, 4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-38-7 CAPLUS
 CN Pyridine, 3-[3-[[4-(3-fluoropropyl)-4-methyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-39-8 CAPLUS
 CN Pyridine, 3-[3-[2-[4-(3-fluoropropyl)-4-methyl-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-40-1 CAPLUS
 CN Pyridine, 3-[3-[[5,5-dimethyl-4-(1-methylethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-41-2 CAPLUS
 CN Pyridine, 3-[3-[2-[5,5-dimethyl-4-(1-methylethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-44-5 CAPLUS
 CN Pyridine, 3-[3-[(5,5-dimethyl-4-phenyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-45-6 CAPLUS
 CN Pyridine, 3-[3-[2-(5,5-dimethyl-4-phenyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-47-8 CAPLUS
 CN Acetamide, N-[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-48-9 CAPLUS
 CN Acetamide, N-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-49-0 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-50-3 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-54-7 CAPLUS
 CN Acetamide, N-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-55-8 CAPLUS
 CN Acetamide, N-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139495-56-9 CAPLUS
 CN 1,3-Dioxane-5-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-57-0 CAPLUS
 CN 1,3-Dioxane-5-methanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-58-1 CAPLUS
 CN Pyridine, 3-[3-[5-(fluoromethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-59-2 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(fluoromethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139495-60-5 CAPLUS
 CN Pyridine, 3-[3-[5-ethyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-61-6 CAPLUS
 CN Pyridine, 3-[3-[2-(5-ethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-62-7 CAPLUS

CN Pyridine, 3-[3-[(5-propyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-63-8 CAPLUS

CN Pyridine, 3-[3-[2-(5-propyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-64-9 CAPLUS

CN Pyridine, 3-[3-[(5-ethyl-5-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-65-0 CAPLUS


CN Pyridine, 3-[3-[2-(5-ethyl-5-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-66-1 CAPLUS
 CN Pyridine, 3-[3-[(5,5-diethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-67-2 CAPLUS
 CN Pyridine, 3-[3-[2-(5,5-diethyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-68-3 CAPLUS
 CN 1,3-Dioxane-5,5-dicarboxylic acid, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 5,5-dimethyl ester (CA INDEX NAME)




RN 1139495-69-4 CAPLUS
 CN 1,3-Dioxane-5,5-dicarboxylic acid, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 5,5-dimethyl ester (CA INDEX NAME)




RN 1139495-70-7 CAPLUS
 CN 1,3-Dioxane-5,5-dicarboxylic acid,
 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
 5,5-diethyl ester (CA INDEX NAME)




RN 1139495-71-8 CAPLUS
 CN 1,3-Dioxane-5,5-dicarboxylic acid,
 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-,
 5,5-diethyl ester (CA INDEX NAME)



RN 1139495-72-9 CAPLUS
 CN Pyridine, 3-[3-[(2-methyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-
 4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-73-0 CAPLUS
 CN Pyridine, 3-[3-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-
 4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-74-1 CAPLUS

CN Pyridine, 3-[3-[(2-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-75-2 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-79-6 CAPLUS

CN Pyridine, 3-[3-[(2-methyl-1,3-dithiolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-80-9 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1,3-dithiolan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-81-0 CAPLUS

CN Pyridine, 3-[3-[(2-methyl-1,3-dithian-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-82-1 CAPLUS

CN Pyridine, 3-[3-[2-(2-methyl-1,3-dithian-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139495-87-6 CAPLUS

CN 1,3-Dioxolan-4-one, 5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-88-7 CAPLUS

CN 1,3-Dioxolan-4-one, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-89-8 CAPLUS

CN 1,3-Dioxolan-4-one, 5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-90-1 CAPLUS

CN 1,3-Dioxolan-4-one, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-93-4 CAPLUS

CN 1,3-Dioxan-4-one, 6-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-94-5 CAPLUS

CN 1,3-Dioxan-4-one, 6-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-95-6 CAPLUS


CN 1,3-Dioxan-4-one, 5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139495-96-7 CAPLUS
 CN 1,3-Dioxan-4-one, 5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-97-8 CAPLUS
 CN 1,3-Dioxan-4-one, 6,6-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139495-98-9 CAPLUS
 CN 1,3-Dioxan-4-one, 6,6-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139495-99-0 CAPLUS
 CN 5-Oxazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-00-6 CAPLUS

CN 5-Oxazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-01-7 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-02-8 CAPLUS

CN 5-Oxazolidinone, 3-acetyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-03-9 CAPLUS


CN 3-Oxazolidinecarboxylic acid, 5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-04-0 CAPLUS
 CN 3-Oxazolidinecarboxylic acid, 5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-05-1 CAPLUS
 CN 5-Oxazolidinone, 3-acetyl-4,4-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-06-2 CAPLUS
 CN 5-Oxazolidinone, 3-acetyl-4,4-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-07-3 CAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-08-4 CAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester
 (CA INDEX NAME)




RN 1139496-09-5 CAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139496-10-8 CAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4,4-dimethyl-5-oxo-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139496-13-1 CAPLUS
 CN 4-Oxazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-14-2 CAPLUS
 CN 4-Oxazolidinone, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-17-5 CAPLUS
 CN 4-Oxazolidinone, 3,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 1139496-18-6 CAPLUS
 CN 4-Oxazolidinone, 3,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-19-7 CAPLUS
 CN 1,3-Dioxane-5-methanol, 5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-24-4 CAPLUS

CN Pyridine, 3-[3-[[5-(1,1-dimethylethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-25-5 CAPLUS

CN Pyridine, 3-[3-[2-[5-(1,1-dimethylethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-26-6 CAPLUS

CN Pyridine, 3-[3-[(5-methyl-5-nitro-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-27-7 CAPLUS

CN 1,3-Dioxane-5,5-dimethanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-28-8 CAPLUS

CN 1,3-Dioxane-5,5-dimethanol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-29-9 CAPLUS

CN Pyridine, 3-[3-[5,5-bis(fluoromethyl)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-30-2 CAPLUS

CN Pyridine, 3-[3-[2-[5,5-bis(fluoromethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-33-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-34-6 CAPLUS

CN 4-Imidazolidinone, 3,5,5-trimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-35-7 CAPLUS

CN 4-Imidazolidinone, 1,3,5,5-tetramethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-36-8 CAPLUS

CN 4-Imidazolidinone, 1,3,5,5-tetramethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-39-1 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-40-4 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-43-7 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-1,3-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139496-44-8 CAPLUS

CN 4(1H)-Pyrimidinone, tetrahydro-1,3-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-45-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1139496-46-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1139496-47-1 CAPLUS
CN Ethanone, 1-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-48-2 CAPLUS
CN Ethanone, 1-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-49-3 CAPLUS
CN Ethanone, 1-[3-methyl-2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-50-6 CAPLUS
CN Ethanone, 1-[3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 1139496-51-7 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 1139496-52-8 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-53-9 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-54-0 CAPLUS
 CN 1-Imidazolidinecarboxylic acid, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)

1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-55-1 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 1139496-56-2 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-57-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-58-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-59-5 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester
(CA INDEX NAME)




RN 1139496-60-8 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, tetrahydro-3-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester
(CA INDEX NAME)




RN 1139496-69-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1139496-70-0 CAPLUS


CN 4-Oxazolidinone, 3,5,5-trimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139496-71-1 CAPLUS
 CN Ethanone, 1-[2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-72-2 CAPLUS
 CN Ethanone, 1-[2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-73-3 CAPLUS
 CN Ethanone, 1-[5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-74-4 CAPLUS
 CN Ethanone, 1-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-75-5 CAPLUS
 CN Ethanone, 1-[4-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-76-6 CAPLUS
 CN Ethanone, 1-[4-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-77-7 CAPLUS
 CN Ethanone, 1-[4,4-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-78-8 CAPLUS
 CN Ethanone, 1-[4,4-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-3-oxazolidinyl]- (CA INDEX NAME)




RN 1139496-79-9 CAPLUS
 CN Ethanone, 1-[dihydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-2H-1,3-oxazin-3(4H)-yl]- (CA INDEX NAME)




RN 1139496-80-2 CAPLUS
 CN Ethanone, 1-[dihydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-2H-1,3-oxazin-3(4H)-yl]- (CA INDEX NAME)




RN 1139496-81-3 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-carboxylic acid, dihydro-5,5-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 1139496-82-4 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-carboxylic acid, dihydro-5,5-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, methyl ester (CA INDEX NAME)




RN 1139496-83-5 CAPLUS
 CN Pyridine, 3-[3-[2-[5-ethyl-5-[(2-propen-1-yloxy)methyl]-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-84-6 CAPLUS

CN Pyridine, 3-[3-[[5-(phenylmethoxy)-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-85-7 CAPLUS

CN Pyridine, 3-[3-[2-[5-(phenylmethoxy)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-86-8 CAPLUS

CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 5-acetate (CA INDEX NAME)




RN 1139496-87-9 CAPLUS


CN 1,3-Dioxan-5-ol, 2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl-, 5-benzoate (CA INDEX NAME)




RN 1139496-88-0 CAPLUS
 CN 1,3-Dioxan-5-ol, 2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 5-benzoate (CA INDEX NAME)




RN 1139496-89-1 CAPLUS
 CN Pyridine, 3-[3-[1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1139496-90-4 CAPLUS
 CN Pyridine, 3-[3-[2-[5-(cyclopropylmethyl)-1,3-dioxan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 1139496-91-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139496-92-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1139496-93-7 CAPLUS

CN Benzamide, N-[5-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139496-94-8 CAPLUS

CN Benzamide, N-[5-methyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-1,3-dioxan-5-yl]- (CA INDEX NAME)




RN 1139497-17-8 CAPLUS

CN 6H-1,3-Oxazin-6-one, 3-acetyltetrahydro-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-18-9 CAPLUS

CN 6H-1,3-Oxazin-6-one, 3-acetyltetrahydro-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1139497-19-0 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-carboxylic acid,
dihydro-6-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139497-20-3 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-carboxylic acid,
dihydro-6-oxo-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1139497-23-6 CAPLUS

CN 4-Imidazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-24-7 CAPLUS


CN 4-Imidazolidinone, 3-methyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1139497-25-8 CAPLUS
 CN 4-Imidazolidinone, 1,3-dimethyl-2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 1139497-26-9 CAPLUS
 CN 4-Imidazolidinone, 1,3-dimethyl-2-[2-[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1196240-70-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1196240-71-7 CAPLUS
 CN 1,3-Dioxolane-4,5-dicarboxylic acid,
 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
 4,5-bis(1-methylethyl) ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-73-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1196240-74-0 CAPLUS
CN 1,3-Dioxolane-4,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
4,5-diethyl ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-75-1 CAPLUS
CN 1,3-Dioxolane-4,5-dicarboxylic acid,
2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]-,
4,5-dimethyl ester, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1196240-78-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1196240-79-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 1196240-80-8 1196240-81-9 1196240-84-2
1196240-85-3 1196240-86-4

RL: PRPH (Prophetic)

(Preparation of heterocycl-alkyl-azole derivatives and use as
pesticidal agents)

RN 1196240-80-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1196240-81-9 CAPLUS

CN Pyridine, 3-[3-[2-[(4S,5S)-4,5-bis(methoxymethyl)-1,3-dioxolan-2-yl]ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1196240-84-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1196240-85-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1196240-86-4 CAPLUS

CN Pyridine, 3-[3-[2-(5-methyl-1,3-dioxan-2-yl)ethyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




IT 398125-56-9P 398125-57-0P 398125-58-1P
 398125-59-2P 398125-60-5P 398125-61-6P
 398125-62-7P 398125-63-8P 398125-64-9P
 398125-65-0P 398125-66-1P 398125-67-2P
 398125-68-3P 398125-69-4P 399035-42-8P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocycl-alkyl-azole derivs. and use as pesticidal agents)

RN 398125-56-9 CAPLUS


CN Pyridine, 3-[3-[(4-methyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-57-0 CAPLUS


CN Pyridine, 3-[3-[(4R,5R)-4,5-dimethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 398125-58-1 CAPLUS


CN Pyridine, 3-[3-[(4-propyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-59-2 CAPLUS
 CN Pyridine, 3-[3-[[4-(fluoromethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-60-5 CAPLUS
 CN 1,3-Dioxolane-4-methanol, 2-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 398125-61-6 CAPLUS
 CN Pyridine, 3-[3-[[4-(ethoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 398125-62-7 CAPLUS
 CN Pyridine, 3-[3-[[4-[(methylthio)methyl]-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-63-8 CAPLUS
 CN Pyridine, 3-[3-[[[(4R,5R)-4,5-bis(methoxymethyl)-1,3-dioxolan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 398125-64-9 CAPLUS

CN Pyridine, 3-[3-[[[(2R,4S)-4-methyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 398125-65-0 CAPLUS


CN Pyridine, 3-[3-[[[(4R,6R)-4,6-dimethyl-1,3-dioxan-2-yl]methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 398125-66-1 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[(4,4-dimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 398125-67-2 CAPLUS

CN Pyridine, 4-(trifluoromethyl)-3-[3-[(4,4,6-trimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 398125-68-3 CAPLUS


CN Pyridine, 3-[3-[(5,5-dimethyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 398125-69-4 CAPLUS

CN Pyridine, 3-[3-[(trans-5-methyl-1,3-dioxan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 399035-42-8 CAPLUS

CN Pyridine, 3-[3-[[4R,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:107339 CAPLUS
DOCUMENT NUMBER: 136:167289
TITLE: Preparation of lactam inhibitors of factor Xa which
are useful for the treatment of thrombosis
INVENTOR(S): Stein, Philip D.; Shi, Yan; O'Connor, Stephen P.; Li,
Chi
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010159	A1	20020207	WO 2001-US23932	20010730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020045616	A1	20020418	US 2001-916941	20010727
US 6511973	B2	20030128		
CA 2418071	A1	20020207	CA 2001-2418071	20010730
EP 1305309	A1	20030502	EP 2001-961808	20010730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000773	A2	20030929	HU 2003-773	20010730
JP 2004507464	T	20040311	JP 2002-515888	20010730
PRIORITY APPLN. INFO.:			US 2000-222498P	P 20000802
			WO 2001-US23932	W 20010730

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:167289

IT 396069-87-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lactam inhibitors of factor Xa for treatment of thrombosis)

RN 396069-87-7 CAPLUS

CN 2,5-Pyridinedicarboxamide, N5-[[[(3S)-hexahydro-2-oxo-1-[[3-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl)methyl]-1H-azepin-3-yl]imino][(2-methyl-5-benzofuranyl)amino]methyl]-N2,N2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2001:780940 CAPLUS
DOCUMENT NUMBER: 135:318515
TITLE: Preparation of tetrahydro-azepinone derivatives as
thrombin inhibitors
INVENTOR(S): Araldi, Gian Luca; Semple, Joseph Edward
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079261	A1	20011025	WO 2001-US12337	20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6541467	B1	20030401	US 2000-550257	20000414
PRIORITY APPLN. INFO.:			US 2000-549091	A 20000414
			US 2000-550092	A 20000414
			US 2000-550257	A 20000414

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:318515

IT 368427-09-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydro-azepinone derivs. as thrombin inhibitors for treatment of abnormal thrombosis)

RN 368427-09-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-[(3S)-hexahydro-2-oxo-3-

[[(phenylmethyl)sulfonyl]amino]-1H-azepin-1-yl)methyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 368427-08-1P 368427-10-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydro-azepinone derivs. as thrombin inhibitors for treatment of abnormal thrombosis)

RN 368427-08-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-[[(3S)-hexahydro-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-1H-azepin-1-yl)methyl]-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 368427-10-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[5-[[(3S)-hexahydro-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-1H-azepin-1-yl)methyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2000:420911 CAPLUS
 DOCUMENT NUMBER: 133:54868
 TITLE: Preparation of 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyrimidines as repellents
 INVENTOR(S): Knauf, Werner; Chapple, Andrew Charles; Wojtech, Eva; Rook, Burkhard
 PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035285	A1	20000622	WO 1999-EP9949	19991215
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19858191	A1	20000621	DE 1998-19858191	19981217
PRIORITY APPLN. INFO.:			DE 1998-19858191	A 19981217
OTHER SOURCE(S): MARPAT 133:54868				
IT 276685-69-9P	276685-71-3P	276685-73-5P		
276685-88-2P	276686-16-9P	276686-17-0P		
276686-18-1P	276686-21-6P	276686-27-2P		
276686-50-1P	276686-51-2P	276686-62-5P		
276686-63-6P				
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation as insect repellent)				
RN 276685-69-9	CAPLUS			
CN	Methanone, (3-methyl-1-piperidiny1)[5-[4-(trifluoromethyl)-3-pyridiny1]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)			




RN 276685-71-3 CAPLUS

CN Methanone, (2,6-dimethyl-4-morpholinyl)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276685-73-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 276685-88-2 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-16-9 CAPLUS

CN Methanone, (4-methyl-1-piperidinyl)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-17-0 CAPLUS

CN Methanone, (2-ethyl-1-piperidiny)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-18-1 CAPLUS

CN Methanone, (3,5-dimethyl-1-piperidiny)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-21-6 CAPLUS

CN Methanone, (2-methyl-1-aziridinyl)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-27-2 CAPLUS

CN 2-Aziridinecarboxylic acid, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)




RN 276686-50-1 CAPLUS

CN Methanone, [2-(methoxymethyl)-1-pyrrolidinyl][5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-51-2 CAPLUS

CN Methanone, (2,5-dimethyl-1-pyrrolidinyl)[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 276686-62-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]carbonyl]- (CA INDEX NAME)



RN 276686-63-6 CAPLUS

CN Proline, 1-[[5-[4-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:890145 CAPLUS

DOCUMENT NUMBER: 123:313628

ORIGINAL REFERENCE NO.: 123:56215a,56218a

TITLE: Heteroaryl mupirocin derivatives useful as
antibacterial, antifungal or herbicidal agents

INVENTOR(S): Brown, Pamela; O'Hanlon, Peter John

PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9516686	A1	19950622	WO 1994-EP4136	19941213
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			GB 1993-25832	A 19931217
OTHER SOURCE(S):		MARPAT 123:313628		
IT 169603-37-6P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of heteroaryl mupirocin derivs. as antibacterial agents)				
RN 169603-37-6 CAPLUS				
CN L-Altritol, 1,5-anhydro-2,6-dideoxy-2-[[3-[1-methyl-2- [(trimethylsilyl)oxy]propyl]oxiranyl]methyl]-6-[3-(3-pyridinyl)-1,2,4- oxadiazol-5-yl]-3,4-bis-O-(trimethylsilyl)-, [2S-[2 α ,3 β (1S*,2R*)]]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 169603-38-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroaryl mupirocin derivs. as antibacterial agents)
 RN 169603-38-7 CAPLUS
 CN L-Altritol, 1,5-anhydro-2,6-dideoxy-2-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-6-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]-, [2S-[2 α ,3 β (1R*,2R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1986:497479 CAPLUS
 DOCUMENT NUMBER: 105:97479
 ORIGINAL REFERENCE NO.: 105:15761a,15764a
 TITLE: Oxa- and thiadiazole derivatives and their use
 INVENTOR(S): Michihiro, Yamamoto; Yukinori, Ozato; Nobuhiko, Tamura; Akira, Miyagishi; Youichi, Hara
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 90 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 177965	A2	19860416	EP 1985-112872	19851010
EP 177965	A3	19870819		
EP 177965	B1	19900321		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 61091185	A	19860509	JP 1984-213786	19841011
JP 02055433	B	19901127		
US 4705786	A	19871110	US 1985-780974	19850927
CA 1326851	C	19940208	CA 1985-492042	19851002
AT 51229	T	19900415	AT 1985-112872	19851010
ES 557234	A5	19890331	ES 1986-557234	19861201
PRIORITY APPLN. INFO.:			JP 1984-213786	A 19841011
			EP 1985-112872	A 19851010

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 105:97479

IT 103898-81-3P 103898-82-4P 103898-83-5P
 103898-85-7P 103899-10-1P 103919-57-9P
 103919-58-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as cardiovascular agent)


RN 103898-81-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(diphenylmethyl)-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl ester (CA INDEX NAME)




RN 103898-82-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-[3-[[4-(tricyclo[3.3.1.3.3,7]dec-1-ylcarbonyl)-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester (CA INDEX NAME)




RN 103898-83-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-[3-[[4-(tricyclo[3.3.1.3.3,7]dec-1-ylmethyl)-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester (CA INDEX NAME)




RN 103898-85-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(4-fluorobenzoyl)-1-piperidinyl]methyl]-1,2,4-oxadiazol-5-yl]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl ester (CA INDEX NAME)




RN 103899-10-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[[4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-fluorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl ester (CA INDEX NAME)




RN 103919-57-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-[3-[[4-[(2,3,4-trimethoxyphenyl)methyl]-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 103919-58-0 CAPLUS
 CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-[3-[[4-[(2,3,4-trimethoxyphenyl)methyl]-1-piperazinyl]methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 1967:464402 CAPLUS
 DOCUMENT NUMBER: 67:64402
 ORIGINAL REFERENCE NO.: 67:12135a,12138a
 TITLE: 3-(β-Pyridyl)-5-dialkylaminoalkyl-1,2,4-oxadiazoles
 PATENT ASSIGNEE(S): Laboratoires Toraude
 SOURCE: Neth. Appl., 26 pp.
 CODEN: NAXXAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Dutch
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6611571		19670220	NL 1966-11571	19660817
FR 5654			FR	
PRIORITY APPLN. INFO.:			GB	19650818
			GB	19660708


OTHER SOURCE(S): MARPAT 67:64402
 IT 15328-09-3P 15328-10-6P 15328-11-7P
 15328-12-8P 15328-13-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 15328-09-3 CAPLUS
 CN Piperazine, 1,4-bis[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-,
 hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 15328-10-6 CAPLUS
 CN Piperazine, 1,4-bis[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA
 INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 15328-11-7 CAPLUS
CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-
(CA INDEX NAME)




RN 15328-12-8 CAPLUS
CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 15328-13-9 CAPLUS
 CN Piperazine, 1-methyl-4-[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

=>
 Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	FEB	1	Instructor-led and on-demand STN training options available from CAS
NEWS	2	MAY	02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS	3	MAY	12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS	4	MAY	23	Enhanced performance of STN biosequence searches
NEWS	5	JUN	20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS	6	JUN	20	INPADOC databases enhanced with first page images
NEWS	7	JUN	20	PATDPA database updates to end in June 2011
NEWS	8	JUN	26	MARPAT Enhancements Save Time and Increase Usability

NEWS 9 JUL 25 STN adds Australian patent full-text database,
AUPATFULL, including the new numeric search feature.

NEWS 10 AUG 01 CA Sections Added to ACS Publications Web Editions
Platform

NEWS 11 AUG 16 INPADOC: Coverage of German Patent Data resumed,
enhanced legal status

NEWS 12 AUG 18 Upgrade now to STN Express, Version 8.5

NEWS 13 SEP 01 CAS Journal Coverage Now Includes Ahead-of-Print
Articles for More Than 100 Journal Titles

NEWS 14 SEP 01 Older Versions of STN Express to be Discontinued
Beginning in March 2012

NEWS 15 SEP 09 USAN Database Updates Offer Superior Currency on STN(R)

NEWS 16 SEP 26 STN Adds Canadian Patent Full-text Database - CANPATFULL

NEWS 17 SEP 26 GEOREF and ENCOMPLIT databases were reloaded on
September 24, 2011.

NEWS 18 SEP 26 Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.

NEWS 19 SEP 26 ECLA Thesaurus in CA/CAPLUS Improves Patent Searching on STN

NEWS 20 SEP 26 Access AUPATFULL and CANPATFULL databases with STN Viewer

NEWS 21 OCT 26 New STN Revolutionizes Patent Searching for Professionals

NEWS 22 DEC 1 CA/CAPLUS Now Includes Examiner Citations for Japanese Patents

NEWS 23 DEC 1 CAS Expands Global Patent Coverage - Intellectual Property
Corporation of Malaysia Becomes 62nd Authority on CA/CAPLUS

NEWS 24 DEC 5 STN on the Web Enhancements Include Compatibility with
Microsoft Windows 7

NEWS 25 DEC 14 Removal of ITRD and PATIPC databases from STN

NEWS 26 DEC 15 Rolled-up IPC Core Codes Removed from IPC Reclassifications in
Patent Databases on STN

NEWS 27 JAN 12 Structure Graphics Have Been Added to Abstracts for
MARPAT and CA/CAPLUS on STN

NEWS 28 JAN 15 Online Access to Very Large Chemical Structure Images
Enhanced on STN

NEWS 29 JAN 26 IFICLS Updates Resume on STN

NEWS 30 JAN 31 MEDLINE Reload - Updated MeSH Vocabulary and Two New
Fields on STN

NEWS 31 FEB 1 INPADOC Databases Enhanced with Japanese Patent
Classifications, Current U.S. Classification and Japanese
Legal Status.

NEWS 32 FEB 3 Access More Than 32,000 Harmonized Tariff Codes Now in
CHEMLIST on STN

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:35:25 ON 09 FEB 2012

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.24	0.24

FILE 'REGISTRY' ENTERED AT 14:35:36 ON 09 FEB 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0
DICTIONARY FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025nf.str



chain nodes :

18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

2-7 5-6 15-18

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-8 6-12 7-13 7-17 8-9 9-10 10-11 11-12 13-14
14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 7-13 7-17 13-14 14-15 15-16 15-18 16-17

exact bonds :

2-7 5-6

normalized bonds :

6-8 6-12 8-9 9-10 10-11 11-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 14:36:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11456 TO ITERATE

100.0% PROCESSED 11456 ITERATIONS 128 ANSWERS
SEARCH TIME: 00.00.01

L2 128 SEA SSS FUL L1

=> file capl
COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
FULL ESTIMATED COST 203.77 204.01

FILE 'CAPLUS' ENTERED AT 14:36:24 ON 09 FEB 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2012 VOL 156 ISS 7
FILE LAST UPDATED: 8 Feb 2012 (20120208/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

Caplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 21

L3 8743 2L

=> s 12


L4 16 L2

=> d 14 1-16 ibib hitstr


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2011:997412 CAPLUS

DOCUMENT NUMBER: 155:328516
 TITLE: Preparation of phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators
 INVENTOR(S): Liao, Jiayu; Hong, Yufeng; Wang, Yong; Von Geldern, Thomas W.; Zhang, Kanyin E.
 PATENT ASSIGNEE(S): Argusina Inc., USA
 SOURCE: PCT Int. Appl., 274pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2011094890	A1	20110811	WO 2010-CN141	20100202
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2011097300	A1	20110811	WO 2011-US23482	20110202
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20120004198	A1	20120105	US 2011-19851	20110202
PRIORITY APPLN. INFO.:			WO 2010-CN141	A 20100202
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 155:328516; MARPAT 155:328516				
IT 1326225-87-9P	1326229-00-8P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of phenylalanine derivs. as non-peptide GLP-1 receptor agonists)				
RN 1326225-87-9	CAPLUS			
CN Phenylalanine, 3-fluoro-N-[[5-(4-methylphenyl)-2-furanyl]carbonyl]-4-[5-[2-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)				



RN 1326229-00-8 CAPLUS
 CN Phenylalanine, 4-[5-[2-(dimethylamino)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-fluoro-N-[[5-(4-methylphenyl)-2-furanyl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:744130 CAPLUS

DOCUMENT NUMBER: 155:211779

TITLE: Triazoles as γ -secretase modulators

AUTHOR(S): Fischer, Christian; Zultanski, Susan L.; Zhou, Hua; Methot, Joey L.; Brown, W. Colby; Mampreian, Dawn M.; Schell, Adam J.; Shah, Sanjiv; Nuthall, Hugh; Hughes, Bethany L.; Smotrov, Nadja; Kenific, Candia M.; Cruz, Jonathan C.; Walker, Deborah; Bouthillette, Melanie; Nikov, George N.; Savage, Dan F.; Jeliaskova-Mecheva, Valentina V.; Diaz, Damaris; Szewczak, Alexander A.; Bays, Nathan; Middleton, Richard E.; Munoz, Benito; Shearman, Mark S.

CORPORATE SOURCE: Merck Research Laboratories Boston, Boston, MA, 02115, USA

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2011), 21(13), 4083-4087

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

OTHER SOURCE(S): CASREACT 155:211779


IT 1093975-99-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of triaryltriazoles as γ -secretase modulators)

RN 1093975-99-5 CAPLUS

CN Pyridine, 4-[3-[4-[[4-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-1,2,3-triazol-1-yl]methyl]phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



IT 1093980-87-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of triaryltriazoles as γ -secretase modulators)
 RN 1093980-87-0 CAPLUS
 CN Pyridine, 4-[3-[4-(azidomethyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2010:1530245 CAPLUS
 DOCUMENT NUMBER: 154:40338
 TITLE: Compositions and methods for inhibiting tumor growth and for identifying antitumor agents and tumor survival kinases
 INVENTOR(S): Baldwin, Amy; Grueneberg, Dorre; Harlow, Ed; Xian, Jun; Munger, Karl; Hellner, Karin; Glicksman, Marcie; Stein, Ross; Cuny, Gregory
 PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA; The Brigham and Women's Hospital, Inc.
 SOURCE: PCT Int. Appl., 88pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010141738	A2	20101209	WO 2010-US37280	20100603
WO 2010141738	A3	20110317		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,

KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ,
TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2009-183851P

P2 20090603


IT 866041-01-2, LDN 0081796

RL: BSU (Biological study, unclassified); CST (Combinatorial study,
unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); CMBI (Combinatorial study); USES (Uses)

(as SGK2 protein kinase inhibitor; compns. and methods for inhibiting
p53-inactivated tumor growth and for identifying antitumor agents and
tumor survival kinases)

RN 866041-01-2 CAPLUS

CN Pyridine, 4-[3-[4-(bromomethyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX
NAME)



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:187799 CAPLUS

DOCUMENT NUMBER: 152:231196

TITLE: Therapeutic compounds for blocking DNA synthesis of
POX viruses

INVENTOR(S): Ricciardi, Robert P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of Appl.
No. PCT/US2008/001553.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100035887	A1	20100211	US 2009-537083	20090806
WO 2009008906	A3	20090528	WO 2008-US1553	20080206
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,			
	CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,			
	FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,			
	KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,			
	ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,			
	PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,			
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AP, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,			
	EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, AT, BE, BG, CH, CY,			
	CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,			
	MC, NL, PL, PT, RO, SE, SI, SK, TR, OA, BF, BJ, CF, CG, CI, CM,			
	GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.:

US 2007-899633P

P 20070206

US 2007-929673P P 20070709
WO 2008-US1553 A2 20080206

OTHER SOURCE(S): MARPAT 152:231196
IT 866041-01-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic compds. for blocking DNA synthesis of POX viruses)
RN 866041-01-2 CAPLUS
CN Pyridine, 4-[3-[4-(bromomethyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2010:55379 CAPLUS
DOCUMENT NUMBER: 152:144687
TITLE: Preparation of disubstituted oxadiazoles as novel
modulators of sphingosine phosphate receptors
INVENTOR(S): Roberts, Edward; Rosen, Hugh; Brown, Steven; Guerrero,
Miguel A.; Peng, Xuemei; Poddutoori, Ramulu
PATENT ASSIGNEE(S): Scripps Research Institute, The, USA
SOURCE: U.S. Pat. Appl. Publ., 203 pp., Chemical Indexing
Equivalent to 152:75043 (WO)
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100010001	A1	20100114	US 2009-465767	20090514
AU 2009258242	A1	20091217	AU 2009-258242	20090514
WO 2009151529	A1	20091217	WO 2009-US3014	20090514
WO 2009151529	A9	20100408		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 2291080	A1	20110309	EP 2009-762826	20090514
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS			
JP 2011523412	T	20110811	JP 2011-509488	20090514
PRIORITY APPLN. INFO.:			US 2008-127603P	P 20080514

US 2009-465767 A 20090514

WO 2009-US3014 W 20090514

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT 1201442-14-9P 1201442-17-2P 1201442-23-0P
1201442-25-2P 1201442-48-9P 1201442-52-5P
1201442-54-7P 1201442-58-1P 1201442-60-5P
1201442-79-6P 1201442-85-4P 1201442-87-6P
1201442-89-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of disubstituted oxadiazoles as novel modulators of sphingosine
phosphate receptors)


RN 1201442-14-9 CAPLUS

CN Pyridine, 2-methoxy-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-17-2 CAPLUS

CN Pyridine, 4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-, 1-oxide
(CA INDEX NAME)




RN 1201442-23-0 CAPLUS

CN Pyridine, 2-fluoro-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-25-2 CAPLUS


CN Pyridine, 2-chloro-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-48-9 CAPLUS
 CN 2-Pyridinamine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
 (CA INDEX NAME)




RN 1201442-52-5 CAPLUS
 CN Pyridine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-, 1-oxide
 (CA INDEX NAME)




RN 1201442-54-7 CAPLUS
 CN 3,5-Pyridinediol, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-2-methyl- (CA INDEX NAME)



RN 1201442-58-1 CAPLUS
 CN Pyridine, 2-chloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-6-methyl- (CA INDEX NAME)




RN 1201442-60-5 CAPLUS
 CN Pyridine, 2-chloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
 (CA INDEX NAME)




RN 1201442-79-6 CAPLUS

CN Pyridine, 2-methoxy-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-85-4 CAPLUS

CN Pyridine, 2-fluoro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-87-6 CAPLUS

CN Pyridine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]- (CA
INDEX NAME)



RN 1201442-89-8 CAPLUS

CN Pyridine, 2,6-dichloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-
yl]- (CA INDEX NAME)



L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:1566247 CAPLUS

DOCUMENT NUMBER: 152:75043

TITLE: Preparation of disubstituted oxadiazoles as novel modulators of sphingosine phosphate receptors

INVENTOR(S): Roberts, Edward; Rosen, Hugh; Brown, Steven; Morales, Miguel; Peng, Xuemei; Poddutoori, Ramulu

PATENT ASSIGNEE(S): The Scripps Research Institute, USA

SOURCE: PCT Int. Appl., 275pp.; Chemical Indexing Equivalent to 152:144687 (US)

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009151529	A1	20091217	WO 2009-US3014	20090514
WO 2009151529	A9	20100408		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2009258242	A1	20091217	AU 2009-258242	20090514
CA 2723904	A1	20091217	CA 2009-2723904	20090514
US 20100010001	A1	20100114	US 2009-465767	20090514
KR 2011010777	A	20110207	KR 2010-7028062	20090514
EP 2291080	A1	20110309	EP 2009-762826	20090514
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS			
CN 102118972	A	20110706	CN 2009-80127478	20090514
JP 2011523412	T	20110811	JP 2011-509488	20090514
PRIORITY APPLN. INFO.:			US 2008-127603P	P 20080514
			US 2009-465767	A 20090514
			WO 2009-US3014	W 20090514

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:75043; MARPAT 152:75043

IT 1201442-14-9P	1201442-17-2P	1201442-23-0P
1201442-25-2P	1201442-48-9P	1201442-52-5P
1201442-54-7P	1201442-58-1P	1201442-60-5P
1201442-79-6P	1201442-85-4P	1201442-87-6P


1201442-89-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted oxadiazoles as novel modulators of sphingosine phosphate receptors)


RN 1201442-14-9 CAPLUS

CN Pyridine, 2-methoxy-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-17-2 CAPLUS

CN Pyridine, 4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-, 1-oxide
(CA INDEX NAME)




RN 1201442-23-0 CAPLUS

CN Pyridine, 2-fluoro-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-25-2 CAPLUS

CN Pyridine, 2-chloro-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-48-9 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-52-5 CAPLUS
 CN Pyridine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-, 1-oxide
 (CA INDEX NAME)




RN 1201442-54-7 CAPLUS
 CN 3,5-Pyridinediol, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-2-methyl- (CA INDEX NAME)



RN 1201442-58-1 CAPLUS
 CN Pyridine, 2-chloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-6-methyl- (CA INDEX NAME)




RN 1201442-60-5 CAPLUS
 CN Pyridine, 2-chloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
 (CA INDEX NAME)




RN 1201442-79-6 CAPLUS

CN Pyridine, 2-methoxy-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-85-4 CAPLUS

CN Pyridine, 2-fluoro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)




RN 1201442-87-6 CAPLUS

CN Pyridine, 4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]- (CA
INDEX NAME)



RN 1201442-89-8 CAPLUS

CN Pyridine, 2,6-dichloro-4-[3-(3-methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-
yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:1533190 CAPLUS

DOCUMENT NUMBER: 150:77691

TITLE: Preparation of triazole derivatives for treating Alzheimer's disease and related conditions

INVENTOR(S): Fischer, Christian; Munoz, Ben; Zultanski, Susan; Methot, Joey; Zhou, Hua; Brown, W. Colby

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 130pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008156580	A1	20081224	WO 2008-US7205	20080609
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 2166854 A1 20100331 EP 2008-768273 20080609 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS US 20100222320 A1 20100902 US 2009-663432 20091207 PRIORITY APPLN. INFO.: US 2007-934515P P 20070613 WO 2008-US7205 W 20080609				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:77691; MARPAT 150:77691

IT 1093975-99-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazole derivs. for treating Alzheimer's disease and related conditions)


RN 1093975-99-5 CAPLUS

CN Pyridine, 4-[3-[4-[[4-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-

1,2,3-triazol-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



IT 1093980-87-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of triazole derivs. for treating Alzheimer's
disease and related conditions)
RN 1093980-87-0 CAPLUS
CN Pyridine, 4-[3-[4-(azidomethyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(11 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2008:1530398 CAPLUS
DOCUMENT NUMBER: 150:71090
TITLE: Antibiotic compounds, screening methods, and methods
for treatment of infections
INVENTOR(S): Lewis, Kim; Casadei, Gabriele
PATENT ASSIGNEE(S): Northeastern University, USA
SOURCE: PCT Int. Appl., 208pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008156610	A2	20081224	WO 2008-US7290	20080611
WO 2008156610	A3	20090528		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2008267026 A1 20081224 AU 2008-267026 20080611
CA 2687217 A1 20081224 CA 2008-2687217 20080611
EP 2167074 A2 20100331 EP 2008-768346 20080611

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS

JP 2010529194 T 20100826 JP 2010-512174 20080611
MX 2009013686 A 20100127 MX 2009-13686 20091211
US 20110046142 A1 20110224 US 2010-664250 20101101

PRIORITY APPLN. INFO.: US 2007-934418P P 20070613
WO 2008-US7290 W 20080611

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 150:71090

IT 866041-01-2

RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotic compds., screening methods, and methods for treatment of infections)

RN 866041-01-2 CAPLUS

CN Pyridine, 4-[3-[4-(bromomethyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:1158632 CAPLUS

DOCUMENT NUMBER: 149:402366

TITLE: Preparation of aminopyridine derivatives, particularly 3-(aminopyridinyl)-5-(alkoxyphenyl)-1,2,4-oxadiazoles, as immunomodulating S1P1/EDG1 receptor agonists

INVENTOR(S): Bolli, Martin; Mathys, Boris; Mueller, Claus; Nayler, Oliver; Steiner, Beat; Velker, Joerg

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd, Switz.

SOURCE: PCT Int. Appl., 121pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008114157	A1	20080925	WO 2008-IB50742	20080229
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,			

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2008227979 A1 20080925 AU 2008-227979 20080229
CA 2679138 A1 20080925 CA 2008-2679138 20080229
EP 2125797 A1 20091202 EP 2008-719519 20080229

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR

KR 2010014738 A 20100210 KR 2009-7020583 20080229
JP 2010521450 T 20100624 JP 2009-553245 20080229
NZ 580454 A 20110527 NZ 2008-580454 20080229
AR 65621 A1 20090617 AR 2008-100929 20080306
CN 101627034 A 20100113 CN 2008-80006910 20090902
MX 2009009597 A 20090916 MX 2009-9597 20090908
US 20100087417 A1 20100408 US 2009-531374 20090915
NO 2009003146 A 20091015 NO 2009-3146 20091015
IN 2009CN06098 A 20100226 IN 2009-CN6098 20091015
ZA 2009007214 A 20110126 ZA 2009-7214 20091015

PRIORITY APPLN. INFO.: WO 2007-IB50921 A 20070316
WO 2008-IB50742 W 20080229


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:402366; MARPAT 149:402366

IT 1062670-28-3P, 3-[2-Ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionic acid
1062670-96-5P, 3-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenyl]propionic acid
1062673-78-2P, 2-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]ethanol 1062673-80-6P,
N-[4-[3-[4-(2-Aminoethyl)phenyl][1,2,4]oxadiazol-5-yl]-6-methylpyridin-2-yl]diethylamine 1062674-02-5P,
1-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]ethane-1,2-diol


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)

RN 1062670-28-3 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062670-96-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-

oxadiazol-3-yl]-2-ethyl-6-methyl- (CA INDEX NAME)




RN 1062673-78-2 CAPLUS

CN Benzeneethanol, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-80-6 CAPLUS

CN 2-Pyridinamine, 4-[3-[4-(2-aminoethyl)phenyl]-1,2,4-oxadiazol-5-yl]-N,N-diethyl-6-methyl- (CA INDEX NAME)



RN 1062674-02-5 CAPLUS

CN 1,2-Ethanediol, 1-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)



IT 1062670-30-7P, 3-[[3-[2-Ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-

methylphenyl]propanoyl]amino]propionic acid 1062670-33-0P,
N-(2-Aminoethyl)-3-[2-ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionamide
1062670-98-7P, 3-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-N-(2-hydroxyethyl)propionamide 1062671-00-4P


1062671-01-5P 1062671-03-7P 1062671-04-8P
 1062671-06-0P 1062671-93-5P 1062671-95-7P
 1062673-09-9P 1062673-27-1P 1062673-29-3P
 1062673-30-6P 1062673-32-8P 1062673-64-6P
 1062673-66-8P 1062673-67-9P 1062673-69-1P
 1062673-70-4P 1062673-72-6P 1062673-74-8P

1062673-77-1P, [4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]methanol 1062673-81-7P
 1062673-83-9P 1062673-84-0P,
 2-[[2-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]ethyl]amino]ethanol 1062673-90-8P,
 [[2-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]ethyl]amino]acetic acid ethyl ester 1062673-93-1P
 1062674-05-8P, 1-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]-2-[(2-hydroxyethyl)amino]ethanol
 1062674-09-2P, N-[2-[4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]-2-hydroxyethyl]methanesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)


RN 1062670-30-7 CAPLUS

CN β -Alanine, N-[3-[2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-1-oxopropyl]-(CA INDEX NAME)




RN 1062670-33-0 CAPLUS

CN Benzenepropanamide, N-(2-aminoethyl)-2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-(CA INDEX NAME)




RN 1062670-98-7 CAPLUS

CN Benzenepropanamide, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-N-(2-hydroxyethyl)-6-methyl-(CA INDEX NAME)




RN 1062671-00-4 CAPLUS

CN Glycine, N-[3-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)




RN 1062671-01-5 CAPLUS

CN β -Alanine, N-[3-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)



RN 1062671-03-7 CAPLUS


CN 3-Azetidinecarboxylic acid, 1-[3-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)



RN 1062671-04-8 CAPLUS


CN L-Proline, 1-[3-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1062671-06-0 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[3-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)




RN 1062671-93-5 CAPLUS

CN Benzenepropanamide, 2-ethyl-N,6-dimethyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062671-95-7 CAPLUS

CN Benzenepropanamide, 2-ethyl-N-(2-hydroxyethyl)-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-09-9 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-27-1 CAPLUS

CN Benzenepropanamide, 2-ethyl-N,6-dimethyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-29-3 CAPLUS

CN Benzenepropanamide, 2-ethyl-N-(2-hydroxyethyl)-6-methyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-30-6 CAPLUS

CN Benzenepropanamide, N-(2-aminoethyl)-2-ethyl-6-methyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-32-8 CAPLUS

CN β -Alanine, N-[3-[2-ethyl-6-methyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-1-oxopropyl]- (CA INDEX NAME)




RN 1062673-64-6 CAPLUS

CN Benzamide, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1062673-66-8 CAPLUS

CN Benzamide, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-N-(2,3-dihydroxypropyl)- (CA INDEX NAME)




RN 1062673-67-9 CAPLUS

CN Glycine, N-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 1062673-69-1 CAPLUS

CN Glycine, N-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]benzoyl]- (CA INDEX NAME)




RN 1062673-70-4 CAPLUS

CN Benzeneacetamide, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1062673-72-6 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]acetyl]- (CA INDEX NAME)




RN 1062673-74-8 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]acetyl]- (CA INDEX NAME)




RN 1062673-77-1 CAPLUS

CN Benzenemethanol, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1062673-81-7 CAPLUS

CN Acetamide, N-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-2-hydroxy- (CA INDEX NAME)




RN 1062673-83-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]- (CA INDEX NAME)




RN 1062673-84-0 CAPLUS

CN Ethanol, 2-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]amino]- (CA INDEX NAME)




RN 1062673-90-8 CAPLUS

CN Glycine, N-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-, ethyl ester (CA INDEX NAME)




RN 1062673-93-1 CAPLUS
 CN Glycine, N-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 1062674-05-8 CAPLUS
 CN Benzenemethanol, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-α-[(2-hydroxyethyl)amino]methyl- (CA INDEX NAME)




RN 1062674-09-2 CAPLUS
 CN Methanesulfonamide, N-[2-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-2-hydroxyethyl]- (CA INDEX NAME)



IT 1062669-77-5P, 3-[2-Ethyl-4-[5-[2-[(ethyl)(methyl)amino]-6-methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionic acid
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (drug candidate; preparation of aminopyridine derivs. as immunomodulating
 S1P1/EDG1 receptor agonists)
 RN 1062669-77-5 CAPLUS


CN Benzenepropanoic acid, 2-ethyl-4-[5-[2-(ethylmethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-6-methyl- (CA INDEX NAME)



IT 1062673-63-5P 1062673-87-3P 1062674-07-0P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)


RN 1062673-63-5 CAPLUS

CN Benzoic acid, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 1062673-87-3 CAPLUS

CN Benzeneethanol, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-, 1-methanesulfonate (CA INDEX NAME)



RN 1062674-07-0 CAPLUS

CN 1,2-Ethanediol, 1-[4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-, 2-methanesulfonate (CA INDEX NAME)



IT 1062669-81-1P, 3-[2-Ethyl-4-[5-[2-[(ethyl)(methyl)amino]-6-

methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionic acid
tert-butyl ester 1062670-32-9P,

3-[[3-[2-Ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-methylpyridin-4-
yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propanoyl]amino]propionic acid
tert-butyl ester 1062670-34-1P,


[2-[[3-[2-Ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-methylpyridin-4-
yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propanoyl]amino]ethyl]carbamic
acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of aminopyridine derivs. as immunomodulating
S1P1/EDG1 receptor agonists)


RN 1062669-81-1 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-4-[5-[2-(ethylmethylamino)-6-methyl-4-
pyridinyl]-1,2,4-oxadiazol-3-yl]-6-methyl-, 1,1-dimethylethyl ester (CA
INDEX NAME)




RN 1062670-32-9 CAPLUS

CN β -Alanine, N-[3-[2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-
methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-1-oxopropyl]-
, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1062670-34-1 CAPLUS


CN Carbamic acid, N-[2-[[3-[2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-
methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]-1-
oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




PAGE 1-A

— OBU-t


IT 1062673-25-9P, 3-[2-Ethyl-6-methyl-4-[5-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl][1,2,4]oxadiazol-3-yl]phenyl]propionic acid
 1062673-61-3P, 4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]benzoic acid 1062673-75-9P, [4-[5-(2-Diethylamino-6-methylpyridin-4-yl)[1,2,4]oxadiazol-3-yl]phenyl]acetic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)
 RN 1062673-25-9 CAPLUS
 CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1062673-61-3 CAPLUS
 CN Benzoic acid, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1062673-75-9 CAPLUS
 CN Benzeneacetic acid, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:322202 CAPLUS

DOCUMENT NUMBER: 148:331565

TITLE: Pyridin-4-yl derivatives as immunomodulating agents and their preparation, pharmaceutical compositions and use in the treatment of immune system disorders

INVENTOR(S): Bolli, Martin; Lehmann, David; Mathys, Boris; Mueller, Claus; Nayler, Oliver; Steiner, Beat; Velker, Joerg

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.

SOURCE: PCT Int. Appl., 132pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008029371	A1	20080313	WO 2007-IB53594	20070906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007292993	A1	20080313	AU 2007-292993	20070906
CA 2661105	A1	20080313	CA 2007-2661105	20070906
AR 62683	A1	20081126	AR 2007-103940	20070906
EP 2069336	A1	20090617	EP 2007-826287	20070906
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
CN 101511827	A	20090819	CN 2007-80033152	20070906
CN 101511827	B	20120201		
JP 2010502695	T	20100128	JP 2009-527264	20070906
NZ 576060	A	20111125	NZ 2007-576060	20070906
MX 2009002233	A	20090316	MX 2009-2233	20090227
KR 2009050102	A	20090519	KR 2009-7006862	20090403
NO 2009001394	A	20090406	NO 2009-1394	20090406
US 20100063108	A1	20100311	US 2009-310801	20090930
PRIORITY APPLN. INFO.:			WO 2006-IB53147	A 20060907
			WO 2007-IB53594	W 20070906

OTHER SOURCE(S): CASREACT 148:331565; MARPAT 148:331565

IT 1011261-87-2P 1011261-88-3P 1011261-89-4P

1011263-77-6P 1011263-78-7P 1011263-79-8P

1011263-80-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridinyl derivs. as immunomodulating agents useful in the treatment of immune system disorders)

RN 1011261-87-2 CAPLUS


CN Benzenepropanamide, 2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-

oxadiazol-3-yl]-N,6-dimethyl- (CA INDEX NAME)




RN 1011261-88-3 CAPLUS

CN Benzenepropanamide, 2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-N-(2-hydroxyethyl)-6-methyl- (CA INDEX NAME)




RN 1011261-89-4 CAPLUS

CN β -Alanine, N-[3-[2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-6-methylphenyl]-1-oxopropyl]- (CA INDEX NAME)




RN 1011263-77-6 CAPLUS

CN Benzeneacetamide, N-(2-hydroxyethyl)-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1011263-78-7 CAPLUS

CN Benzeneacetamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 1011263-79-8 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]acetyl]- (CA INDEX NAME)



RN 1011263-80-1 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[2-[4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenyl]acetyl]- (CA INDEX NAME)



IT 1011264-25-7P 1011264-28-0P 1011264-29-1P


1011264-30-4P 1011264-32-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinyl derivs. as immunomodulating agents useful in the treatment of immune system disorders)

RN 1011264-25-7 CAPLUS


CN Benzeneacetic acid, 4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1011264-28-0 CAPLUS


CN Benzenepropanoic acid, 2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-

oxadiazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 1011264-29-1 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-6-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1011264-30-4 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1011264-32-6 CAPLUS

CN Benzenepropanoic acid, 2,6-dimethyl-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



IT 1011264-52-0P

1011264-73-5P


RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prophetic intermediate; preparation of pyridinyl derivs. as immunomodulating agents useful in the treatment of immune system disorders)


RN 1011264-52-0 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-(2-methylpropyl)-

4-pyridinyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1011264-73-5 CAPLUS
CN β -Alanine, N-[3-[2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-6-methylphenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:441558 CAPLUS

DOCUMENT NUMBER: 148:403137

TITLE: Reproducibility and scalability of solvent-free microwave-assisted reactions: from domestic ovens to controllable parallel applications

AUTHOR(S): Diaz-Ortiz, Angel; de la Hoz, Antonio; Alcazar, Jesus; Carrillo, Jose Ramon; Herrero, Maria Antonia; Fontana, Alberto; de Mata Munoz, Juan

CORPORATE SOURCE: Departamento de Q. Inorganica, Q. Organica y Bioquimica, Facultad de Quimica, Universidad de Castilla-La Mancha, Ciudad Real, 13071, Spain

SOURCE: Combinatorial Chemistry & High Throughput Screening

(2007), 10(3), 163-169

CODEN: CCHSFU; ISSN: 1386-2073

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 148:403137

IT 1015698-50-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(reproducibility and scalability of solvent-free microwave-assisted reactions under controllable parallel conditions)

RN 1015698-50-6 CAPLUS

CN Pyridine, 4-[3-(2,4,6-trimethylphenyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2006:515902 CAPLUS
 DOCUMENT NUMBER: 145:27870
 TITLE: Preparation of 4-aminopiperidine derivatives for treatment and/or prevention of protozoal infections
 INVENTOR(S): Boss, Christoph; Corminboeuf, Olivier; Grisostomi, Corinna; Weller, Thomas; Bur, Daniel; Prade, Lars
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056930	A2	20060601	WO 2005-IB53838	20051121
WO 2006056930	A3	20080117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2587888	A1	20060601	CA 2005-2587888	20051121
EP 1824822	A2	20070829	EP 2005-807179	20051121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008521793	T	20080626	JP 2007-542449	20051121
AR 52249	A1	20070307	AR 2005-104912	20051124
US 20080076762	A1	20080327	US 2007-720181	20070524
CN 101208302	A	20080625	CN 2005-80040599	20070525
PRIORITY APPLN. INFO.:			WO 2004-EP13369	A 20041125
			WO 2005-IB53838	W 20051121

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 145:27870; MARPAT 145:27870

IT 888943-90-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopiperidine derivs. with antiprotozoal activity)

RN 888943-90-6 CAPLUS
 CN 2-Pyridinecarboxamide, N-[1-(3-methylbutyl)-4-piperidinyl]-5-pentyl-N-[[4-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:588949 CAPLUS

DOCUMENT NUMBER: 143:115543

TITLE: Preparation of heterocyclic derivatives as GPCR
 receptor agonists

INVENTOR(S): Fyfe, Matthew; Gardner, Lisa; King-Underwood, John;
 Procter, Martin; Rasamison, Chrystelle; Schofield,
 Karen; Thomas, Gerard Hugh

PATENT ASSIGNEE(S): Prosidion Limited, UK

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061489	A1	20050707	WO 2004-GB50046	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303604	A1	20050707	AU 2004-303604	20041223
AU 2004303604	B2	20110324		
CA 2549955	A1	20050707	CA 2004-2549955	20041223
EP 1711491	A1	20061018	EP 2004-806264	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898235	A	20070117	CN 2004-80039018	20041223
BR 2004018149	A	20070417	BR 2004-18149	20041223
JP 2007517010	T	20070628	JP 2006-546340	20041223
NZ 547965	A	20091224	NZ 2004-547965	20041223

IN 2006MN00699	A	20070309	IN 2006-MN699	20060614
IN 227515	A1	20090306		
MX 2006007135	A	20060907	MX 2006-7135	20060621
ZA 2006005164	A	20071128	ZA 2006-5164	20060622
KR 2006127011	A	20061211	KR 2006-7012739	20060623
IN 2008KN02387	A	20090123	IN 2008-KN2387	20080612
US 20090281060	A1	20091112	US 2008-584025	20080826
PRIORITY APPLN. INFO.:			US 2003-532370P	P 20031224
			WO 2004-GB50046	W 20041223
			IN 2006-MN699	A3 20060614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:115543; MARPAT 143:115543

IT 857652-43-8P 857652-44-9P 857652-47-2P

857652-48-3P 857652-54-1P 857652-56-3P

857652-70-1P 857652-74-5P 857652-75-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxadiazoles as GPCR receptor agonists)

RN 857652-43-8 CAPLUS

CN Pyridine, 4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)


Relative stereochemistry.



RN 857652-44-9 CAPLUS

CN Pyridine, 2-chloro-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)


Relative stereochemistry.



RN 857652-47-2 CAPLUS


CN Pyridine, 2-chloro-6-methyl-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.




RN 857652-48-3 CAPLUS
 CN 2-Pyridinecarbonitrile, 4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.




RN 857652-54-1 CAPLUS
 CN Pyridine, 2,6-dichloro-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.




RN 857652-56-3 CAPLUS
 CN Pyridine, 2-chloro-6-methoxy-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Relative stereochemistry.




RN 857652-70-1 CAPLUS
CN Pyridine, 2-fluoro-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)

Relative stereochemistry.




RN 857652-74-5 CAPLUS
CN Pyridine, 2-methyl-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 857652-75-6 CAPLUS
CN Pyridine, 3-methyl-4-[3-(trans-4-pentylcyclohexyl)-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)


Relative stereochemistry.



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
RECORD (13 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2001:207055 CAPLUS
DOCUMENT NUMBER: 135:46140
TITLE: An improved synthesis of 1,2,4-oxadiazoles on solid
support
AUTHOR(S): Rice, K. D.; Nuss, J. M.
CORPORATE SOURCE: Departments of Medicinal and Combinatorial Chemistry,

Exelixis, Inc., South San Francisco, CA, 94083-0511,
USA
SOURCE: Bioorganic & Medicinal
Chemistry Letters (2001),
11(6), 753-755
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:46140
IT 344399-39-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of oxadiazole library)
RN 344399-39-9 CAPLUS
CN Benzamide, N-(phenylmethyl)-4-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]- (CA
INDEX NAME)




OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS
RECORD (28 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2001:118532 CAPLUS
DOCUMENT NUMBER: 134:326461
TITLE: Parallel synthesis of 1,2,4-oxadiazoles from
carboxylic acids using an improved, uronium-based,
activation
AUTHOR(S): Poulain, R. F.; Tartar, A. L.; Deprez, B. P.
CORPORATE SOURCE: Laboratoire de Chimie Organique, UMR 8525, Faculte des
Sciences Pharmaceutiques et Biologiques, Lille,
F-59006, Fr.
SOURCE: Tetrahedron Letters (2001), 42(8), 1495-1498
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:326461
IT 336784-71-5P 336784-72-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(parallel synthesis of oxadiazoles from carboxylic acids using
improved, uronium-based activation)
RN 336784-71-5 CAPLUS
CN Quinoline, 4-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-2-
phenyl- (CA INDEX NAME)



RN 336784-72-6 CAPLUS

CN Quinoline, 2-phenyl-4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 42 THERE ARE 42 CAPLUS RECORDS THAT CITE THIS
RECORD (42 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1997:776160 CAPLUS

DOCUMENT NUMBER: 128:23138

ORIGINAL REFERENCE NO.: 128:4543a, 4546a

TITLE: 1,2,4-oxadiazoles as adhesion-receptor antagonists

INVENTOR(S): Juraszyk, Horst; Gante, Joachim; Wurziger, Hanns;
Bernotat-Danielowski, Sabine; Melzer, Guido

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany; Juraszyk, Horst;
Gante, Joachim; Wurziger, Hanns; Bernotat-Danielowski,
Sabine; Melzer, Guido

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9744333	A1	19971127	WO 1997-EP2555	19970520
W: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19620041	A1	19980129	DE 1996-19620041	19960517
IN 1997CA00796	A	20050311	IN 1997-CA796	19970502
ZA 9704234	A	19971211	ZA 1997-4234	19970515
AU 9729579	A	19971209	AU 1997-29579	19970520
PRIORITY APPLN. INFO.:			DE 1996-19620041	A 19960517
			WO 1997-EP2555	W 19970520
OTHER SOURCE(S): CASREACT 128:23138; MARPAT 128:23138				
IT 199446-96-3P 199447-74-0P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(oxadiazoles as adhesion-receptor antagonists)				
RN 199446-96-3 CAPLUS				
CN β -Alanine, N-[4-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)				



● HCl

RN 199447-74-0 CAPLUS
 CN β -Alanine, N-[4-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]benzoyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
 Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 FEB 1 Instructor-led and on-demand STN training options available
from CAS

NEWS 2 MAY 02 MEDLINE Improvements Provide Fast and Simple Access to DOI and
Chemical Name Information

NEWS 3 MAY 12 European Patent Classification thesauri added to the INPADOC
files, PCTFULL, GBFULL and FRFULL

NEWS 4 MAY 23 Enhanced performance of STN biosequence searches

NEWS 5 JUN 20 STN on the Web Enhanced with New Patent Family Assistant and
Updated Structure Plug-In

NEWS 6 JUN 20 INPADOC databases enhanced with first page images

NEWS 7 JUN 20 PATDPA database updates to end in June 2011

NEWS 8 JUN 26 MARPAT Enhancements Save Time and Increase Usability

NEWS 9 JUL 25 STN adds Australian patent full-text database,
AUPATFULL, including the new numeric search feature.

NEWS 10 AUG 01 CA Sections Added to ACS Publications Web Editions
Platform

NEWS 11 AUG 16 INPADOC: Coverage of German Patent Data resumed,
enhanced legal status

NEWS 12 AUG 18 Upgrade now to STN Express, Version 8.5

NEWS 13 SEP 01 CAS Journal Coverage Now Includes Ahead-of-Print
Articles for More Than 100 Journal Titles

NEWS 14 SEP 01 Older Versions of STN Express to be Discontinued
Beginning in March 2012

NEWS 15 SEP 09 USAN Database Updates Offer Superior Currency on STN(R)

NEWS 16 SEP 26 STN Adds Canadian Patent Full-text Database - CANPATFULL

NEWS 17 SEP 26 GEOREF and ENCOMPLIT databases were reloaded on
September 24, 2011.

NEWS 18 SEP 26 Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.

NEWS 19 SEP 26 ECLA Thesaurus in CA/CAPLUS Improves Patent Searching on STN

NEWS 20 SEP 26 Access AUPATFULL and CANPATFULL databases with STN Viewer

NEWS 21 OCT 26 New STN Revolutionizes Patent Searching for Professionals

NEWS 22 DEC 1 CA/CAPLUS Now Includes Examiner Citations for Japanese Patents

NEWS 23 DEC 1 CAS Expands Global Patent Coverage - Intellectual Property
Corporation of Malaysia Becomes 62nd Authority on CA/CAPLUS

NEWS 24 DEC 5 STN on the Web Enhancements Include Compatibility with
Microsoft Windows 7

NEWS 25 DEC 14 Removal of ITRD and PATIPC databases from STN

NEWS 26 DEC 15 Rolled-up IPC Core Codes Removed from IPC Reclassifications in
Patent Databases on STN

NEWS 27 JAN 12 Structure Graphics Have Been Added to Abstracts for
MARPAT and CA/CAPLUS on STN

NEWS 28 JAN 15 Online Access to Very Large Chemical Structure Images
Enhanced on STN

NEWS 29 JAN 26 IFICLS Updates Resume on STN

NEWS 30 JAN 31 MEDLINE Reload - Updated MeSH Vocabulary and Two New
Fields on STN

NEWS 31 FEB 1 INPADOC Databases Enhanced with Japanese Patent
Classifications, Current U.S. Classification and Japanese
Legal Status.

NEWS 32 FEB 3 Access More Than 32,000 Harmonized Tariff Codes Now in
CHEMLIST on STN

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,

AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 22:16:30 ON 09 FEB 2012

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.24	0.24

FILE 'REGISTRY' ENTERED AT 22:16:38 ON 09 FEB 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0
DICTIONARY FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025k.str



```

chain nodes :
12
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
2-6 5-12
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-12
exact bonds :
2-6
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom
Generic attributes :
12:
Saturation           : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

```

L1 STRUCTURE UPLOADED

```

=> s 11 sss full
FULL SEARCH INITIATED 22:16:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     58208 TO ITERATE

```

```

100.0% PROCESSED     58208 ITERATIONS                    1113 ANSWERS
SEARCH TIME: 00.00.02

```

L2 1113 SEA SSS FUL L1

```

=> file capl
COST IN U.S. DOLLARS                    SINCE FILE            TOTAL
                                         ENTRY            SESSION
FULL ESTIMATED COST                    203.77            204.01

```

```

FILE 'CAPLUS' ENTERED AT 22:17:03 ON 09 FEB 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

```

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2012 VOL 156 ISS 7
FILE LAST UPDATED: 8 Feb 2012 (20120208/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> sl2

SL2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s 12


L3 32 L2

=> d l3 1-32 ibib hitstr

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2011:1630564 CAPLUS
DOCUMENT NUMBER: 156:122788
TITLE: Libraries on Oxetane δ -Amino Acid Scaffolds:
Syntheses and Evaluation of Physicochemical and
Metabolic Properties
AUTHOR(S): Lucas, Susana Dias; Fischer, Holger; Alker, Andre;
Rauter, Amelia P.; Wessel, Hans Peter
CORPORATE SOURCE: Faculdade de Ciencias, Departamento de Quimica e
Bioquimica, Centro de Quimica e Bioquimica, Edificio
C8, 5^o Piso, Universidade de Lisboa, Campo
Grande, Lisbon, 1749-016, Port.
SOURCE: Journal of Carbohydrate Chemistry (2011), 30(7-9),
498-548
CODEN: JCACDM; ISSN: 0732-8303
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 1354051-53-8P 1354051-63-0P
RL: BSU (Biological study, unclassified); PRP (Properties); RCT
(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent)
(preparation of libraries of oxetane delta-amino acid scaffolds, and (in
silico) determination of their physicochem., metabolic and permeation
properties)
RN 1354051-53-8 CAPLUS

CN Carbamic acid, N-[[[(2R,3R,4R)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1354051-63-0 CAPLUS


CN 2-Oxetanemethanamine, 3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1354051-62-9

CMF C12 H14 N4 O3


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 1354051-68-5P 1354051-73-2P


RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of libraries of oxetane delta-amino acid scaffolds, and (in silico) determination of their physicochem., metabolic and permeation properties)

RN 1354051-68-5 CAPLUS

CN Acetamide, N-[[[(2R,3R,4R)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1354051-73-2 CAPLUS

CN Methanesulfonamide, N-[[(2R,3R,4R)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 1354051-03-8P 1354051-13-0P 1354051-28-7P

1354051-38-9P 1354051-78-7P 1354051-88-9P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of libraries of oxetane delta-amino acid scaffolds, and (in silico) determination of their physicochem., metabolic and permeation properties)

RN 1354051-03-8 CAPLUS

CN Carbamic acid, N-[[(2R,3S,4S)-3-[(4-methoxyphenyl)methoxy]-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1354051-13-0 CAPLUS


CN 3-Oxetanol, 2-(aminomethyl)-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, (2R,3S,4S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1354051-12-9

CMF C11 H12 N4 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1354051-28-7 CAPLUS

CN Carbamic acid, N-[[(2R,3S,4S)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetan-1-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1354051-38-9 CAPLUS


CN 2-Oxetanemethanamine, 3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, (2R,3S,4S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1354051-37-8

CMF C12 H14 N4 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1354051-78-7 CAPLUS

CN Carbamic acid, N-[[[(2R,3R,4R)-3-fluoro-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1354051-88-9 CAPLUS


CN 2-Oxetanemethanamine, 3-fluoro-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1354051-87-8


CMF C11 H11 F N4 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 1354051-18-5P 1354051-23-2P 1354051-43-6P
1354051-48-1P 1354051-93-6P 1354051-98-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of libraries of oxetane delta-amino acid scaffolds, and (in
silico) determination of their physicochem., metabolic and permeation
properties)
RN 1354051-18-5 CAPLUS
CN Acetamide, N-[[(2R,3S,4S)-3-hydroxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 1354051-23-2 CAPLUS
CN Methanesulfonamide, N-[[(2R,3S,4S)-3-hydroxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1354051-43-6 CAPLUS
CN Acetamide, N-[[(2R,3S,4S)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1354051-48-1 CAPLUS

CN Methanesulfonamide, N-[[(2R,3S,4S)-3-methoxy-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1354051-93-6 CAPLUS

CN Acetamide, N-[[(2R,3R,4R)-3-fluoro-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1354051-98-1 CAPLUS

CN Methanesulfonamide, N-[[(2R,3R,4R)-3-fluoro-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-oxetanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

38

THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:1490854 CAPLUS

DOCUMENT NUMBER: 156:64872

TITLE: Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

AUTHOR(S): Flipo, Marion; Desroses, Matthieu; Lecat-Guillet, Nathalie; Villemagne, Baptiste; Blondiaux, Nicolas; Leroux, Florence; Piveteau, Catherine; Mathys, Vanessa; Flament, Marie-Pierre; Siepmann, Juergen; Villaret, Vincent; Wohlkonig, Alexandre; Wintjens, Rene; Soror, Sameh H.; Christophe, Thierry; Jeon, Hee Kyoung; Loch, Camille; Brodin, Priscille; Deprez, Benoit; Baulard, Alain R.; Willand, Nicolas

CORPORATE SOURCE: Universite Lille Nord de France, Lille, F-59000, Fr.

SOURCE: Journal of Medicinal Chemistry (2012), 55(1), 68-83

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English


IT 1352079-02-7P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oxadiazole EthR inhibitors preparation, SAR, and tuberculostatic potential)

RN 1352079-02-7 CAPLUS

CN 1-Butanone, 4,4,4-trifluoro-1-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)




IT 276236-93-2P 276237-03-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oxadiazole EthR inhibitors preparation, SAR, and tuberculostatic potential)


RN 276236-93-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 276237-03-7 CAPLUS

CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:1301625 CAPLUS

DOCUMENT NUMBER: 155:545473

TITLE: Combinations of medicaments containing PDE4 inhibitors and EP4 receptor antagonists for treatment of respiratory diseases

INVENTOR(S): Nickolaus, Peter

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: PCT Int. Appl., 141pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2011124525	A1	20111013	WO 2011-EP55074	20110401
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2010-159390 A 20100408

OTHER SOURCE(S): MARPAT 155:545473


IT 1146358-29-3P 1146358-57-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combinations of medicaments containing PDE4 inhibitors and EP4 receptor antagonists for treatment of respiratory diseases)


RN 1146358-29-3 CAPLUS

CN Thieno[3,2-d]pyrimidin-4-amine, N-(3-fluorophenyl)-6,7-dihydro-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-, 5-oxide (CA INDEX NAME)



RN 1146358-57-7 CAPLUS
 CN 1-Butanol, 2-[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2011:1061091 CAPLUS
 DOCUMENT NUMBER: 155:448649
 TITLE: Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors
 AUTHOR(S): Ontoria, Jesus M.; Bui, Laura Llauger; Torrisi, Caterina; Bresciani, Alberto; Giomini, Claudia; Rowley, Michael; Serafini, Sergio; Bin, Hu; Hao, Wu; Steinkuehler, Christian; Jones, Philip
 CORPORATE SOURCE: IRBM, Merck Research Laboratories Rome, Rome, 00040, Italy
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2011), 21(18), 5274-5282
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English

IT 1334321-92-4
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (identification of quinolinyl oxadiazolyl piperazinyl ureas as potent
 hedgehog pathway inhibitors)
 RN 1334321-92-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-(2-methoxyphenyl)-4-[3-(4-pyridinyl)-1,2,4-
 oxadiazol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2011:789499 CAPLUS
 DOCUMENT NUMBER: 155:123432
 TITLE: Preparation of aminopyrimidines, particularly
 5-[[2-substituted
 aminopyrimidin-4-yl]methylene]thiazolidine-2,4-dione,
 as kinase, especially Pim and CK1, inhibitors
 INVENTOR(S): Baldino, Carmen M.; Caserta, Justin L.; Lee,
 Chee-Seng; Nicewonger, Robert B.; Flanders, Yvonne L.;
 Dumas, Stephane A.
 PATENT ASSIGNEE(S): Jasco Pharmaceuticals, LLC, USA
 SOURCE: U.S. Pat. Appl. Publ., 175pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20110152235	A1	20110623	US 2010-978089	20101223
WO 2011079274	A1	20110630	WO 2010-US62024	20101223
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2009-289685P P 20091223
 US 2010-324481P P 20100415


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 155:123432; MARPAT 155:123432

IT 1312662-79-5P, (Z)-5-[[2-[4-[3-(Pyridin-4-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]pyrimidin-4-yl]methylene]thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aminopyrimidines as inhibitors of Pim and CK1 kinases)
 RN 1312662-79-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-4-pyrimidinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 276237-03-7, 5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminopyrimidines as inhibitors of Pim and CK1 kinases)
 RN 276237-03-7 CAPLUS
 CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2011:225552 CAPLUS

DOCUMENT NUMBER: 154:450247

TITLE: Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors

AUTHOR(S): Shen, Hong C.; Ding, Fa-Xiang; Zhou, Changyou; Xiong, Yusheng; Verras, Andreas; Chabin, Renee M.; Xu, Suoyu; Tong, Xinchun; Xie, Dan; Lassman, Michael E.; Bhatt, Urmi R.; Garcia-Calvo, Margarita M.; Geissler, Wayne; Shen, Zhu; Chen, Dunlu; SinhaRoy, Ranabir; Hale, Jeffery J.; Tata, James R.; Pinto, Shirley; Shen, Dong-Ming; Colletti, Steven L.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2011),

21(5), 1299-1305

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 154:450247

IT 1287730-45-3
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (SAR of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors and potential food intake and body weight modulators)
 RN 1287730-45-3 CAPLUS
 CN 1-Propanone, 1-[(2S)-2-(5,6-dichloro-1H-benzimidazol-2-yl)-1-pyrrolidinyl]-3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:1101846 CAPLUS

DOCUMENT NUMBER: 153:382976

TITLE: Preparation of pyrimidinylpiperidines as PDE4 inhibitors

INVENTOR(S): Nickolaus, Peter; Goeggel, Rolf; Peter, Daniel

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: PCT Int. Appl., 134pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010097334	A1	20100902	WO 2010-EP52079	20100218
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2753604	A1	20100902	CA 2010-2753604	20100218

EP 2400962 A1 20120104 EP 2010-704932 20100218
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, SM, TR

PRIORITY APPLN. INFO.:

EP 2009-153855 A 20090227
 EP 2009-166131 A 20090722
 WO 2010-EP52079 W 20100218


OTHER SOURCE(S): MARPAT 153:382976

IT 1146358-29-3P 1146358-57-7P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidinylpiperidines as PDE4 inhibitors)

RN 1146358-29-3 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(3-fluorophenyl)-6,7-dihydro-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-, 5-oxide (CA INDEX NAME)



RN 1146358-57-7 CAPLUS

CN 1-Butanol, 2-[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 276237-03-7

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrimidinylpiperidines as PDE4 inhibitors)

RN 276237-03-7 CAPLUS

CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:852000 CAPLUS

DOCUMENT NUMBER: 153:175007

TITLE: Substituted pyrimidine and triazine compounds as bradykinin receptor 1 inhibitors useful in the treatment of pain and other disorders

INVENTOR(S): Schunk, Stefan; Reich, Melanie; Hennig, Kamila; Engels, Michael; Germann, Tieno; Jostock, Ruth; Hees, Sabine

PATENT ASSIGNEE(S): Gruenenthal GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 124pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100173889	A1	20100708	US 2009-604691	20091023
PRIORITY APPLN. INFO.:			EP 2008-18514	A 20081023
			US 2008-107877P	P 20081023

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 153:175007; MARPAT 153:175007

IT 1224585-08-3P 1224585-21-0P 1224585-47-0P

1224586-00-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidine and triazine compds. as bradykinin receptor 1 inhibitors useful in the treatment of pain and other disorders)


RN 1224585-08-3 CAPLUS

CN Pyrimidine, 2-[[[(2S)-1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-pyrrolidinyl]methoxy]-4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1224585-21-0 CAPLUS
 CN Pyrimidine, 2-[[1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-piperidinyl]methoxy]-4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 1224585-47-0 CAPLUS
 CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[1-phenyl-2-[[4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-pyrimidinyl]oxy]ethyl]- (CA INDEX NAME)



RN 1224586-00-8 CAPLUS
 CN Pyrimidine, 4-[[[(2S)-1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-pyrrolidinyl]methoxy]-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2010:649702 CAPLUS
DOCUMENT NUMBER: 152:591861
TITLE: Preparation of 4,6-diaminonicotinamide compounds as
JAK3 kinase inhibitors
INVENTOR(S): Shirakami, Shohei; Takahashi, Fumie; Nakajima, Yutaka;
Omura, Hirofumi; Aoyama, Naohiro; Sasaki, Hiroshi;
Hondo, Takeshi; Tominaga, Hiroaki
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 225pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010058846	A1	20100527	WO 2009-JP69731	20091120
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU			

IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
 ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 EP 2361902 A1 20110831 EP 2009-827627 20091120
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, SM, TR
 US 20110230467 A1 20110922 US 2011-130527 20110520
 PRIORITY APPLN. INFO.: JP 2008-297770 A 20081121
 WO 2009-JP69731 W 20091120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 152:591861


IT 1227482-64-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4,6-diaminonicotinamide compds. as JAK3 kinase inhibitors
 for treatment or prevention of diseases caused by undesirable and/or
 abnormal cytokine signaling)

RN 1227482-64-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-[(phenylmethyl)amino]-6-[[3-[[4-[3-(4-pyridinyl)-
 1,2,4-oxadiazol-5-yl]-1-piperidinyl]carbonyl]phenyl]amino]- (CA INDEX
 NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:530495 CAPLUS

DOCUMENT NUMBER: 152:525868

TITLE: Preparation of pyrimidinylsulfonamides as b1
 bradykinin receptor (blr) inhibitors for the treatment
 of pain

INVENTOR(S): Schunk, Stefan; Reich, Melanie; Hennig, Kamila;
 Engels, Michael; Germann, Tieno; Jostock, Ruth; Hees,
 Sabine

PATENT ASSIGNEE(S): Gruenenthal GmbH, Germany

SOURCE: PCT Int. Appl., 215pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010046109	A1	20100429	WO 2009-EP7568	20091022
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,			
	CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,			
	ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,			
	KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,			

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
AU 2009306723 A1 20100429 AU 2009-306723 20091022
CA 2741349 A1 20100429 CA 2009-2741349 20091022
AR 73919 A1 20101209 AR 2009-104060 20091022
EP 2356101 A1 20110817 EP 2009-740860 20091022
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
SI, SK, SM, TR
MX 2011004211 A 20110524 MX 2011-4211 20110419
PRIORITY APPLN. INFO.: EP 2008-18514 A 20081023
WO 2009-EP7568 W 20091022

OTHER SOURCE(S): MARPAT 152:525868


IT 1224585-08-3P 1224585-21-0P,
5-[1-[2-[[1-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]piperidin-2-
yl]methoxy]pyrimidin-4-yl]piperidin-4-yl]-3-pyridin-4-yl-[1,2,4]oxadiazole
1224585-47-0P 1224586-00-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidinylsulfonamides as b1 bradykinin receptor (b1r)
inhibitors for the treatment of pain)

RN 1224585-08-3 CAPLUS


CN Pyrimidine, 2-[[[(2S)-1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-
pyrrolidinyl]methoxy]-4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-
piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1224585-21-0 CAPLUS

CN Pyrimidine, 2-[[[1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-
piperidinyl]methoxy]-4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-
piperidinyl]- (CA INDEX NAME)



RN 1224585-47-0 CAPLUS


CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[1-phenyl-2-[[4-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-pyrimidinyl]oxy]ethyl]- (CA INDEX NAME)



RN 1224586-00-8 CAPLUS

CN Pyrimidine, 4-[[[(2S)-1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-pyrrolidinyl]methoxy]-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 276237-03-7, 5-(Piperidin-4-yl)-3-(pyridin-4-yl)[1,2,4]oxadiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinylsulfonamides as b1 bradykinin receptor (b1r) inhibitors for the treatment of pain)

RN 276237-03-7 CAPLUS

CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2010:243485 CAPLUS

DOCUMENT NUMBER: 152:311635

TITLE: Preparation of triazine compounds as inhibitors of
voltage-gated sodium channels for treating chronic
pain disorders

INVENTOR(S): Buchanan, John L.; Bregman, Howard; Chakka, Nagasree;
Dimauro, Erin F.; Du, Bingfan; Nguyen, Hanh Nho;
Zheng, Xiao Mei

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 298pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010022055	A2	20100225	WO 2009-US54169	20090818
WO 2010022055	A3	20100617		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-189501P P 20080820
US 2008-196012P P 20081014


OTHER SOURCE(S): CASREACT 152:311635; MARPAT 152:311635

IT 1211866-02-2P, N-[3-[[4-[4-[3-(3-Chloro-4-pyridinyl)-1,2,4-
oxadiazol-5-yl]-1-piperidinyl]-1,3,5-triazin-2-yl]amino]phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of triazine compds. as inhibitors of
voltage-gated sodium channels for treating chronic pain disorders)

RN 1211866-02-2 CAPLUS

CN Acetamide, N-[3-[[4-[4-[3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-
piperidinyl]-1,3,5-triazin-2-yl]amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:930581 CAPLUS

DOCUMENT NUMBER: 151:304181

TITLE: Discovery of a Highly Potent, Selective, and Bioavailable Soluble Epoxide Hydrolase Inhibitor with Excellent Ex Vivo Target Engagement

AUTHOR(S): Shen, Hong C.; Ding, Fa-Xiang; Wang, Siyi; Deng, Qiaolin; Zhang, Xiaoping; Chen, Yuli; Zhou, Gaochao; Xu, Suoyu; Chen, Hsuan-shen; Tong, Xinchun; Tong, Vincent; Mitra, Kaushik; Kumar, Sanjeev; Tsai, Christine; Stevenson, Andra S.; Pai, Lee-Yuh; Alonso-Galicia, Magdalena; Chen, Xiaoli; Soisson, Stephen M.; Roy, Sophie; Zhang, Bei; Tata, James R.; Berger, Joel P.; Colletti, Steven L.

CORPORATE SOURCE: Merck Research Laboratories, Merck and Co. Inc., Rahway, NJ, 07065-0900, USA

SOURCE: Journal of Medicinal Chemistry (2009), 52(16), 5009-5012

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 151:304181


IT 1185008-94-9P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(soluble epoxide hydrolase inhibitors preparation, SAR, and vasodilating action)

RN 1185008-94-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-phenylcyclopropyl)-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:914152 CAPLUS

DOCUMENT NUMBER: 151:173470

TITLE: Preparation of 1,2,4-oxadiazolyl-substituted piperidines for the treatment of cardiovascular diseases, thromboembolic disorders and tumor

INVENTOR(S): Heimbach, Dirk; Roehrig, Susanne; Schneider, Dirk; Rester, Ulrich; Bender, Eckhard; Meininghaus, Mark; Zimmermann, Katja; Zubov, Dmitry; Buchmueller, Anja; Degenfeld, Georges; Gerdes, Christoph; Gerisch, Michael; Gnoth, Mark Jean

PATENT ASSIGNEE(S): Bayer HealthCare AG, Germany

SOURCE: Ger. Offen., 95pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102007057718	A1	20090730	DE 2007-102007057718	20071130
CA 2706991	A1	20090604	CA 2008-2706991	20081120
WO 2009068214	A2	20090604	WO 2008-EP9792	20081120
WO 2009068214	A3	20090820		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2227466	A2	20100915	EP 2008-854224	20081120
EP 2227466	B1	20110420		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
KR 2010114018	A	20101022	KR 2010-7014447	20081120
CN 101932577	A	20101229	CN 2008-80126026	20081120
JP 2011504889	T	20110217	JP 2010-535272	20081120
AT 506359	T	20110515	AT 2008-854224	20081120
PT 2227466	E	20110701	PT 2008-854224	20081120
ES 2363945	T3	20110819	ES 2008-854224	20081120
AR 69417	A1	20100120	AR 2008-105089	20081124
US 20090306139	A1	20091210	US 2008-323454	20081125
IN 2010DN03251	A	20101015	IN 2010-DN3251	20100510
PRIORITY APPLN. INFO.:			DE 2007-102007057718A	20071130
			DE 2008-102008010221A	20080220
			WO 2008-EP9792	W 20081120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 1159307-40-0P 1159307-42-2P 1159308-21-0P
1159308-24-3P 1159308-36-7P 1159308-38-9P
1159308-40-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of oxadiazolyl-substituted piperidines for the treatment of cardiovascular diseases, thromboembolic disorders and tumor)

RN 1159307-40-0 CAPLUS

CN Methanone, cyclopentyl[(3R,5R)-3-(4-ethylphenyl)-5-[3-(4-pyridinyl)-1,2,4-

oxadiazol-5-yl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159307-42-2 CAPLUS

CN Methanone, 4-morpholinyl[(3R,5R)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-21-0 CAPLUS

CN Methanone, [(3R,5R)-3-[3-(2-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-24-3 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-(2-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-N-ethyl-5-(4-ethylphenyl)-N-methyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-36-7 CAPLUS

CN Methanone, [(3R,5R)-3-[3-[2-[(2-methoxyethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-38-9 CAPLUS

CN Methanone, 4-morpholinyl[(3R,5R)-3-[3-[2-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-40-3 CAPLUS

CN Methanone, [(3R,5R)-3-[3-[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:846112 CAPLUS

DOCUMENT NUMBER: 151:92849

TITLE: Method using lifespan-altering compounds for altering
the lifespan of eukaryotic organisms, and screening
for such compounds

INVENTOR(S): Goldfarb, David Scott

PATENT ASSIGNEE(S): University of Rochester, USA

SOURCE: U.S. Pat. Appl. Publ., 57pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
JP 2011507910	T	20110310	JP 2010-539936	20081222
PRIORITY APPLN. INFO.:			US 2008-23801P	P 20080125
			US 2007-16362P	P 20071221
			US 2008-341615	20081222
			WO 2008-US88016	W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT 837412-47-2 837412-52-9

RL: PAC (Pharmacological activity); BIOL (Biological study)


(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)

RN 837412-47-2 CAPLUS

CN Piperidine, 1-[(4-chloro-3-fluorophenyl)sulfonyl]-4-[3-(4-pyridinyl)-1,2,4-
oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 837412-52-9 CAPLUS
 CN 1-Piperidinecarboxamide, N,N-bis(1-methylethyl)-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2009:846109 CAPLUS
 DOCUMENT NUMBER: 151:92846
 TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds
 INVENTOR(S): Goldfarb, David Scott
 PATENT ASSIGNEE(S): University of Rochester, USA
 SOURCE: U.S. Pat. Appl. Publ., 57pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 20
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
JP 2011507910	T	20110310	JP 2010-539936	20081222
PRIORITY APPLN. INFO.:			US 2008-23801P	P 20080125
			US 2007-16362P	P 20071221
			US 2008-341615	20081222
			WO 2008-US88016	W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 837412-46-1
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)
 RN 837412-46-1 CAPLUS
 CN Piperidine, 1-[(3-nitrophenyl)sulfonyl]-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-

5-y1]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:675939 CAPLUS

DOCUMENT NUMBER: 151:8316

TITLE: Isoquinolinone derivatives as NK3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of psychosis and schizophrenia

INVENTOR(S): Simonsen, Klaus Baek; Kehler, Jan; Juhl, Karsten;
Khanzhin, Nikolay; Nielsen, Soren Moller

PATENT ASSIGNEE(S) : H. Lundbeck A/S, Den.

SOURCE: U.S. Pat. Appl. Publ., 111pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
1000000	A	1990-01-01	1000000	1990-01-01
1000001	A	1990-01-01	1000001	1990-01-01
1000002	A	1990-01-01	1000002	1990-01-01
1000003	A	1990-01-01	1000003	1990-01-01
1000004	A	1990-01-01	1000004	1990-01-01
1000005	A	1990-01-01	1000005	1990-01-01
1000006	A	1990-01-01	1000006	1990-01-01
1000007	A	1990-01-01	1000007	1990-01-01
1000008	A	1990-01-01	1000008	1990-01-01
1000009	A	1990-01-01	1000009	1990-01-01
1000010	A	1990-01-01	1000010	1990-01-01
1000011	A	1990-01-01	1000011	1990-01-01
1000012	A	1990-01-01	1000012	1990-01-01
1000013	A	1990-01-01	1000013	1990-01-01
1000014	A	1990-01-01	1000014	1990-01-01
1000015	A	1990-01-01	1000015	1990-01-01
1000016	A	1990-01-01	1000016	1990-01-01
1000017	A	1990-01-01	1000017	1990-01-01
1000018	A	1990-01-01	1000018	1990-01-01
1000019	A	1990-01-01	1000019	1990-01-01
1000020	A	1990-01-01	1000020	1990-01-01
1000021	A	1990-01-01	1000021	1990-01-01
1000022	A	1990-01-01	1000022	1990-01-01
1000023	A	1990-01-01	1000023	1990-01-01
1000024	A	1990-01-01	1000024	1990-01-01
1000025	A	1990-01-01	1000025	1990-01-01
1000026	A	1990-01-01	1000026	1990-01-01
1000027	A	1990-01-01	1000027	1990-01-01
1000028	A	1990-01-01	1000028	1990-01-01
1000029	A	1990-01-01	1000029	1990-01-01
1000030	A	1990-01-01	1000030	1990-01-01
1000031	A	1990-01-01	1000031	1990-01-01
1000032	A	1990-01-01	1000032	1990-01-01
1000033	A	1990-01-01	1000033	1990-01-01
1000034	A	1990-01-01	1000034	1990-01-01
1000035	A	1990-01-01	1000035	1990-01-01
1000036	A	1990-01-01	1000036	1990-01-01
1000037	A	1990-01-01	1000037	1990-01-01
1000038	A	1990-01-01	1000038	1990-01-01
1000039	A	1990-01-01	1000039	1990-01-01
1000040	A	1990-01-01	1000040	1990-01-01
1000041	A	1990-01-01	1000041	1990-01-01
1000042	A	1990-01-01	1000042	1990-01-01
1000043	A	1990-01-01	1000043	1990-01-01
1000044	A	1990-01-01	1000044	1990-01-01
1000045	A	1990-01-01	1000045	1990-01-01
1000046	A	1990-01-01	1000046	1990-01-01
1000047	A	1990-01-01	1000047	1990-01-01
1000048	A	1990-01-01	1000048	1990-01-01
1000049	A	1990-01-01	1000049	1990-01-01
1000050	A	1990-01-01	1000050	1990-01-01
1000051	A	1990-01-01	1000051	1990-01-01
1000052	A	1990-01-01	1000052	1990-01-01
1000053	A	1990-01-01	1000053	1990-01-01
1000054	A	1990-01-01	1000054	1990-01-01
1000055	A	1990-01-01	1000055	1990-01-01
1000056	A	1990-01-01	1000056	1990-0

US 20090143402 A1 20090604 US 2008-101592 20080411

PRIORITY APPLN. INFO.: US 2007-914159P P 20070426

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:8316

IT 1075713-30-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoquinolinone derivs. as NK3 antagonists useful in the treatment of psychosis and schizophrenia)


RN 1075713-30-2 CAPLUS

CN 4-Isoquinolinecarboxamide, 1,2-dihydro-1-oxo-2-phenyl-N-[(1S)-1-phenylpropyl]-3-[[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 276237-03-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of isoquinolinone derivs. as NK3 antagonists
 useful in the treatment of psychosis and schizophrenia)
 RN 276237-03-7 CAPLUS
 CN Pyridine, 4-[5-(4-piperidiny1)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:675111 CAPLUS

DOCUMENT NUMBER: 151:33604

TITLE: Preparation of 1,2,4-oxadiazolyl-substituted
 piperidines for the treatment of cardiovascular
 diseases, thromboembolic disorders and tumor

INVENTOR(S): Heimbach, Dirk; Roehrig, Susanne; Schneider, Dirk;
 Rester, Ulrich; Bender, Eckhard; Meininghaus, Mark;
 Zimmermann, Katja; Zubov, Dmitry; Buchmueller, Anja;
 Degenfeld, Georges; Gerdes, Christoph; Gerisch,
 Michael; Gnoth, Mark Jean; Cancho-Grande, Yolanda
 PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 561 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009068214	A2	20090604	WO 2008-EP9792	20081120
WO 2009068214	A3	20090820		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
DE 102007057718	A1	20090730	DE 2007-102007057718	20071130
DE 102008010221	A1	20090827	DE 2008-102008010221	20080220
CA 2706991	A1	20090604	CA 2008-2706991	20081120
EP 2227466	A2	20100915	EP 2008-854224	20081120
EP 2227466	B1	20110420		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
KR 2010114018	A	20101022	KR 2010-7014447	20081120

CN 101932577	A	20101229	CN 2008-80126026	20081120
JP 2011504889	T	20110217	JP 2010-535272	20081120
AT 506359	T	20110515	AT 2008-854224	20081120
IN 2010DN03251	A	20101015	IN 2010-DN3251	20100510
PRIORITY APPLN. INFO.:			DE 2007-102007057718A	20071130
			DE 2008-102008010221A	20080220
			WO 2008-EP9792	W 20081120

OTHER SOURCE(S): CASREACT 151:33604; MARPAT 151:33604

IT 1159307-40-0P	1159307-42-2P	1159308-21-0P
1159308-24-3P	1159308-36-7P	1159308-38-9P
1159308-40-3P	1159309-28-0P	1159311-84-8P
1159312-27-2P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxadiazolyl-substituted piperidines for the treatment of cardiovascular diseases, thromboembolic disorders and tumor)

RN 1159307-40-0 CAPLUS

CN Methanone, cyclopentyl[(3R,5R)-3-(4-ethylphenyl)-5-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159307-42-2 CAPLUS

CN Methanone, 4-morpholinyl[(3R,5R)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-21-0 CAPLUS

CN Methanone, [(3R,5R)-3-[3-(2-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-24-3 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-(2-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-N-ethyl-5-(4-ethylphenyl)-N-methyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-36-7 CAPLUS

CN Methanone, [(3R,5R)-3-[3-[2-[(2-methoxyethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-38-9 CAPLUS

CN Methanone, 4-morpholinyl[(3R,5R)-3-[3-[2-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159308-40-3 CAPLUS

CN Methanone, [(3R, 5R)-3-[3-[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]-4-morpholinyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159309-28-0 CAPLUS

CN Methanone, 4-morpholinyl[(3R, 5R)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethyl)phenyl]-1-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159311-84-8 CAPLUS

CN Methanone, (4-hydroxy-1-piperidiny] [(3R,5R)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethyl)phenyl]-1-piperidiny]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1159312-27-2 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[(3R,5R)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethyl)phenyl]-1-piperidiny]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:534352 CAPLUS

DOCUMENT NUMBER: 151:93232

TITLE: Synthesis, SAR and Unanticipated Pharmacological Profiles of Analogues of the mGluR5 Ago-potentiator ADX-47273

AUTHOR(S): Engers, Darren W.; Rodriguez, Alice L.; Williams, Richard; Hammond, Alexis S.; Venable, Daryl; Oluwatola, Oluwatomi; Sulikowski, Gary A.; Conn, P. Jeffrey; Lindsley, Craig W.

CORPORATE SOURCE: Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, MRBIV (Langford)-12415D, Nashville, TN, 37232-6600, USA

SOURCE: ChemMedChem (2009), 4(4), 505-511

CODEN: CHEMGX; ISSN: 1860-7179

PUBLISHER: Wiley-VCH Verlag GmbH

& Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 151:93232

IT 851881-95-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis, SAR and unanticipated pharmacol. profiles of analogs of the mGluR5 Ago-potentiator ADX-47273)

RN 851881-95-3 CAPLUS

CN Methanone, (4-fluorophenyl)[(3S)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS
RECORD (19 CITINGS)
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:490032 CAPLUS

DOCUMENT NUMBER: 150:472737

TITLE: Preparation of piperidinodihydrothienopyrimidines as
phosphodiesterase PDE4 inhibitors.

INVENTOR(S): Pouzet, Pascale; Anderskewitz, Ralf; Dollinger, Horst;
Fiegen, Dennis; Fox, Thomas; Goeggel, Rolf; Hoenke,
Christoph; Martyres, Domnic; Nickolaus, Peter;
Klinder, Klaus

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: PCT Int. Appl., 290pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009050248	A1	20090423	WO 2008-EP63999	20081016
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2008313660	A1	20090423	AU 2008-313660	20081016
CA 2705414	A1	20090423	CA 2008-2705414	20081016
EP 2215092	A1	20100811	EP 2008-839793	20081016
EP 2215092	B1	20120125		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
KR 2010100807	A	20100915	KR 2010-7010905	20081016
JP 2011500640	T	20110106	JP 2010-529389	20081016
NZ 585346	A	20110930	NZ 2008-585346	20081016
EP 2380891	A1	20111026	EP 2011-174754	20081016
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BA, RS			
AR 69075	A1	20091230	AR 2008-104560	20081017
ZA 2010001683	A	20101027	ZA 2010-1683	20100309
MX 2010004026	A	20100430	MX 2010-4026	20100414
CN 101827852	A	20100908	CN 2008-80112254	20100419
IN 2010DN02946	A	20111104	IN 2010-DN2946	20100428
US 20110021501	A1	20110127	US 2010-738344	20100713
PRIORITY APPLN. INFO.:			EP 2007-118901	A 20071019
			EP 2008-839793	A3 20081016
			WO 2008-EP63999	W 20081016

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:472737; MARPAT 150:472737


IT 1146357-69-8P 1146358-02-2P 1146358-29-3P
 1146358-57-7P 1146359-01-4P 1146363-09-8P
 1146363-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of piperidinodihydrothienopyrimidines as phosphodiesterase PDE4
 inhibitors)


RN 1146357-69-8 CAPLUS

CN Cyclopropanemethanol, 1-[[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-
 oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA
 INDEX NAME)




RN 1146358-02-2 CAPLUS

CN Thieno[3,2-d]pyrimidin-4-amine, 6,7-dihydro-2-[4-[3-(4-pyridinyl)-1,2,4-
 oxadiazol-5-yl]-1-piperidinyl]-N-(tetrahydro-2H-pyran-4-yl)-, 5-oxide (CA
 INDEX NAME)



RN 1146358-29-3 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(3-fluorophenyl)-6,7-dihydro-2-[4-[3-(4-
 pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-, 5-oxide (CA INDEX NAME)



RN 1146358-57-7 CAPLUS

CN 1-Butanol, 2-[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1146359-01-4 CAPLUS

CN 2-Piperidinone, 5-[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]-1-methyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1146363-09-8 CAPLUS

CN Thieno[3,2-d]pyrimidin-4-amine, N-(3-fluorophenyl)-6,7-dihydro-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-, 5-oxide, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1146358-29-3


CMF C24 H22 F N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1146363-12-3 CAPLUS


CN 1-Butanol, 2-[[6,7-dihydro-5-oxido-2-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]thieno[3,2-d]pyrimidin-4-yl]amino]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1146358-57-7

CMF C23 H29 N7 O3 S


Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 276237-03-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperidinodihydrothienopyrimidines as phosphodiesterase PDE4 inhibitors)
RN 276237-03-7 CAPLUS
CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2008:1338111 CAPLUS
DOCUMENT NUMBER: 149:534072
TITLE: Isoquinolinone derivatives as NK3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of psychosis and schizophrenia
INVENTOR(S): Simonsen, Klaus Baek; Kehler, Jan; Juhl, Karsten; Khanzhin, Nikolay; Nielsen, Soeren Moeller
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 276pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008131779	A1	20081106	WO 2008-DK50092	20080424
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AR 66260	A1	20090805	AR 2008-101703	20080423

AU 2008243514	A1	20081106	AU 2008-243514	20080424
CA 2683159	A1	20081106	CA 2008-2683159	20080424
EP 2150534	A1	20100210	EP 2008-734547	20080424
EP 2150534	B1	20120111		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
KR 2010015933	A	20100212	KR 2009-7022393	20080424
JP 2010524980	T	20100722	JP 2010-504454	20080424
NZ 580637	A	20110729	NZ 2008-580637	20080424
AT 540929	T	20120115	AT 2008-734547	20080424
AU 2009239990	A1	20091029	AU 2009-239990	20090422
CA 2721260	A1	20091029	CA 2009-2721260	20090422
WO 2009130240	A1	20091029	WO 2009-EP54806	20090422
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2010134667	A	20101223	KR 2010-7023117	20090422
EP 2276741	A1	20110126	EP 2009-734883	20090422
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS				
CN 102026980	A	20110420	CN 2009-80114280	20090422
JP 2011518801	T	20110630	JP 2011-505497	20090422
NZ 588689	A	20110930	NZ 2009-588689	20090422
ZA 2009007295	A	20110126	ZA 2009-7295	20091019
CN 101679276	A	20100324	CN 2008-80013510	20091023
MX 2009011541	A	20091109	MX 2009-11541	20091026
IN 2009CN06318	A	20100115	IN 2009-CN6318	20091026
ZA 2010007126	A	20111228	ZA 2010-7126	20101006
MX 2010011266	A	20101101	MX 2010-11266	20101014
IN 2010CN06746	A	20110701	IN 2010-CN6746	20101021
US 20110130420	A1	20110602	US 2011-988631	20110104
PRIORITY APPLN. INFO.:			DK 2007-620	A 20070426
			WO 2008-DK50092	W 20080424
			WO 2009-EP54806	W 20090422

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:534072; MARPAT 149:534072

IT 1075713-30-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoquinolinone derivs. as NK3 antagonists useful in the treatment of psychosis and schizophrenia)


RN 1075713-30-2 CAPLUS

CN 4-Isoquinolinecarboxamide, 1,2-dihydro-1-oxo-2-phenyl-N-[(1S)-1-phenylpropyl]-3-[[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 276237-03-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of isoquinolinone derivs. as NK3 antagonists
 useful in the treatment of psychosis and schizophrenia)
 RN 276237-03-7 CAPLUS
 CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2008:1244685 CAPLUS
 DOCUMENT NUMBER: 149:471110
 TITLE: N-Hydroxy carboxamides as inhibitors of histone
 deacetylase and their preparation and use in the
 treatment of HDAC-mediated diseases
 INVENTOR(S): Tessier, Pierre; Leit, Silvana; Smil, David; Deziel,
 Robert; Ajamian, Alain; Chantigny, Yves Andre;
 Dominguez, Celia
 PATENT ASSIGNEE(S): Methylogene Inc., Can.
 SOURCE: PCT Int. Appl., 333pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122115	A1	20081016	WO 2008-CA631	20080409
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				

IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2008235212	A1	20081016	AU 2008-235212	20080409
CA 2683557	A1	20081016	CA 2008-2683557	20080409
US 20090181943	A1	20090716	US 2008-100200	20080409
EP 2139850	A1	20100106	EP 2008-748100	20080409

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, TR, AL, BA, RS

KR 2010016351	A	20100212	KR 2009-7023348	20080409
JP 2010523601	T	20100715	JP 2010-502392	20080409
ZA 2009006609	A	20100526	ZA 2009-6609	20090922
CN 101679220	A	20100324	CN 2008-80019410	20091209

PRIORITY APPLN. INFO.:

US 2007-922505P	P	20070409
WO 2008-CA631	W	20080409

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:471110; MARPAT 149:471110


IT 1070701-65-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of N-hydroxy carboxamide derivs. as histone
 deacetylase inhibitors useful in the treatment of HDAC-mediated
 diseases)

RN 1070701-65-3 CAPLUS

CN 1-Piperidineacetamide, N-hydroxy- α -phenyl-4-[3-(4-pyridinyl)-1,2,4-
 oxadiazol-5-yl]- (CA INDEX NAME)




IT 276237-03-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of N-hydroxy carboxamide derivs. as histone
 deacetylase inhibitors useful in the treatment of HDAC-mediated
 diseases)

RN 276237-03-7 CAPLUS


CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2008:1136078 CAPLUS
 DOCUMENT NUMBER: 149:439374
 TITLE: Structural modifications of N-arylamide oxadiazoles:
 Identification of N-arylpiperidine oxadiazoles as
 potent and selective agonists of CB2. [Erratum to
 document cited in CA149:369632]
 AUTHOR(S): DiMauro, Erin F.; Buchanan, John L.; Chen, Alan;
 Emkey, Renee; Hitchcock, Stephen A.; Huang, Liyue;
 Huang, Ming Y.; Janosky, Brett; Lee, Josie H.; Li,
 Xingwen; Martin, Matthew W.; Tomlinson, Susan A.;
 White, Ryan D.; Zheng, Xiao Mei; Patel, Vinod F.;
 Fremeau, Robert T.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Amgen Inc.,
 Cambridge, MA, 02139, USA
 SOURCE: Bioorganic & Medicinal
 Chemistry Letters (2008),
 18(18), 5156
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 1059063-74-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (structural modifications of N-arylamide oxadiazoles and identification
 of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2
 (Erratum))
 RN 1059063-74-9 CAPLUS
 CN Quinoline, 3-[4-[3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-
 piperidinyl]- (CA INDEX NAME)




IT 1059063-71-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (structural modifications of N-arylamide oxadiazoles and identification
 of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2
 (Erratum))
 RN 1059063-71-6 CAPLUS
 CN Quinoline, 3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-
 (CA INDEX NAME)



ACCESSION NUMBER: 2008:903960 CAPLUS
 DOCUMENT NUMBER: 149:369632
 TITLE: Structural modifications of N-arylamide oxadiazoles:
 Identification of N-arylpiperidine oxadiazoles as
 potent and selective agonists of CB2
 AUTHOR(S): DiMauro, Erin F.; Buchanan, John L.; Cheng, Alan;
 Emkey, Renee; Hitchcock, Stephen A.; Huang, Liyue;
 Huang, Ming Y.; Janosky, Brett; Lee, Josie H.; Li,
 Xingwen; Martin, Matthew W.; Tomlinson, Susan A.;
 White, Ryan D.; Zheng, Xiao Mei; Patel, Vinod F.;
 Fremeau, Robert T., Jr.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Amgen Inc.,
 Cambridge, MA, 02139, USA
 SOURCE: Bioorganic & Medicinal
 Chemistry Letters (2008),
 18(15), 4267-4274
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:369632
 IT 1059063-74-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (structural modifications of N-arylamide oxadiazoles and identification
 of N-arylpiperidine oxadiazoles as potent and selective agonists of
 CB2)
 RN 1059063-74-9 CAPLUS
 CN Quinoline, 3-[4-[3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-
 piperidinyl]- (CA INDEX NAME)



IT 1059063-71-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (structural modifications of N-arylamide oxadiazoles and identification
 of N-arylpiperidine oxadiazoles as potent and selective agonists of
 CB2)
 RN 1059063-71-6 CAPLUS
 CN Quinoline, 3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-
 (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2008:445930 CAPLUS

DOCUMENT NUMBER: 148:449465

TITLE: Preparation of 1-(phenylsulfonyl)piperidines as bradykinin BK1 receptor inhibitors

INVENTOR(S): Oberboersch, Stefan; Schunk, Stefan; Reich, Melanie; Hees, Sabine; Jostock, Ruth; Engels, Michael; Kless, Achim; Christoph, Thomas; Schiene, Klaus; Germann, Tieno; Bijsterveld, Edward

PATENT ASSIGNEE(S): Gruenenthal GmbH, Germany

SOURCE: PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008040492	A1	20080410	WO 2007-EP8417	20070927
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2007304475	A1	20080410	AU 2007-304475	20070927
CA 2664810	A1	20080410	CA 2007-2664810	20070927
EP 2066659	A1	20090610	EP 2007-818500	20070927
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
KR 2009079914	A	20090722	KR 2009-7008960	20070927
JP 2010504930	T	20100218	JP 2009-529606	20070927
NZ 575566	A	20110527	NZ 2007-575566	20070927
EP 2383267	A1	20111102	EP 2011-6169	20070927
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR			
US 20080153843	A1	20080626	US 2007-905381	20070928
MX 2009003382	A	20090408	MX 2009-3382	20090330
NO 2009001299	A	20090429	NO 2009-1299	20090330
IN 2009KN01610	A	20090529	IN 2009-KN1610	20090429
CN 101553481	A	20091007	CN 2007-80043610	20090525
US 20100317644	A1	20101216	US 2010-862297	20100824
US 20100324009	A1	20101223	US 2010-862271	20100824
PRIORITY APPLN. INFO.:			DE 2006-102006046743A	20060929
			US 2006-849438P	P 20061005
			EP 2007-818500	A3 20070927
			WO 2007-EP8417	W 20070927
			US 2007-905381	A1 20070928

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 148:449465; MARPAT 148:449465

IT 1018821-26-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylsulfonylpiperidines as bradykinin BK1 receptor inhibitors)

RN 1018821-26-5 CAPLUS

CN Ethanone, 2-[[1-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-2-piperidinyl]methoxy]-1-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)




IT 276237-03-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylsulfonylpiperidines as bradykinin BK1 receptor inhibitors)

RN 276237-03-7 CAPLUS

CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:761334 CAPLUS

DOCUMENT NUMBER: 147:166196

TITLE: Bicyclic nitrogen compounds as modulators of ghrelin receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Burstein, Ethan; Eeg Knapp, Anne; Olsson, Roger; Eskildsen, Jorgen; Ek, Fredrik

PATENT ASSIGNEE(S): Acadia Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 481pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007079239	A2	20070712	WO 2006-US49609	20061229
WO 2007079239	A3	20071101		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070213359	A1	20070913	US 2006-618724	20061229
PRIORITY APPLN. INFO.:			US 2005-755714P	P 20051230
			US 2006-835241P	P 20060802

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 147:166196; MARPAT 147:166196


IT	944075-19-8P	944075-48-3P	944075-66-5P
	944076-95-3P	944078-90-4P	944079-01-0P
	944079-21-4P	944079-35-0P	944079-43-0P
	944079-53-2P	944079-62-3P	944079-93-0P
	944080-09-5P	944082-94-4P	944083-01-6P
	944083-28-7P		

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of bicyclic nitrogen compds. as modulators of ghrelin receptors for treating various diseases)


RN 944075-19-8 CAPLUS

CN 1H-Indole-3-carboxamide, 7-methoxy-N-[(3-methylphenyl)methyl]-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]- (CA INDEX NAME)




RN 944075-48-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3-chlorophenyl)methyl]-7-methoxy-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]- (CA INDEX NAME)




RN 944075-66-5 CAPLUS

CN 1H-Indole-3-carboxamide, 7-methoxy-N-(2-methylpropyl)-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]- (CA INDEX NAME)




RN 944076-95-3 CAPLUS

CN Methanone, [7-methoxy-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]phenyl- (CA INDEX NAME)




RN 944078-90-4 CAPLUS

CN Ethanone, 1-[7-bromo-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-01-0 CAPLUS

CN Ethanone, 1-[7-bromo-2-methyl-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-21-4 CAPLUS

CN Ethanone, 1-[7-chloro-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-35-0 CAPLUS

CN Ethanone, 1-[7-ethyl-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-43-0 CAPLUS

CN Ethanone, 1-[7-methoxy-1-[2-methyl-3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-53-2 CAPLUS

CN Ethanone, 1-[7-methoxy-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]-2-phenyl- (CA INDEX NAME)




RN 944079-62-3 CAPLUS

CN Ethanone, 1-[7-methyl-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944079-93-0 CAPLUS

CN 1H-Indole-7-carbonitrile, 3-acetyl-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]- (CA INDEX NAME)




RN 944080-09-5 CAPLUS

CN Methanone, cyclopropyl[7-methoxy-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 944082-94-4 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]- (CA INDEX NAME)




RN 944083-01-6 CAPLUS

CN Ethanone, 1-[1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]- (CA INDEX NAME)



RN 944083-28-7 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-methoxy-1-[3-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]propyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2007:619478 CAPLUS

DOCUMENT NUMBER: 147:52814

TITLE: Heteroaryl substituted piperidine derivatives as
L-CPT1 inhibitors and their preparation,
pharmaceutical compositions and use in the treatment
of diseases

INVENTOR(S): Ackermann, Jean; Bleicher, Konrad; Ceccarelli Grenz,
Simona M.; Chomienne, Odile; Mattei, Patrizio;
Schulz-Gasch, Tanja

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 179pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063012	A1	20070607	WO 2006-EP68745	20061122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, ZM, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006319247	A1	20070607	AU 2006-319247	20061122
AU 2006319247	B2	20100311		
CA 2630460	A1	20070607	CA 2006-2630460	20061122
EP 1959951	A1	20080827	EP 2006-819660	20061122
EP 1959951	B1	20091223		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009517438	T	20090430	JP 2008-542722	20061122
JP 4855478	B2	20120118		
AT 452635	T	20100115	AT 2006-819660	20061122
PT 1959951	E	20100302	PT 2006-819660	20061122
ES 2335698	T3	20100331	ES 2006-819660	20061122
RU 2396269	C2	20100810	RU 2008-126398	20061122
BR 2006019086	A2	20110920	BR 2006-19086	20061122
US 20070129544	A1	20070607	US 2006-605904	20061129
US 7645776	B2	20100112		
AR 56821	A1	20071024	AR 2006-105273	20061129
ZA 2008004393	A	20090429	ZA 2008-4393	20080521
MX 2008006776	A	20080602	MX 2008-6776	20080526
NO 2008002388	A	20080826	NO 2008-2388	20080526
CN 101321525	A	20081210	CN 2006-80045344	20080602
IN 2008DN04829	A	20080815	IN 2008-DN4829	20080605
KR 2008072097	A	20080805	KR 2008-7015998	20080630
PRIORITY APPLN. INFO.:			EP 2005-111560	A 20051201
			WO 2006-EP68745	W 20061122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 147:52814; MARPAT 147:52814

IT 939996-93-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of heteroaryl substituted

piperidine derivs. as L-CPT1 inhibitors useful as therapeutic and prophylactic agents)

RN 939996-93-7 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 939995-50-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of heteroaryl substituted piperidine derivs. as L-CPT1 inhibitors useful as therapeutic and prophylactic agents)

RN 939995-50-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT	939995-22-9P	939995-46-7P	939995-47-8P
	939995-48-9P	939995-49-0P	939995-52-5P
	939995-56-9P	939995-68-3P	939995-71-8P
	939995-88-7P	939995-91-2P	939995-95-6P
	939995-98-9P	939996-03-9P	939996-23-3P
	939996-33-5P	939996-34-6P	939996-53-9P
	939996-57-3P	939997-23-6P	939997-24-7P
	939997-25-8P	939997-26-9P	939997-27-0P
	939997-28-1P	939997-43-0P	939997-70-3P
	939997-72-5P	939998-23-9P	939998-26-2P
	939999-31-2P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl substituted piperidine derivs. as L-CPT1 inhibitors useful as therapeutic and prophylactic agents)

RN 939995-22-9 CAPLUS

CN Ethanone, 2-(4-fluorophenoxy)-1-[(2R)-2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-46-7 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-[2-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-47-8 CAPLUS

CN Ethanone, 2-phenoxy-1-[(2R)-2-[3-[2-(1-piperidinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-48-9 CAPLUS

CN Ethanone, 2-phenoxy-1-[(2R)-2-[3-[2-(4-thiomorpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-49-0 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-[2-(diethylamino)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-52-5 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-[2-(1H-imidazol-1-yl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-56-9 CAPLUS

CN Ethanone, 2-phenoxy-1-[(2R)-2-[3-[2-(1H-pyrazol-1-yl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-68-3 CAPLUS

CN Acetamide, N-[4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939995-71-8 CAPLUS


CN 2(1H)-Pyridinone, 4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 939995-88-7 CAPLUS


CN Acetamide, N-[4-[5-[4-(2-phenoxyacetyl)-3-morpholinyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl]- (CA INDEX NAME)



RN 939995-91-2 CAPLUS


CN 2(1H)-Pyridinone, 4-[5-[(3R)-4-(2-phenoxyacetyl)-3-morpholinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 939995-95-6 CAPLUS

CN Ethanone, 2-phenoxy-1-[3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-4-thiomorpholinyl]- (CA INDEX NAME)




RN 939995-98-9 CAPLUS

CN Ethanone, 1-[2-[3-[2-(1H-imidazol-1-yl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperazinyl]-2-phenoxy- (CA INDEX NAME)




RN 939996-03-9 CAPLUS

CN Ethanone, 2-phenoxy-1-[2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperazinyl]- (CA INDEX NAME)




RN 939996-23-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[5-[1-(2-phenoxyacetyl)-2-piperazinyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 939996-33-5 CAPLUS

CN Ethanone, 1-[2-[3-[2-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperazinyl]-2-phenoxy- (CA INDEX NAME)



RN 939996-34-6 CAPLUS


CN Ethanone, 2-phenoxy-1-[2-[3-[2-(4-thiomorpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperazinyl]- (CA INDEX NAME)



RN 939996-53-9 CAPLUS


CN 2(1H)-Pyridinone, 4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperazinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 939996-57-3 CAPLUS


CN Ethanone, 1-[4-acetyl-2-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperazinyl]-2-phenoxy- (CA INDEX NAME)



RN 939997-23-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-24-7 CAPLUS

CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-25-8 CAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-26-9 CAPLUS

CN 2-Pyridinecarboxamide, N,N-diethyl-4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-27-0 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-[2-(4-morpholinylcarbonyl)-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-28-1 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-[2-[3-(methanesulfonyl)-1-piperidinyl]carbonyl]-4-pyridinyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939997-43-0 CAPLUS


CN 2-Pyridinecarboxamide, 4-[5-[(2R)-1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 939997-70-3 CAPLUS

CN Ethanone, 1-[2-[3-(2-amino-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)




RN 939997-72-5 CAPLUS
 CN 2(1H)-Pyridinone, 4-[5-[1-(2-phenoxyacetyl)-2-piperidinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 939998-23-9 CAPLUS
 CN Ethanone, 1-[(3R)-3-[3-(2-amino-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-4-morpholinyl]-2-phenoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 939998-26-2 CAPLUS
 CN Ethanone, 1-[(2R)-2-[3-(2-amino-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperazinyl]-2-phenoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 939999-31-2 CAPLUS

CN Ethanone, 1-[(2R)-2-[3-(2-amino-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-2-phenoxy- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2006:1226437 CAPLUS

DOCUMENT NUMBER: 145:505457

TITLE: Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors and their preparation, pharmaceutical compositions and use in the treatment of central and peripheral nervous system disorders

INVENTOR(S): Bugada, Piergiuliano; Gagliardi, Stefania; Le Poul, Emmanuel; Mutel, Vincent; Palombi, Giovanni; Rocher, Jean-Philippe

PATENT ASSIGNEE(S): Addex Pharmaceuticals SA, Switz.

SOURCE: PCT Int. Appl., 88pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006123249	A2	20061123	WO 2006-IB1674	20060517
WO 2006123249	A3	20070208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006248649	A1	20061123	AU 2006-248649	20060517
CA 2608012	A1	20061123	CA 2006-2608012	20060517
EP 1896463	A2	20080312	EP 2006-779742	20060517
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008540634	T	20081120	JP 2008-511819	20060517

BR 2006010681	A2	20100720	BR 2006-10681	20060517
NZ 564253	A	20110429	NZ 2006-564253	20060517
MX 2007014405	A	20080421	MX 2007-14405	20071116
ZA 2007010277	A	20090325	ZA 2007-10277	20071128
IN 2007DN09399	A	20080620	IN 2007-DN9399	20071205
KR 2008031676	A	20080410	KR 2007-7029357	20071214
NO 2007006479	A	20080129	NO 2007-6479	20071217
CN 101218232	A	20080709	CN 2006-80025172	20080110
US 20090197897	A1	20090806	US 2008-920489	20081216
PRIORITY APPLN. INFO.:			GB 2005-10142	A 20050518
			WO 2006-IB1674	W 20060517

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:505457

IT 915233-05-5P 915233-06-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of oxadiazoles as pos. allosteric modulators of metabotropic glutamate receptors and their use for treatment of central and peripheral nervous system disorders)

RN 915233-05-5 CAPLUS

CN Methanone, (3,4-difluorophenyl)[(3S)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915233-06-6 CAPLUS

CN Methanone, (4-fluoro-2-methylphenyl)[(3S)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 851882-68-3P 851882-69-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of oxadiazoles as pos. allosteric modulators of metabotropic glutamate receptors and their use for treatment of central and peripheral nervous system disorders)

RN 851882-68-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851882-69-4 CAPLUS

CN Pyridine, 4-[5-(3S)-3-piperidinyl-1,2,4-oxadiazol-3-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2006:1095650 CAPLUS

DOCUMENT NUMBER: 145:438642

TITLE: Preparation of 1,4-substituted piperazine derivatives
as metabotropic glutamate receptor 1 inhibitors

INVENTOR(S): Satoh, Atsushi; Kawamoto, Hiroshi; Kimura, Toshifumi;
Suzuki, Gentaroh; Sato, Akio; Ohta, Hisashi

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 89pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006109817	A1	20061019	WO 2006-JP307691	20060405
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2006235759	A1	20061019	AU 2006-235759	20060405
CA 2603701	A1	20061019	CA 2006-2603701	20060405
EP 1870401	A1	20071226	EP 2006-731638	20060405

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 20090062293	A1	20090305	US 2007-887671	20070928
US 8101618	B2	20120124		
IN 2007DN08080	A	20080704	IN 2007-DN8080	20071019

PRIORITY APPLN. INFO.: JP 2005-109517 A 20050406
 WO 2006-JP307691 W 20060405


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:438642

IT 912921-86-9P, 4-[4-[5-(Pyrrolidin-1-yl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl]-1-piperazinecarboxylic acid 2,2-dimethylpropyl ester
 912922-19-1P, 4-[4-(5-Piperidinyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl]-1-piperazinecarboxylic acid 2,2-dimethylpropyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,4-substituted piperazine derivs. as mGluR1 inhibitors)


RN 912921-86-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[5-(1-pyrrolidinyl)-1,2,4-oxadiazol-3-yl]-2-pyridinyl]-, 2,2-dimethylpropyl ester (CA INDEX NAME)



RN 912922-19-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[5-(1-piperidinyl)-1,2,4-oxadiazol-3-yl]-2-pyridinyl]-, 2,2-dimethylpropyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:588949 CAPLUS

DOCUMENT NUMBER: 143:115543

TITLE: Preparation of heterocyclic derivatives as GPCR receptor agonists

INVENTOR(S): Fyfe, Matthew; Gardner, Lisa; King-Underwood, John;
 Procter, Martin; Rasamison, Chrystelle; Schofield,
 Karen; Thomas, Gerard Hugh
 PATENT ASSIGNEE(S): Prosidion Limited, UK
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061489	A1	20050707	WO 2004-GB50046	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303604	A1	20050707	AU 2004-303604	20041223
AU 2004303604	B2	20110324		
CA 2549955	A1	20050707	CA 2004-2549955	20041223
EP 1711491	A1	20061018	EP 2004-806264	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898235	A	20070117	CN 2004-80039018	20041223
BR 2004018149	A	20070417	BR 2004-18149	20041223
JP 2007517010	T	20070628	JP 2006-546340	20041223
NZ 547965	A	20091224	NZ 2004-547965	20041223
IN 2006MN00699	A	20070309	IN 2006-MN699	20060614
IN 227515	A1	20090306		
MX 2006007135	A	20060907	MX 2006-7135	20060621
ZA 2006005164	A	20071128	ZA 2006-5164	20060622
KR 2006127011	A	20061211	KR 2006-7012739	20060623
IN 2008KN02387	A	20090123	IN 2008-KN2387	20080612
US 20090281060	A1	20091112	US 2008-584025	20080826
PRIORITY APPLN. INFO.:			US 2003-532370P	P 20031224
			WO 2004-GB50046	W 20041223
			IN 2006-MN699	A3 20060614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 143:115543; MARPAT 143:115543

IT 276236-93-2P 276237-03-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted oxadiazoles as GPCR receptor agonists)


RN 276236-93-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 276237-03-7 CAPLUS

CN Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



IT 857652-87-0P 857652-88-1P 857652-89-2P

857652-90-5P 857652-91-6P 857652-92-7P


857652-93-8P 857652-94-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxadiazoles as GPCR receptor agonists)


RN 857652-87-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 2-methylpropyl ester (CA INDEX NAME)




RN 857652-88-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 2-methoxyethyl ester (CA INDEX NAME)




RN 857652-89-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, ethyl ester (CA INDEX NAME)




RN 857652-90-5 CAPLUS

CN 1-Butanone, 3,3-dimethyl-1-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 857652-91-6 CAPLUS

CN Ethanone, 2-cyclopentyl-1-[4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 857652-92-7 CAPLUS

CN Piperidine, 1-(butylsulfonyl)-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 857652-93-8 CAPLUS

CN 1-Piperidinecarboxamide, N-propyl-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 857652-94-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-(1,1-dimethylethyl)-4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2005:429396 CAPLUS
 DOCUMENT NUMBER: 142:481951
 TITLE: Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5)
 INVENTOR(S): Bessis, Anne-Sophie; Bonnet, Beatrice; Le Poul, Emmanuel; Rocher, Jean-Philippe; Epping-Jordan, Mark
 PATENT ASSIGNEE(S): Addex Pharmaceuticals S. A., Switz.
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044797	A1	20050519	WO 2004-IB3822	20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004287642	A1	20050519	AU 2004-287642	20041104
CA 2544748	A1	20050519	CA 2004-2544748	20041104
EP 1685105	A1	20060802	EP 2004-798939	20041104
EP 1685105	B1	20081015		

R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS		
CN 1898206	A	20070117	CN 2004-80038377 20041104
CN 1898206	B	20110914	
JP 2007510713	T	20070426	JP 2006-538992 20041104
AT 411290	T	20081015	AT 2004-798939 20041104
PT 1685105	E	20090122	PT 2004-798939 20041104
EP 2030970	A1	20090304	EP 2008-17193 20041104
EP 2030970	B1	20120104	
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR		
ES 2315722	T3	20090401	ES 2004-798939 20041104
RU 2360902	C2	20090710	RU 2006-119623 20041104
AT 540024	T	20120115	AT 2008-17193 20041104
CN 102336749	A	20120201	CN 2011-10204684 20041104
WO 2006048771	A1	20060511	WO 2005-IB3498 20051102
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
EP 1809620	A1	20070725	EP 2005-801781 20051102
EP 1809620	B1	20101229	
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
AT 493397	T	20110115	AT 2005-801781 20051102
US 20070219187	A1	20070920	US 2006-578589 20061213
US 7834035	B2	20101116	
HK 1094204	A1	20090430	HK 2007-101305 20070202
US 20070299110	A1	20071227	US 2007-667096 20070504
US 20110112143	A1	20110512	US 2010-899542 20101006
US 8030331	B2	20111004	
US 20120022108	A1	20120126	US 2011-251197 20110930
PRIORITY APPLN. INFO.:			GB 2003-25956 A 20031106
			CN 2004-80038377 A3 20041104
			EP 2004-798939 A3 20041104
			WO 2004-IB3822 W 20041104
			GB 2005-10143 A 20050518
			WO 2005-IB3498 W 20051102
			US 2006-578589 A1 20061213
			US 2010-899542 A1 20101006

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:481951; MARPAT 142:481951

IT 851881-95-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as modulators of metabotropic glutamate receptors (mGluR5))

RN 851881-95-3 CAPLUS


CN Methanone, (4-fluorophenyl)[(3S)-3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT	851882-68-3P	851882-69-4P	
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)		
	(preparation of piperidine derivs. as modulators of metabotropic glutamate receptors (mGluR5))		
RN	851882-68-3	CAPLUS	
CN	1-Piperidinecarboxylic acid, 3-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)		

Absolute stereochemistry.



RN 851882-69-4 CAPLUS
CN Pyridine, 4-[5-(3S)-3-piperidinyl-1,2,4-oxadiazol-3-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

 $\bullet 2 \text{ HCl}$


```
OS.CITING REF COUNT:      18      THERE ARE 18 CAPLUS RECORDS THAT CITE THIS
                                RECORD (18 CITINGS)
REFERENCE COUNT:          8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 2000:228770 CAPLUS
DOCUMENT NUMBER: 133:58754
TITLE: A solution-phase combinatorial synthesis of selective
dopamine D4 ligands
AUTHOR(S): Williams, John P.; Lavrador, Karine
CORPORATE SOURCE: Department of Medicinal Chemistry, CombiChem, Inc.,
San Diego, CA, 92121, USA
SOURCE: Combinatorial Chemistry and High Throughput Screening


(2000), 3(1), 43-50
CODEN: CCHSFU; ISSN: 1386-2073

PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:58754


IT 276237-14-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solution-phase combinatorial synthesis of selective dopamine D4 ligands)
RN 276237-14-0 CAPLUS
CN Pyridine, 4-[5-[1-(phenylmethyl)-4-piperidiny]-1,2,4-oxadiazol-3-yl]-
(CA INDEX NAME)



IT 276236-93-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(solution-phase combinatorial synthesis of selective dopamine D4 ligands)
RN 276236-93-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 276237-03-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solution-phase combinatorial synthesis of selective dopamine D4 ligands)
RN 276237-03-7 CAPLUS
CN Pyridine, 4-[5-(4-piperidiny)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2012 ACS on STN
ACCESSION NUMBER: 1965:90891 CAPLUS

DOCUMENT NUMBER: 62:90891
 ORIGINAL REFERENCE NO.: 62:16230b-h,16231a-g
 TITLE: Synthesis and reactions of mercaptoformamide chlorides
 AUTHOR(S): Eilingsfeld, Heinz; Moebius, Leander
 CORPORATE SOURCE: Badische Anilin-Soda-Fabrik A.-G., Ludwigshafen,
 Germany
 SOURCE: Chemische Berichte (1965), 98(4), 1293-307
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 62:90891
 IT 3035-87-8P, Piperidine, 1-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]-
 RL: PREP (Preparation)
 (preparation of)
 RN 3035-87-8 CAPLUS
 CN Piperidine, 1-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]- (7CI, 8CI) (CA INDEX
 NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.78	344.79

FILE 'REGISTRY' ENTERED AT 22:20:48 ON 09 FEB 2012
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0
 DICTIONARY FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.



Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\sshterengarts\Documents\STN Express 8.4\Queries\10584025kd.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

2-6 5-13 12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 12-13

exact bonds :

2-6 5-13

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS

Generic attributes :

12:

Saturation : Saturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

L4 STRUCTURE UPLOADED

=> s l4 sss full

FULL SEARCH INITIATED 22:21:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 57710 TO ITERATE

100.0% PROCESSED 57710 ITERATIONS

424 ANSWERS

SEARCH TIME: 00.00.02

L5 424 SEA SSS FUL L4

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

203.77

548.56

FILE 'CAPLUS' ENTERED AT 22:21:25 ON 09 FEB 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2012 VOL 156 ISS 7
 FILE LAST UPDATED: 8 Feb 2012 (20120208/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2011
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15
 L6 3 L5

=> d 16 1-3 ibib

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2012 ACS on STN
 ACCESSION NUMBER: 2010:437160 CAPLUS
 DOCUMENT NUMBER: 152:429549
 TITLE: Preparation of pyrrolidinone and piperidinone based compounds as therapeutic calcium channel blockers
 INVENTOR(S): Bhatia, Pramila A.; Doherty, George A.; Drizin, Irene; Mack, Helmut; Perner, Richard J.; Stewart, Andrew O.; Zhang, Qing Wei
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 219pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010039947	A1	20100408	WO 2009-US59215	20091001
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2737480	A1	20100408	CA 2009-2737480	20091001
US 20100093730	A1	20100415	US 2009-571862	20091001

US 8044069 B2 20111025
 EP 2350002 A1 20110803 EP 2009-737258 20091001
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
 SI, SK, SM, TR
 CN 102239146 A 20111109 CN 2009-80148415 20091001
 MX 2011003533 A 20110616 MX 2011-3533 20110401
 PRIORITY APPLN. INFO.: US 2008-102132P P 20081002
 WO 2009-US59215 W 20091001

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:429549; MARPAT 152:429549
 OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2006:1173938 CAPLUS

DOCUMENT NUMBER: 145:471411

TITLE: Preparation of
 4-[ω -(2-oxopyrrolidinyl)/2-oxopiperidinyl]alkoxy]benzonitriles as androgen
 receptor modulators for treating conditions like
 excess sebum secretions and hair loss

INVENTOR(S): Barrett, Stephen Douglas; Fedij, Victor; Hu, Lain-Yen;
 Iula, Donna Michele; Lefker, Bruce Allen; Raheja, Raj
 Kumar; Sexton, Karen Elaine; Van Camp, Jennifer Ann

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 94pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117677	A1	20061109	WO 2006-IB1266	20060424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006242927	A1	20061109	AU 2006-242927	20060424
CA 2603866	A1	20061109	CA 2006-2603866	20060424
CA 2603866	C	20110531		
EP 1888524	A1	20080220	EP 2006-744704	20060424
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 4174068	B1	20081029	JP 2008-509535	20060424
JP 2008540397	T	20081120		
AP 1932	A	20081231	AP 2007-4197	20060424
BR 2006010998	A2	20100810	BR 2006-10998	20060424
US 20060252796	A1	20061109	US 2006-415935	20060502

US 7674819	B2	20100309		
AR 53721	A1	20070516	AR 2006-101785	20060503
NL 1031752	A1	20061113	NL 2006-1031752	20060504
NL 1031752	C2	20070319		
US 20070072936	A1	20070329	US 2006-557225	20061107
US 7799823	B2	20100921		
IN 2007DN07726	A	20071109	IN 2007-DN7726	20071009
CN 101166718	A	20080423	CN 2006-80014500	20071031
ZA 2007009385	A	20081029	ZA 2007-9385	20071031
KR 2007116970	A	20071211	KR 2007-7025374	20071101
CR 9496	A	20071204	CR 2007-9496	20071102
MX 2007013823	A	20080205	MX 2007-13823	20071105
NO 2007006026	A	20071122	NO 2007-6026	20071122
PRIORITY APPLN. INFO.:			US 2005-678035P	P 20050505
			US 2005-682112P	P 20050518
			WO 2006-IB1266	W 20060424
			US 2006-415935	A1 20060502
OTHER SOURCE(S):		CASREACT 145:471411; MARPAT 145:471411		
OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)		
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:588949 CAPLUS

DOCUMENT NUMBER: 143:115543

TITLE: Preparation of heterocyclic derivatives as GPCR receptor agonists

INVENTOR(S): Fyfe, Matthew; Gardner, Lisa; King-Underwood, John; Procter, Martin; Rasamison, Chrystelle; Schofield, Karen; Thomas, Gerard Hugh

PATENT ASSIGNEE(S): Prosidion Limited, UK

SOURCE: PCT Int. Appl., '73 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061489	A1	20050707	WO 2004-GB50046	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303604	A1	20050707	AU 2004-303604	20041223
AU 2004303604	B2	20110324		
CA 2549955	A1	20050707	CA 2004-2549955	20041223
EP 1711491	A1	20061018	EP 2004-806264	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898235	A	20070117	CN 2004-80039018	20041223
BR 2004018149	A	20070417	BR 2004-18149	20041223

JP 2007517010	T	20070628	JP 2006-546340	20041223
NZ 547965	A	20091224	NZ 2004-547965	20041223
IN 2006MN00699	A	20070309	IN 2006-MN699	20060614
IN 227515	A1	20090306		
MX 2006007135	A	20060907	MX 2006-7135	20060621
ZA 2006005164	A	20071128	ZA 2006-5164	20060622
KR 2006127011	A	20061211	KR 2006-7012739	20060623
IN 2008KN02387	A	20090123	IN 2008-KN2387	20080612
US 20090281060	A1	20091112	US 2008-584025	20080826
PRIORITY APPLN. INFO.:			US 2003-532370P	P 20031224
			WO 2004-GB50046	W 20041223
			IN 2006-MN699	A3 20060614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 143:115543; MARPAT 143:115543
 OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
 RECORD (13 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	4.88	553.44

FILE 'REGISTRY' ENTERED AT 22:21:39 ON 09 FEB 2012
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0
 DICTIONARY FILE UPDATES: 8 FEB 2012 HIGHEST RN 1356058-28-0

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>